US20140245468A1 - Non-human animals with modified immunoglobulin heavy chain sequences - Google Patents

Non-human animals with modified immunoglobulin heavy chain sequences Download PDF

Info

Publication number
US20140245468A1
US20140245468A1 US14/185,679 US201414185679A US2014245468A1 US 20140245468 A1 US20140245468 A1 US 20140245468A1 US 201414185679 A US201414185679 A US 201414185679A US 2014245468 A1 US2014245468 A1 US 2014245468A1
Authority
US
United States
Prior art keywords
heavy chain
human
chain variable
sequence
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/185,679
Other languages
English (en)
Inventor
John McWhirter
Cagan Gurer
Karolina A. MEAGHER
Lynn MacDonald
Andrew J. Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority to US14/185,679 priority Critical patent/US20140245468A1/en
Assigned to REGENERON PHARMACEUTICALS, INC. reassignment REGENERON PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MURPHY, ANDREW J., MCWHIRTER, JOHN, GURER, CAGAN, MACDONALD, LYNN, MEAGHER, KAROLINA A.
Publication of US20140245468A1 publication Critical patent/US20140245468A1/en
Priority to US14/498,523 priority patent/US9204624B2/en
Priority to US14/961,642 priority patent/US9930871B2/en
Priority to US16/990,517 priority patent/US20210076648A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Definitions

  • Non-human animals e.g., rodents such as mice and rats, comprising a rearranged human heavy chain variable region nucleic acid sequence (i.e., a rearranged heavy chain VDJ sequence) operably linked to a constant region nucleic acid sequence.
  • the animals are genetically engineered to have an immunoglobulin locus comprising a rearranged heavy chain variable region (a VDJ sequence) nucleic acid sequence operably linked to an immunoglobulin constant region gene sequence, wherein the VDJ sequence is a human VDJ sequence, and the constant region gene sequence is human or non-human.
  • the non-human animals containing a genetically modified immunoglobulin locus comprise: (1) a first nucleotide sequence that encodes a rearranged heavy chain variable domain (i.e., where the first nucleotide sequence is a rearranged human immunoglobulin heavy chain variable region nucleotide sequence), wherein the first nucleotide sequence is operably linked to a light chain (e.g., a ⁇ or ⁇ light chain) constant region gene sequence; and (2) a second nucleotide sequence that encodes a human or non-human light chain (e.g., a ⁇ or ⁇ light chain) variable domain (i.e., where the second nucleotide sequence is an unrearranged human immunoglobulin light chain variable nucleotide sequence), wherein the second nucleotide sequence is operably linked to a heavy chain constant region gene sequence.
  • a light chain e.g., a ⁇ or ⁇ light chain
  • the non-human animals comprise a genetically modified immunoglobulin heavy chain locus comprising a rearranged human immunoglobulin heavy chain variable region nucleotide sequence, wherein the rearranged heavy chain variable domain comprises a heavy chain V gene segment (V H ) sequence operably linked, via a spacer, to a heavy chain J gene segment (J H ) sequence, and wherein the spacer comprises at least one amino acid residue.
  • V H heavy chain V gene segment
  • J H heavy chain J gene segment
  • Genetically modified non-human animals e.g., rodents such as mice and rats, are provided comprising in their genomes: (i) a rearranged human heavy chain variable region nucleic acid sequence operably linked to a constant region nucleic acid sequence; and (ii) an immunoglobulin light chain locus comprising one or more but less than the wild type number of human light chain variable region gene segments.
  • Genetically modified non-human animals are provided comprising in their genomes: (i) a rearranged human heavy chain variable region nucleic acid sequence operably linked to a constant region nucleic acid sequence; and (ii) an immunoglobulin light chain locus comprising one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments.
  • variable region gene segments encodes one or more histidine residues that is/are not encoded by a corresponding human germline light chain variable region gene segment.
  • Methods of making the genetically modified non-human animals described herein are provided.
  • Methods for producing immunoglobulin light chain (e.g., a ⁇ or ⁇ light chain) variable region sequences that can bind an antigen in the absence of a heavy chain, and/or can be associated with a rearranged heavy chain variable domain and/or exhibit pH-dependent antigen binding characteristics, are provided, which are useful for producing bispecific antibodies.
  • Bispecific antibodies are multifunctional antibodies that comprise antigen-binding sites that can bind two distinct antigenic determinants and have emerged as one of the major therapeutic biologics for treating many diseases, including cancer. While a variety of bispecific antibodies with dual antigen-binding properties have been developed recently, the specificity and affinity of immunoglobulin light chain or heavy chain variable domains in the conventional bispecific antibodies had to be sacrificed to some extent because, in the conventional bispecific antibodies, either only a heavy chain or a light chain variable domain contributes to binding to each antigenic determinant, whereas, in regular antibodies, both light and heavy chain variable regions can contribute to binding to the same antigenic determinant. In addition, in achieving a desirable level of efficacy, therapeutic antibodies, e.g., bispecific therapeutic antibodies, often require high or multiple doses of antibodies due to their limited recyclability in vivo.
  • antigen-binding proteins that target two antigens or epitopes developed so far comprise two antigen-binding arms: (i) a first antigen-binding arm comprising an immunoglobulin heavy-light chain variable domain pair that contributes to binding to a first antigen or epitope; and (ii) a second antigen-binding arm comprising a second heavy-light chain variable domain pair that contributes to binding to a second antigen or epitope.
  • These antigen-binding proteins though bispecific in the context of the whole antigen-binding protein, are not necessarily bispecific within each antigen-binding arm, limiting the use of the antigen-binding proteins in multi-specific formats, e.g., tri-specific antigen-binding proteins.
  • a non-human animal that expresses a universal heavy chain variable domain may be employed as a general tool for making antigen-binding proteins for use in many different formats of antigen-binding proteins.
  • immunoglobulin light chain variable domain sequences in which antigen specificity and affinity results solely or primarily from, and/or resides solely or primarily in, immunoglobulin light chain variable domain diversity.
  • Such sequences would be extremely useful in designing antigen-binding proteins, e.g., bispecific antibodies, in which each variable domain is separately responsible for distinct antigen-specific binding.
  • antigen-binding proteins e.g., bispecific antibodies
  • each variable domain is separately responsible for distinct antigen-specific binding.
  • Various aspects and embodiments described herein are based in part on the surprising discovery that genetically modified non-human animals comprising immunoglobulin heavy chain variable domains encoded by a rearranged heavy chain variable gene sequence (e.g., a rearranged heavy chain VDJ sequence) can meet this need.
  • Non-human animals encoding a rearranged immunoglobulin heavy chain variable domain focus the mechanisms of antibody diversification on unrearranged (i.e., diversifiable) antibody light chain variable domain(s).
  • Non-human animals include, e.g., mammals and, in particular embodiments, rodents (e.g., mice, rats, or hamsters).
  • Light chain antibody variable domain amino acids and corresponding nucleic acid sequences can be identified from antibodies produced by such genetically modified animals, and the sequences can be utilized in recombinant antibodies or other antigen-binding proteins to develop light chain variable domains that bind an antigenic determinant independently (and with sufficient specificity and affinity) from heavy chain variable domains.
  • rearranged heavy chain variable domain i.e., comprising a prearranged heavy chain variable domain gene sequence
  • a nucleotide sequence encoding the rearranged heavy chain variable domain in a variety of genomic contexts, e.g., in different immunoglobulin loci.
  • Rearranged heavy chain variable domain gene sequences can be targeted to a heavy chain locus or a light chain locus such that the rearranged heavy chain variable domain sequences can be operably linked to a heavy or light chain constant sequence, either human or non-human.
  • Rearranged heavy chain variable domain gene sequences can be placed anywhere in the genome in operable linkage with human, non-human, or mixed human/non-human immunoglobulin constant region sequences.
  • non-human animals comprising a nucleotide sequence encoding a rearranged heavy chain variable domain can be combined with additional genetic modifications of immunoglobulin loci (e.g., crossbred to animals comprising additional genetic modifications of immunoglobulin loci).
  • the focused diversification imparted by a rearranged heavy chain variable domain gene sequence targeted to a light chain locus can be paired with a light chain variable domain gene sequence inserted into a heavy chain locus, thereby generating animals that fully utilize the timing and diversification of a genomic context of choice (e.g., the diversification mechanisms of the heavy chain locus) to increase diversity of antibody variable gene sequence of choice (e.g., antibody light chain variable gene sequences).
  • a genomic context of choice e.g., the diversification mechanisms of the heavy chain locus
  • mice that have a restricted (limited) light chain variable region gene segment repertoire e.g., a restricted number of light chain variable gene sequences that comprise one or more but less than the wild type number of human V L gene segments in combination with the single rearranged heavy chain sequence described above
  • a restricted (limited) light chain variable region gene segment repertoire e.g., a restricted number of light chain variable gene sequences that comprise one or more but less than the wild type number of human V L gene segments in combination with the single rearranged heavy chain sequence described above
  • genetically modified non-human animals e.g., rodents such as mice, rats, or hamsters
  • an immunoglobulin locus comprising a rearranged human immunoglobulin heavy chain variable region (i.e., a nucleotide sequence that encodes a rearranged heavy chain variable domain; i.e., a rearranged heavy chain VDJ sequence).
  • the only genomic heavy chain variable domain-encoding nucleic acid sequence expressed by the genetically modified non-human animals is the rearranged heavy chain variable domain. Accordingly, the diversity of antibody heavy chain variable domains produced by the genetically modified non-human animals is extremely restricted.
  • genetically modified non-human animals have in their genome an immunoglobulin locus that has been genetically modified so that its variable region sequences consist essentially of a single rearranged human heavy chain variable region. It is understood that different cells in such genetically modified non-human animals may not always have completely identical sequences in the single rearranged human heavy chain variable region (e.g., due to replication errors, somatic hypermutation, or other mechanisms), but regardless, such genetically modified non-human animals show dramatically restricted diversity of antibody heavy chain variable domains as compared with animals having unrearranged heavy chain variable sequences, and/or animals whose genomes include multiple heavy chain variable region gene segments (e.g., multiple V, D, and/or J segments, particularly if unrearranged).
  • multiple heavy chain variable region gene segments e.g., multiple V, D, and/or J segments, particularly if unrearranged.
  • a genetically modified immunoglobulin heavy chain locus comprising a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (i.e., comprising a nucleotide sequence that encodes a rearranged heavy chain variable domain).
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence and the rearranged heavy chain variable domain it encodes are derived from a human V, D, and J gene segment.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence and the rearranged heavy chain variable domain it encodes are derived from a human V H gene and a human J H segment.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a heavy chain constant region region gene sequence. In various aspects, the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a light chain constant region region gene sequence. In various aspects, the genetically modified immunoglobulin locus is present in the germline of a non-human animal. In various aspects, the genetically modified non-human animals comprise the full complement of unrearranged light chain variable gene segments capable of rearranging to form a light chain gene in operable linkage with a light chain constant region gene sequence.
  • the genetically modified non-human animals comprise a plurality but less than a full complement (i.e., less than a wild type number) of unrearranged light chain variable gene segments.
  • the unrearranged light chain variable gene segments are operably linked to a heavy chain constant region gene sequence.
  • the non-human animal is a rodent, e.g., a mouse, rat, or hamster.
  • a nucleic acid construct is provided comprising a rearranged human immunoglobulin heavy chain variable region (i.e., comprising a nucleotide sequence that encodes a rearranged heavy chain variable domain; i.e., a pre-rearranged heavy chain VDJ sequence) as described herein.
  • a nucleotide sequence that encodes a rearranged heavy chain variable domain i.e., a heavy chain variable domain encoded by a rearranged human immunoglobulin heavy chain variable region nucleotide sequence
  • a human or non-human heavy chain constant region gene sequence e.g., a heavy chain constant region gene sequence that encodes an immunoglobulin isotype selected from IgM, IgD, IgA, IgE, IgG, and combinations thereof.
  • genetically modified non-human animals comprising immunoglobulin loci in which: (a) a first nucleotide sequence encodes a rearranged heavy chain variable domain (i.e., where the first nucleotide sequence is a rearranged human immunoglobulin heavy chain variable region nucleotide sequence), wherein the first nucleotide sequence is operably linked to a human or non-human (or mixed human/non-human) heavy chain constant region gene sequence; and (b) a second nucleotide sequence encodes a light chain variable domain (i.e., where the second nucleotide sequence is an unrearranged human immunoglobulin light chain variable nucleotide sequence), wherein the second nucleotide sequence is operably linked to a human or non-human light chain constant region gene sequence.
  • a first nucleotide sequence encodes a rearranged heavy chain variable domain (i.e., where the first nucleotide sequence is a rearranged human immunoglobulin heavy chain variable region
  • modified non-human animals comprise a rearranged nucleotide sequence that encodes a heavy chain variable domain, wherein the heavy chain variable domain comprises a heavy chain variable (V H ) sequence that is operably linked, via a spacer, to a heavy chain J segment (J H ) sequence, wherein the spacer encodes at least one amino acid residue.
  • V H heavy chain variable
  • J H heavy chain J segment
  • a non-human animal comprising a genetically modified immunoglobulin locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (i.e., comprise a nucleic acid sequence encoding a rearranged heavy chain variable domain; i.e., a rearranged heavy chain VDJ sequence), wherein the genetically modified immunoglobulin locus is present in the germline of the non-human animal.
  • the genetically modified immunoglobulin locus is a heavy chain locus.
  • the genetically modified immunoglobulin locus is a light chain locus
  • genetically modified non-human animals e.g., rodents such as mice, rats, or hamsters
  • a genetically modified immunoglobulin genomic locus a rearranged human immunoglobulin heavy chain variable region nucleotide sequence, wherein the nucleotide sequence is operably linked to a human or non-human light chain (e.g., ⁇ or ⁇ light chain) constant region gene sequence.
  • a human or non-human light chain e.g., ⁇ or ⁇ light chain
  • a non-human animal comprising a genetically modified immunoglobulin locus comprising: (a) a rearranged human immunoglobulin heavy chain variable region nucleotide sequence operably linked to a light chain constant region gene sequence; and (b) a unrearranged human or non-human light chain (e.g., ⁇ or ⁇ light chain) variable region nucleotide sequence operably linked to a human or non-human heavy chain constant region gene sequence (e.g., a heavy chain constant region gene sequence that encodes an immunoglobulin isotype selected from IgM, IgD, IgA, IgE, IgG, and a combination thereof).
  • a heavy chain constant region gene sequence that encodes an immunoglobulin isotype selected from IgM, IgD, IgA, IgE, IgG, and a combination thereof.
  • a genetically modified non-human animal comprising:
  • genetically modified non-human animals with unrearranged light chain variable region gene sequences or loci comprise a wild type number (i.e., all or substantially all) of human immunoglobulin light chain variable region gene segments (i.e., sequences).
  • the non-human animals described herein comprises a limited repertoire of light chain variable gene segments, e.g., (i) one, two or more but less than the wild type number of human V L gene segments; and (ii) one or more human J L gene segments, operably linked to a non-human light chain constant region nucleic acid sequence.
  • the heavy chain nucleic acid sequence and/or the light chain segments may be present, e.g., in a transgene or at an endogenous immunoglobulin locus.
  • genetically modified non-human animals wherein all immunoglobulin heavy chain variable domains of the animal are derived from the same rearranged variable heavy chain gene sequence, and wherein said variable domains are expressed cognate with a light chain variable domain derived from one of at least one, two, or three or more V L gene segments and at least one, two, or three or more J L gene segments.
  • genetically modified non-human animals comprising in their genomes: (i) an immunoglobulin heavy chain locus that comprises a rearranged human heavy chain variable region nucleic acid sequence operably linked to a human or non-human heavy chain constant region nucleic acid sequence; and (ii) an immunoglobulin light chain locus comprising one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments (e.g., two human V ⁇ gene segments and one or more human J ⁇ gene segments), operably linked to a human or non-human light chain constant region nucleic acid sequence.
  • the light chain constant region is a rat or a mouse constant region, e.g., a rat or a mouse C ⁇ constant region.
  • the genetically modified non-human animals as described herein upon stimulation with an antigen of interest, express an antigen-binding protein comprising an immunoglobulin heavy chain and a light chain amino acid sequence, wherein the heavy chain amino acid sequence is derived from a genetically modified heavy chain locus comprising a rearranged human heavy chain variable region nucleic acid sequence operably linked to a heavy chain constant region nucleic acid sequence.
  • the light chain amino acid sequence is derived from a genetically modified immunoglobulin light chain locus comprising one or more but less than the wild type number of human V L gene segments and (ii) two or more human J L gene segments, operably linked to a non-human light chain constant region nucleic acid sequence.
  • Genetically modified non-human animals comprising in their genomes a rearranged human immunoglobulin heavy chain variable region nucleic acid sequence that comprises a heavy chain V gene segment (V H ) that is operably linked, via a spacer, to a heavy chain J gene segment (J H ) sequence, wherein the spacer encodes at least one amino acid (e.g., 2 amino acids, 3 amino acids, or 4 amino acids) and/or a modified D gene segment.
  • the rearranged heavy chain variable region nucleic acid sequence is operably linked to a human or non-human heavy chain constant region nucleic acid sequence.
  • the non-human animals further comprise in their genomes a genetically modified immunoglobulin light chain locus comprising one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments, e.g., two human V ⁇ gene segments and one or more human J ⁇ gene segments, operably linked to a human or non-human light chain constant region nucleic acid sequence.
  • a genetically modified immunoglobulin light chain locus comprising one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments, e.g., two human V ⁇ gene segments and one or more human J ⁇ gene segments, operably linked to a human or non-human light chain constant region nucleic acid sequence.
  • Methods of making and using the genetically modified non-human animals described herein are also provided. Methods are provided for placing a rearranged human heavy chain variable region nucleic acid sequence in operable linkage with an immunoglobulin heavy or light chain constant region nucleic acid sequence in the genome of a non-human animal.
  • V L immunoglobulin light chain variable region
  • a genetically modified immunoglobulin locus obtainable by any of the methods as described herein is provided.
  • antigen-binding proteins e.g., antibodies
  • methods for making antigen-binding proteins including multispecific (e.g., bispecific or trispecific) antigen-binding proteins.
  • methods for making an effector light chain immunoglobulin variable domains are provided.
  • a pluripotent cell, induced pluripotent, or totipotent stem cells derived from a non-human animal comprising the various genomic modifications described herein are provided.
  • Cells that comprise a nucleus containing a genetic modification as described herein are also provided, e.g., a modification introduced into a cell by pronuclear injection.
  • a non-human animal embryo comprising a cell whose genome comprises an immunoglobulin heavy chain locus comprising a rearranged human heavy chain variable region nucleic acid sequence operably linked to a constant region nucleic acid sequence.
  • the non-human animal embryo further comprises an immunoglobulin light chain locus comprising two or more but less than the wild type number of human immunoglobulin light chain variable region gene segments, operably linked to a light chain constant region nucleic acid sequence.
  • nucleic acid sequences that encode an immunoglobulin light chain variable region (V L ) amino acid sequence capable of binding an antigen or an epitope thereof independently from a heavy chain variable domain, comprising: (a) immunizing a non-human animal with an antigen of interest or an immunogen thereof, wherein the non-human animal comprises in its genome (i) a rearranged human immunoglobulin heavy chain variable region nucleic acid sequence operably linked to a heavy chain constant region nucleic acid sequence, and (ii) an unrearranged human immunoglobulin light chain variable region nucleic acid sequence operably linked to a light chain constant region nucleic acid sequence; (b) allowing the non-human animal to mount an immune response; (c) isolating from the immunized non-human animal a cell comprising a nucleic acid sequence that encodes a light chain variable domain that can bind the antigen; and (d) obtaining from the cell a nucleic acid sequence that encodes the light chain variable domain (V
  • the cell is a lymphocyte, including, but not limited to, natural killer cells, T cells, and B cells.
  • the method further comprises (c)′ fusing the lymphocyte with a cancer cells, e.g., a myeloma cell.
  • nucleic acid sequences that encode an immunoglobulin light chain variable region (V L ) amino acid sequence capable of binding an antigen or an epitope thereof independently from a heavy chain variable domain, comprising: (a) immunizing a non-human animal with an antigen of interest or an immunogen thereof, wherein the non-human animal comprises in its genome (i) a rearranged human immunoglobulin heavy chain variable region nucleic acid sequence operably linked to a heavy chain constant region nucleic acid sequence, and (ii) two or more but less than the wild type number of human immunoglobulin light chain variable region gene segments (V L and J L ) operably linked to a light chain constant region nucleic acid sequence; (c) isolating from the immunized non-human animal a cell comprising a nucleic acid sequence that encodes a light chain variable domain that can bind the antigen; and (d) obtaining from the cell a nucleic acid sequence that encodes the light chain variable domain (V L domain) that
  • the cell is a lymphocyte, including, but not limited to, natural killer cells, T cells, and B cells.
  • the method further comprises (c)′ fusing the lymphocyte with a cancer cells, e.g., a myeloma cell.
  • nucleic acid sequences that encode an immunoglobulin light chain variable region (V L ) amino acid sequence capable of binding an antigen or an epitope thereof independently from a heavy chain variable domain, comprising: (a) immunizing a non-human animal with an antigen of interest or an immunogen thereof, wherein the non-human animal comprises in its genome: (i) a rearranged human immunoglobulin heavy chain variable region nucleic acid sequence operably linked to a light chain constant region nucleic acid sequence, and (ii) human immunoglobulin light chain variable region gene segments (V L and J L ) operably linked to a heavy chain constant region nucleic acid sequence; (c) isolating from the immunized non-human animal a cell comprising a nucleic acid sequence that encodes a light chain variable domain that can bind the antigen; and (d) obtaining from the cell a nucleic acid sequence that encodes the light chain variable domain (V L domain) that can bind the antigen.
  • V L immunoglobulin
  • the cell is a lymphocyte, including, but not limited to, natural killer cells, T cells, and B cells.
  • the method further comprises (c)′ fusing the lymphocyte with a cancer cells, e.g., a myeloma cell.
  • Also provided are methods for making antigen-binding proteins comprising:
  • Also provided are methods for making antigen-binding proteins comprising:
  • Also provided are methods for making antigen-binding proteins comprising:
  • a non-human animal comprising in its germline genome an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence.
  • the non-human animal is a mammal.
  • the mammal is a rodent.
  • the rodent selected from the group consisting of a mouse, a rat, and a hamster.
  • the non-human animal is homozygous for the rearranged human immunoglobulin heavy chain variable region nucleotide sequence.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a non-human heavy chain constant region gene sequence.
  • the non-human heavy chain constant region gene sequence encodes an Fc.
  • the non-human heavy chain constant region gene sequence is a mouse or a rat heavy chain constant region gene sequence.
  • the non-human animal is a rodent, and the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a human heavy chain constant region gene sequence.
  • the heavy chain constant region gene sequence is selected from a C H 1, a hinge, a C H 2, a C H 3, and a combination thereof.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is derived from a human heavy chain V H gene segment, a human heavy chain D gene segment, and a human heavy chain J H gene segment. In certain embodiments, the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is derived from a human germline heavy chain V H segment, a human germline heavy chain D segment, and a human germline heavy chain J H segment. In some embodiments, the rearranged human immunoglobulin heavy chain variable region nucleotide sequence encodes the sequence of human V H 3-23/GY/J H 4-4.
  • substantially all endogenous functional V H , D, and J H gene segments are deleted from the immunoglobulin heavy chain locus of the non-human animal or rendered non-functional.
  • the non-human animal comprises a modification that deletes or renders non-functional endogenous functional V H , D, and J H gene segments; and the non-human animal comprises the rearranged human immunoglobulin heavy chain variable region nucleotide sequence, wherein the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is present ectopically.
  • an immunoglobulin heavy chain variable domain encoded by the rearranged heavy chain variable region nucleotide sequence is not immunogenic to the non-human animal.
  • the non-human animal comprises an Adam6a gene, an Adam6b gene, or both.
  • the non-human animal further comprises a nucleotide sequence encoding an unrearranged human immunoglobulin light chain (V L ) gene segment and an unrearranged human immunoglobulin light chain J gene segment.
  • the nucleotide sequence encoding the unrearranged light chain V gene segment (V L ) and the unrearranged light chain (J L ) gene segment is operably linked to an immunoglobulin light chain constant region gene sequence.
  • the light chain constant region gene sequence is selected from a rodent and a human constant region gene sequence.
  • the rodent is selected from a mouse, a rat, and a hamster.
  • the unrearranged human immunoglobulin light chain (V L ) gene segment and the unrearranged human immunoglobulin (J L ) gene segment are operably linked, at an endogenous rodent locus, to a rodent immunoglobulin constant region gene sequence.
  • the immunoglobulin heavy chain locus comprises a plurality of copies of the rearranged human immunoglobulin heavy chain variable region nucleotide sequence.
  • a non-human immunoglobulin heavy chain locus in a genome of a non-human germ cell comprising a rearranged human immunoglobulin heavy chain variable region nucleotide sequence operably linked to a heavy chain constant region gene sequence, wherein the constant region gene sequence comprises a non-human sequence, a human sequence, or a combination thereof.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to an endogenous non-human immunoglobulin constant region gene sequence.
  • the endogenous non-human immunoglobulin constant region gene sequence is a mouse or a rat heavy chain constant region gene sequence.
  • methods for making a non-human animal, the methods comprising:
  • non-human animals comprising a genetically modified immunoglobulin locus comprising:
  • Additional aspects provide an immunoglobulin locus in a germline genome of a non-human animal comprising:
  • Additional aspects provide methods of making a non-human animal that comprise a modified immunoglobulin locus, the methods comprising:
  • non-human animals comprising a modified immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence comprising a heavy chain V segment (V H ) sequence that is operably linked, via a spacer, to a heavy chain J segment (J H ) sequence, wherein the spacer comprises at least one amino acid residue.
  • the non-human animal is a rodent.
  • the rodent is selected from the group consisting of a mouse, a rat, and a hamster.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a non-human heavy chain constant region gene sequence.
  • the non-human heavy chain constant region gene sequence is a mouse or a rat constant region gene sequence.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a human heavy chain constant region gene sequence.
  • the heavy chain constant region gene sequence encodes a sequence selected from a C H 1, a hinge, a C H 2, a C H 3, and a combination thereof.
  • the V H sequence and the J H sequence are derived from a human V H gene segment and a human J H gene segment.
  • the human V H gene segment is selected from the group consisting of V H 1-2, V H 1-3, V H 1-8, V H 1-18, V H 1-24, V H 1-45, V H 1-46, V H 1-58, V H 1-69, V H 2-5, V H 2-26, V H 2-70, V H 3-7, V H 3-9, V H 3-11, V H 3-13, V H 3-15, V H 3-16, V H 3-20, V H 3-21, V H 3-23, V H 3-30, V H 3-30-3, V H 3-30-5, V H 3-33, V H 3-35, V H 3-38, V H 3-43, V H 3-48, V H 3-49, V H 3-53, V H 3-64, V H 3-66, V H 3-72, V H 3-73, V H 3-74, V H 4-4, V H 4-28, V H 4-30-1, V H 4-30-2, V H 4-30-4, V H 4-31, V H 4-34, V H 4-39, V H 4-59, V H 4-6
  • the human V H gene segment is V H 3-23 or a polymorphic variant thereof.
  • the spacer encodes a sequence derived from a human D gene segment.
  • the human D gene segment is selected from the group consisting of D1-1, D1-7, D1-14, D1-20, D1-26, D2-2, D2-8, D2-15, D2-21, D3-3, D3-9, D3-10, D3-16, D3-22, D4-4, D4-11, D4-17, D4-23, D5-12, D5-5, D5-18, D5-24, D6-6, D6-13, D6-19, D6-25, D7-27, and a polymorphic variant thereof.
  • the spacer encodes the sequence of D4-4 or a polymorphic variant thereof.
  • the human J H gene segment is selected from the group consisting of J H 1, J H 2, J H 3, J H 4, J H 5, J H 6, and a polymorphic variant thereof.
  • the human J H segment is J H 4-4 or a polymorphic variant thereof.
  • the rearranged immunoglobulin heavy chain variable region nucleotide sequence encodes the sequence of human V H 3-23/GY/J H 4-4 (SEQ ID NO: 137).
  • substantially all endogenous functional V H , D, and J H gene segments are deleted from the immunoglobulin heavy chain variable locus of the non-human animal or rendered non-functional.
  • the non-human animal comprises a modification that deletes or renders non-functional endogenous functional V H , D, and J H gene segments; and the non-human animal comprises the rearranged human immunoglobulin heavy chain variable region nucleotide sequence at an ectopic locus of its genome.
  • a heavy chain variable domain encoded by the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is not immunogenic to the non-human animal.
  • the non-human animal comprises an Adam6a gene, an Adam6b gene, or both.
  • an immunoglobulin heavy chain locus in a germline genome of a non-human animal comprising a rearranged human immunoglobulin heavy chain variable region nucleotide sequence comprising a heavy chain variable gene segment (V H ) that is operably linked, via a spacer, to a heavy chain J gene segment (J H ), wherein the spacer encodes at least one amino acid residue.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a non-human heavy chain constant region gene sequence.
  • the non-human heavy chain constant region gene sequence is a mouse or a rat heavy chain constant region gene sequence.
  • the immunoglobulin locus comprises a plurality of copies of the rearranged heavy chain variable region nucleotide sequence.
  • Additional aspects provide methods for making a non-human animal comprising a modified immunoglobulin locus, comprising:
  • Additional aspects provide methods for obtaining a nucleic acid sequence that encodes an immunoglobulin light chain variable domain (V L ) capable of binding an antigen independently from a heavy chain variable domain, comprising:
  • Additional aspects provide methods for making an antigen-binding protein that comprises an immunoglobulin light chain variable domain that can bind an antigen independently from a heavy chain variable domain, comprising:
  • Additional aspects provide methods for obtaining a nucleic acid sequence that encodes an immunoglobulin light chain variable domain (V L ) capable of binding an antigen independently from a heavy chain variable domain, comprising:
  • Additional aspect provide methods for obtaining a nucleic acid sequence that encodes an immunoglobulin light chain variable domain (V L ) capable of binding an antigen independently from a heavy chain variable domain, comprising:
  • an antigen-binding protein that comprises an immunoglobulin light chain variable domain that can bind an antigen independently from a heavy chain variable domain, comprising:
  • Additional aspects provided methods for making an antigen-binding protein that comprises an immunoglobulin light chain variable domain that can bind an antigen independently from a heavy chain variable domain comprising:
  • FIG. 1 illustrates schemes for constructing a rearranged heavy chain variable domain mini-locus (“UHC mini-locus”) comprising a rearranged human immunoglobulin variable region nucleotide sequence (V H 3-23/D/J H 4; SEQ ID NO: 136) and an intron of J H 4 (SEQ ID NO: 140), which are operably linked to a human V H 3-23 promoter (SEQ ID NO: 139).
  • the UHC mini-locus was flanked 5′ and 3′ by mouse homology arms.
  • Step 1 I-CeuI/SpeI Ligation (Amp+Spec)
  • a spectinomycin selection cassette was introduced into the upstream of the promoter between the I-CeuI and SpeI sites to generate pJSh0038 (UHC mini-locus;).
  • FIG. 2 illustrates schemes for (A) targeting a hygromycin selection cassette (EM7-HYG) into the 5′ end of the MAID 1115 BAC clone (2. BHR (Hyg+Kan)); and (B) targeting the UHC mini-locus (pJSh0038) into the upstream of the IgM locus in the VI432 BAC clone (3. BHR (Spec+Hyg)).
  • E7-HYG hygromycin selection cassette
  • pJSh0038 UHC mini-locus
  • FIG. 3 illustrates schemes for (A) targeting the pDBa0049 construct comprising a chloramphenicol cassette into the 3′ end of the VI421 clone, which comprises, from 5′ to 3′, an Adam6a gene (present in a 3′ to 5′ direction); a neomycin cassette (present in a 3′ to 5′ direction) flanked by FRT sites; an Adam6b gene (present in a 3′ to 5′ direction); Intergenic Control Region 1 (IGCR1; a key V(D)J recombination regulatory region); and a spectinomycin cassette (present in a 5′ to 3′ direction) (4.
  • IGCR1 Intergenic Control Region 1
  • V(D)J recombination regulatory region a spectinomycin cassette
  • BHR (Cm+Kan)); and (B) targeting the genomic locus of the VI444 BAC clone containing the Adam6a and 6b genes into the upstream of the universal heavy chain (UHC) genomic locus of the VI443 BAC clone between the I-CeuI and the AscI sites via restriction digestion and ligation (5. I-CeuI/AscI ligation (Hyg+Kan)).
  • FIG. 4 illustrates schemes for (A) targeting the final construct (MAID6031 BAC DNA) into ES cells isolated from the 1661 heterozygous mouse; and shows (B) the genomic location of the probes and primers used in the screening assays.
  • FIG. 5 shows a list of antibodies in the ASAP database of Regeneron Pharmaceuticals that contain CDR3 sequences similar to the UHC CDR3 sequence (AK DYSNY YFDY; SEQ ID NO: 143).
  • FIG. 6 illustrates the genomic organization of the 6031 bacterial artificial chromosome (BAC) DNA and 6031 heterozygous ES cells, and the genomic location of the primers and probes used in the screening assays.
  • BAC bacterial artificial chromosome
  • FIG. 7 shows a list of primers and probes used to confirm a loss of allele (LOA), a gain of allele (GOA), or a parental allele (parental) in the screening assays.
  • LOA loss of allele
  • GOA gain of allele
  • parental parental allele
  • FIG. 8 shows sequences of primers and probes used in the screening assays.
  • FIG. 9 illustrates the genomic structure of the immunoglobulin heavy chain locus of genetically modified F0 mice, which contains one copy of the targeted allele (including the Adam6a/6b genes and the rearranged human immunoglobulin heavy chain variable region nucleotide sequence (hV H 3-23(D)J H 4;).
  • MAID 6031 het a heterozygous F0 mouse comprising a genetically modified immunoglobulin heavy chain locus with a selection cassette
  • MAID 6032 het a heterozygous F0 mouse comprising a genetically modified immunoglobulin heavy chain locus without a selection cassette.
  • FIG. 10 shows the result of fluorescence-activated cell sorting (FACS) analysis of the bone marrow cells isolated from a wild type or 6032 heterozygous mouse.
  • Upper Panel Bone marrow cells isolated from a wild type or an F0 6032 heterozygous mouse were gated on singlets and sorted based on CD19 expression (a B cell marker) and CD3 expression (a T cell marker).
  • CD19+-gated B cells were sorted based on the presence of IgM b antibodies (antibodies produced from a wild type allele; B6 allele) or IgM a antibodies (antibodies produced from the genetically modified allele (129 allele) encoding a rearranged heavy chain variable domain (hV H 3-23(D)J H 4).
  • FIG. 11 shows the result of FACS analysis of the spleen cells isolated from a wild type or 6032 heterozygous mouse.
  • Upper Panel Spleen cells isolated from a wild type or F0 6032 heterozygous mouse were gated on singlets and sorted based on CD19 expression (a B cell marker) and CD3 expression (a T cell marker).
  • Lower Panel CD19+-gated B cells were sorted based on the presence of IgM b antibodies (antibodies produced from a wild type allele; B6 allele) or IgM a antibodies (antibodies produced from the genetically modified allele (129 allele) encoding a rearranged heavy chain variable domain (hV H 3-23(D)J H 4).
  • FIG. 12 shows the result of FACS analysis of the blood cells isolated from a wild type or 6032 heterozygous mouse.
  • Upper Panel Blood cells isolated from a wild type or F0 6032 heterozygous mouse were gated on singlets and sorted based on CD19 expression (a B cell marker) and CD3 expression (a T cell marker).
  • Lower Panel CD19+-gated B cells were sorted based on the presence of IgM b antibodies (antibodies produced from a wild type allele; B6 allele) or IgM a antibodies (antibodies produced from the genetically modified allele (129 allele) encoding a rearranged heavy chain variable domain (hV H 3-23(D)J H 4).
  • FIG. 13A shows the results of FACS analysis for the total number of CD19+ B cells immature B cells (CD19+IgD int IgMhi) and mature B cells (CD19+IgM lo IgG hi ) in harvested spleens from wild type mice (WT) and mice homozygous (6032HO) for a rearranged human immunoglobulin variable region nucleotide sequence (V H 3-23/D/J H 4).
  • Upper Panel Spleen cells isolated from a wild type or F2 6032 homozygous mouse were gated on singlets and sorted based on CD19 expression (a B cell marker) and CD3 expression (a T cell marker).
  • the bottom panel shows representative contour plots of splenocytes gated on CD19+ and stained for immunoglobulin D (IgD) and immunoglobulin M (IgM) from a wild type mouse (WT) and a mouse homozygous for a rearranged heavy chain human immunoglobulin variable region nucleotide sequence (V H 3-23/D/J H 4). Percentage of cells within each gated region is shown.
  • IgD immunoglobulin D
  • IgM immunoglobulin M
  • FIG. 13B shows the total number of B cells (CD19+), mature B cells (CD19+IgD hi IgM lo ) and immature B cells (CD19+IgD int IgM hi ) in harvested spleens from wild type (WT) and mice homozygous for a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (V H 3-23/D/J H 4).
  • FIG. 13C shows representative contour plots of Ig ⁇ + and Ig ⁇ + splenocytes gated on CD19+ from a wild type mouse (WT) and a mouse (6032HO) homozygous for a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (V H 3-23/D/J H 4).
  • FIG. 13D shows the total number of B cells (CD19+), Ig ⁇ + B cells (CD19+Igkappa+) and Ig ⁇ + B cells (CD19+Iglambda+) in harvested spleens from wild type (WT) and mice homozygous for a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (V H 3-23/D/J H 4).
  • FIG. 13E shows the peripheral B cell development in a wild type mouse and mice homozygous for a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (V H 3-23/D/J H 4).
  • the first column (left) of contour plots show CD93+ and B220+ splenocytes gated on CD19+ indicating immature and mature B cells.
  • the second column (middle) of contour plot shows IgM+ and CD23+ expression in immature B cells indicating T1 (IgD ⁇ IgM+CD21 lo CD23 ⁇ ), T2 (IgD hi IgM hi CD21 mid CD23+) and T3 B cell populations.
  • the third column (right) of contour plots shows CD21+ (CD35+) and IgM+ expression of mature B cells indicating a smaller first population that give rise to marginal zone B cells and a second population that gives rise to follicular (FO) B cells. Percentage of cells within each gated region is shown.
  • FIG. 14A shows representative contour plots of bone marrow stained for B and T cells (CD19+ and CD3+, respectively) from a wild type mouse (WT) and a mouse homozygous for a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (V H 3-23/D/J H 4).
  • FIG. 14B shows the absolute number of cells (left), the total number of cells (middle) and the total number of B (CD19+) cells (right) in bone marrow isolated from the femurs of wild type mice (WT) and mice homozygous for rearranged human immunoglobulin heavy chain variable region nucleotide sequence (V H 3-23/D/J H 4).
  • FIG. 14C shows representative contour plots of bone marrow gated on singlets stained for immunoglobulin M (IgM) and B220 from a wild type mouse (WT) and a mouse homozygous for a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (V H 3-23/D/J H 4). Immature, mature and pro/pre B cells are noted on each of the contour plots.
  • IgM immunoglobulin M
  • WT wild type mouse
  • V H 3-23/D/J H 4 a rearranged human immunoglobulin heavy chain variable region nucleotide sequence
  • FIG. 14D shows the total number and mature B (B220 hi IgM+) and immature B (B220 int IgM+) cells in bone marrow isolated from the femurs of wild type mice (WT) and mice homozygous for a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (V H 3-23/D/J H 4).
  • FIG. 14E shows representative contour plots of bone marrow gated on singlets stained for immunoglobulin M (IgM) and B220 from a wild type mouse (WT) and mice homozygous for a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (V H 3-23/D/J H 4). Immature, mature and pro/pre B cells are noted on each of the contour plots.
  • IgM immunoglobulin M
  • WT wild type mouse
  • V H 3-23/D/J H 4 rearranged human immunoglobulin heavy chain variable region nucleotide sequence
  • FIG. 14F shows representative contour plots of bone marrow gated on immature (B220 int IgM+) and mature (B220 hi IgM+) B cells stained for Ig ⁇ and Ig ⁇ expression isolated from the femurs of a wild type mouse (WT) and mice homozygous for a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (V H 3-23/D/J H 4).
  • FIG. 15 shows the levels of antigen-specific mIgGs in the mouse sera (Wild type or 6031 HET F0 and F1) at Day 15 and Day 24 following footpad immunization.
  • FIG. 16 shows codon-optimized nucleotide sequence and deduced amino acid sequence of hV H 3-23(D4-4_Reading Frame 3)J H 6 (SEQ ID NO: 145).
  • FIG. 17 shows codon-optimized nucleotide sequence and deduced amino acid sequence of hV H 3-23(D4-4_Reading Frame 2)J H 6 (SEQ ID NO: 146).
  • FIG. 18 shows codon-optimized nucleotide sequence and deduced amino acid sequence of hV H 3-23(D4-4_Reading Frame 3)J H 4 (SEQ ID NO: 147).
  • FIG. 19 shows codon-optimized nucleotide sequence and deduced amino acid sequence of hV H 3-23(D4-4_Reading Frame 2)J H 4 (SEQ ID NO: 148).
  • FIG. 20 shows examples of two genetically modified dual light chain (DLC) loci.
  • the locus on the top (DLC-5J) contains an engineered human DNA fragment containing two human V ⁇ gene segments and five human J ⁇ gene segments.
  • the locus on the bottom (DLC-1J) contains an engineered human DNA fragment containing two human V ⁇ gene segments and one human J ⁇ gene segment.
  • Each locus is capable of rearranging to form a human V ⁇ region operably linked to an endogenous light chain constant region (e.g., a C ⁇ ).
  • an endogenous light chain constant region e.g., a C ⁇
  • Immunoglobulin promoters (P, open arrow above locus), leader exons (L, short open arrows), and the two human V ⁇ gene segments (long open arrows), all flanked upstream (5′) by a neomycin cassette containing Frt recombination sites are shown.
  • Recombination signal sequences engineered with each of the human gene segments (V ⁇ and J ⁇ ) are indicated by open ovals juxtaposed with each gene segment.
  • filled shapes and solid lines represent mouse sequences
  • open shapes and double lines represent human sequences. The diagrams are not presented to scale.
  • FIGS. 21A-21C show a general strategy for construction of a targeting vector for the engineering of an immunoglobulin kappa locus comprising two human V ⁇ segments (hV ⁇ 1-39 and hV ⁇ 3-20) and one human J ⁇ segment (J ⁇ 5), as well as mouse enhancers and Ig ⁇ C arm.
  • FIG. 21D shows introduction of this targeting vector into ES cells and generation of heterozygous mice with the same; while FIG. 21E shows deletion of the selection cassette in ES cells using FLP enzyme.
  • filled shapes and solid lines represent mouse sequences, and open shapes and double lines represent human sequences. The diagrams are not presented to scale.
  • FIGS. 22A-22D show the nucleotide sequence (SEQ ID NO:82) of the engineered portion of immunoglobulin ⁇ locus comprising two human V ⁇ segments (hV ⁇ 1-39 and hV ⁇ 3-20) and one human J ⁇ segment; the nucleotide sequence spans the engineered human sequence and comprising 100 base pairs of endogenous mouse sequence at both the 5′ and the 3′ end.
  • SEQ ID NO:82 the nucleotide sequence of the engineered portion of immunoglobulin ⁇ locus comprising two human V ⁇ segments (hV ⁇ 1-39 and hV ⁇ 3-20) and one human J ⁇ segment; the nucleotide sequence spans the engineered human sequence and comprising 100 base pairs of endogenous mouse sequence at both the 5′ and the 3′ end.
  • Bottom of FIG. 22D explains different fonts used to depict various sequences.
  • FIGS. 23A-23B show a general strategy for construction of a targeting vector for the engineering of an immunoglobulin kappa locus comprising two human V ⁇ segments (hV ⁇ 1-39 and hV ⁇ 3-20) and five human J ⁇ segments, as well as mouse enhancers and Ig ⁇ C arm.
  • FIG. 23C shows introduction of this targeting vector into ES cells and generation of heterozygous mice with the same; while FIG. 23D shows deletion of the selection cassette in ES cells using FLP enzyme.
  • filled shapes and solid lines represent mouse sequences, and open shapes and double lines represent human sequences. The diagrams are not presented to scale.
  • FIGS. 24A-24D show the nucleotide sequence (SEQ ID NO:83) of the engineered immunoglobulin ⁇ locus comprising two human V ⁇ segments (hV ⁇ 1-39 and hV ⁇ 3-20) and five human J ⁇ segments; the nucleotide sequence spans the engineered sequence and 100 base pairs of endogenous mouse sequence at both the 5′ and the 3′ end. Bottom of FIG. 24D explains different fonts used to depict various sequences.
  • FIG. 25A in the top panel, shows representative contour plots of bone marrow stained for B and T cells (CD19+ and CD3+, respectively) from a wild type mouse (WT) and a mouse homozygous for two human V ⁇ and five human J ⁇ gene segments (DLC-5J).
  • the bottom panel shows representative contour plots of bone marrow gated on CD19+ and stained for ckit+ and CD43+ from a wild type mouse (WT) and a mouse homozygous for two human V ⁇ and five human J ⁇ gene segments (DLC-5J). Pro and Pre B cells are noted on the contour plots of the bottom panel.
  • FIG. 25B shows the number of Pro (CD19+CD43+ckit+) and Pre (CD19+CD43 ⁇ ckit ⁇ ) B cells in bone marrow harvested from the femurs of wild type mice (WT) and mice homozygous for two human V ⁇ and five human J ⁇ gene segments (DLC-5J).
  • FIG. 26A shows representative contour plots of bone marrow gated on singlets stained for immunoglobulin M (IgM) and B220 from a wild type mouse (WT) and a mouse homozygous for two human V ⁇ and five human J ⁇ gene segments (DLC-5J). Immature, mature and pro/pre B cells are noted on each of the contour plots.
  • IgM immunoglobulin M
  • WT wild type mouse
  • DLC-5J human J ⁇ gene segments
  • FIG. 26B shows the total number of B (CD19+), immature B (B220 int IgM+) and mature B (B220 hi IgM+) cells in bone marrow isolated from the femurs of wild type mice (WT) and mice homozygous for two human V ⁇ and five human J ⁇ gene segments (DLC-5J).
  • FIG. 27A shows representative contour plots of bone marrow gated on singlets stained for immunoglobulin M (IgM) and B220 from a wild type mouse (WT) and a mouse homozygous for two human V ⁇ and five human J ⁇ gene segments (DLC-5J). Immature, mature and pro/pre B cells are noted on each of the contour plots.
  • IgM immunoglobulin M
  • WT wild type mouse
  • DLC-5J human J ⁇ gene segments
  • FIG. 27B shows representative contour plots of bone marrow gated on immature (B220 int IgM+) and mature (B220 hi IgM+) B cells stained for Ig ⁇ and Ig ⁇ expression isolated from the femurs of a wild type mouse (WT) and a mouse homozygous for two human V ⁇ and five human J ⁇ gene segments (DLC-5J).
  • FIG. 28A in the top panel, shows representative contour plots of splenocytes gated on singlets and stained for B and T cells (CD19+ and CD3+, respectively) from a wild type mouse (WT) and a mouse homozygous for two human V ⁇ and five human J ⁇ gene segments (DLC-5J).
  • the bottom panel shows representative contour plots of splenocytes gated on CD19+ and stained for immunoglobulin D (IgD) and immunoglobulin M (IgM) from a wild type mouse (WT) and a mouse homozygous for two human V ⁇ and five human J ⁇ gene segments (DLC-5J). Mature (54 for WT, 56.9 for DLC-5J) and transitional (23.6 for WT, 25.6 for DLC-5J) B cells are noted on each of the contour plots.
  • IgD immunoglobulin D
  • IgM immunoglobulin M
  • FIG. 28B shows the total number of CD19+ B cells, transitional B cells (CD19+IgM hi IgDlo) and mature B cells (CD19+IgM lo IgDhi) in harvested spleens from wild type mice (WT) and mice homozygous for two human V ⁇ and five human J ⁇ gene segments (DLC-5J).
  • FIG. 29A shows representative contour plots of Ig ⁇ + and Ig ⁇ + splenocytes gated on CD19+ from a wild type mouse (WT) and a mouse homozygous for two human V ⁇ and five human J ⁇ gene segments (DLC-5J).
  • WT wild type mouse
  • DLC-5J mouse homozygous for two human V ⁇ and five human J ⁇ gene segments
  • FIG. 29B shows the total number of B cells (CD19+), Ig ⁇ + B cells (CD19+I ⁇ +) and Ig ⁇ + B cells (CD19+Ig ⁇ +) in harvested spleens from wild type (WT) and mice homozygous for two human V ⁇ and five human J ⁇ gene segments (DLC-5J).
  • FIG. 30A shows the peripheral B cell development in mice homozygous for two human V ⁇ and five human J ⁇ gene segments.
  • the first (far left) contour plot shows CD93+ and B220+ splenocytes gated on CD19+ indicating immature (39.6) and mature (57.8) B cells.
  • the second (top middle) contour plot shows IgM+ and CD23+ expression in immature B cells indicating T1 (33.7; IgD ⁇ IgM+CD21 lo CD23 ⁇ ), T2 (21.2; IgD hi IgM hi CD21 mid CD23+) and T3 (29.1) B cell populations.
  • the third (bottom middle) contour plot shows CD21+ (CD35+) and IgM+ expression of mature B cells indicating a small population (14.8) which give rise to marginal zone B cells and a second population (70.5) which gives rise to follicular (FO) B cells.
  • the fourth (top right) contour plot shows B220+ and CD23+ expression in mature B cells indicating marginal zone (90.5; MZ) and marginal zone precursor (7.3; IgM hi IgD hi CD21 hi CD23+) B cell populations.
  • the fifth (bottom right) contour plot shows IgD+ and IgM+ expression in mature B cells indicating FO-I (79.0; IgD hi IgM lo CD21 mid CD23+) and FO-II (15.1; IgD hi IgM hi CD21 mid CD23+) B cell populations. Percentage of cells within each gated region is shown.
  • FIG. 30B shows the peripheral B cell development in wild type mice.
  • the first (far left) contour plot shows CD93+ and B220+ splenocytes gated on CD19+ indicating immature (31.1) and mature (64.4) B cells.
  • the second (top middle) contour plot shows IgM+ and CD23+ expression in immature B cells indicating T1 (28.5; IgD ⁇ IgM+CD21 lo CD23 ⁇ ), T2 (28.7; IgD hi IgM hi CD21 mid CD23+) and T3 (30.7) B cell populations.
  • the third (bottom middle) contour plot shows CD21+ (CD35+) and IgM+ expression of mature B cells indicating a small population (7.69) which give rise to marginal zone B cells and a second population (78.5) which gives rise to follicular (FO) B cells.
  • the fourth (top right) contour plot shows B220+ and CD23+ expression in mature B cells indicating marginal zone (79.9; MZ) and marginal zone precursor (19.4; IgM hi IgD hi CD21 hi CD23+) B cell populations.
  • the fifth (bottom right) contour plot shows IgD+ and IgM+ expression in mature B cells indicating FO-I (83.6; IgD hi IgM lo CD21 mid CD23+) and FO-II (13.1; IgD hi IgM hi CD21 mid CD23+) B cell populations. Percentage of cells within each gated region is shown.
  • FIG. 31 shows the total number of transitional, marginal zone and follicular B cell populations in harvested spleens of wild-type (WT) and mice homozygous for two human V ⁇ and five human J ⁇ gene segments (DLC-5J).
  • FIG. 32 shows the relative mRNA expression in bone marrow (y-axis) of V ⁇ 3-20-derived and V ⁇ 1-39-derived light chains in a quantitative PCR assay using probes specific for V ⁇ 3-20 or V ⁇ 1-39 gene segments in mice homozygous for a replacement of the endogenous V ⁇ and J ⁇ gene segments with human V ⁇ and J ⁇ gene segments (H ⁇ ) (human light chain of a VELOCIMMUNE® mouse), wild type mice (WT), mice homozygous for two human V ⁇ gene segments and five human J ⁇ gene segments (DLC-5J) and mice homozygous for two human V ⁇ gene segments and one human J ⁇ gene segment (DLC-1J). Signals are normalized to expression of mouse C ⁇ . ND: not detected.
  • FIG. 33 shows the relative mRNA expression in whole spleens (y-axis) of V ⁇ 3-20-derived and V ⁇ 1-39-derived light chains in a quantitative PCR assay using probes specific for V ⁇ 3-20 or V ⁇ 1-39 gene segments in mice homozygous for a replacement of the endogenous V ⁇ and J ⁇ gene segments with human V ⁇ and J ⁇ gene segments (HK) (human light chain of a VELOCIMMUNE® mouse), wild type mice (WT), mice homozygous for two human V ⁇ gene segments and five human J ⁇ gene segments (DLC-5J) and mice homozygous for two human V ⁇ gene segments and one human J ⁇ gene segment (DLC-1J). Signals are normalized to expression of mouse C ⁇ . ND: not detected.
  • FIG. 35A shows introduction of a targeting vector comprising two human V ⁇ light chain segments each substituted with four histidine residues and five human J ⁇ into ES cells and generation of heterozygous mice with the same; while FIG. 35B shows deletion of the selection cassette in ES cells using FLPo enzyme.
  • filled shapes and solid lines represent mouse sequences, and open shapes and double lines represent human sequences. The diagrams are not presented to scale.
  • FIG. 37A shows introduction of a targeting vector comprising two human V ⁇ light chain segments each substituted with three histidine residues and five human J ⁇ into ES cells and generation of heterozygous mice with the same; while FIG. 37B shows deletion of the selection cassette in ES cells using FLPo enzyme.
  • filled shapes and solid lines represent mouse sequences, and open shapes and double lines represent human sequences. The diagrams are not presented to scale.
  • FIG. 38A shows alignment of amino acid sequence encoded by human germline V ⁇ 3-20 sequence (bottom sequence) with exemplary amino acid translation of IgM light kappa chain variable sequence expressed in a mouse comprising two V kappa segments (V ⁇ 3-20 and V ⁇ 1-39), each substituted with 3 histidine residues in CDR3 sequence (top sequence); the alignment shows IgM kappa chain variable sequence expressed in a mouse that retained all three histidine substitutions introduced into the germline sequence.
  • FIG. 38A shows alignment of amino acid sequence encoded by human germline V ⁇ 3-20 sequence (bottom sequence) with exemplary amino acid translation of IgM light kappa chain variable sequence expressed in a mouse comprising two V kappa segments (V ⁇ 3-20 and V ⁇ 1-39), each substituted with 3 histidine residues in CDR3 sequence (top sequence); the alignment shows IgM kappa chain variable sequence expressed in a mouse that retained all three histidine substitutions introduced into the germline sequence.
  • FIG. 38A shows alignment of amino
  • 38B shows alignment of amino acid sequence encoded by human germline V ⁇ 1-39 sequence (bottom sequence in each alignment) with exemplary amino acid translation of IgM light kappa chain variable sequence expressed in a mouse comprising two V kappa segments (V ⁇ 3-20 and V ⁇ 1-39), each substituted with 3 histidine residues in CDR3 sequence (top sequence in each alignment); top alignment shows IgM kappa chain variable sequence expressed in a mouse that retained all three histidine modifications introduced into the germline sequence, the bottom alignment shows IgM kappa chain variable sequence expressed in a mouse that retained two out of three histidine modifications introduced into the germline sequence.
  • histidine introduced into the last position of the V ⁇ may be lost during V-J rearrangement.
  • FIG. 39 illustrates the genomic structure of genetically modified F2 mice comprising rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci (MAID6032; “UHC mouse”) and further comprising genetically engineered light chain loci containing two human V ⁇ gene segments (e.g., a human V ⁇ 1-39 and human V ⁇ 3-20 gene segment) and five human J ⁇ gene segments (hJ ⁇ 1-5; DLC-5J) (MAID 1912HO).
  • MAID6032 rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci
  • UHC mouse genetically engineered light chain loci containing two human V ⁇ gene segments (e.g., a human V ⁇ 1-39 and human V ⁇ 3-20 gene segment) and five human J ⁇ gene segments (hJ ⁇ 1-5; DLC-5J)
  • FIG. 40A in the top panel, shows representative contour plots of splenocytes gated on singlets and stained for B and T cells (CD19 + and CD3 + , respectively) from genetically modified control mice (VI3; 1293HO 1460HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci and two human V ⁇ and five human J ⁇ gene segments in the light chain loci (MAID 1912HO 6032 HO; DLC ⁇ UHC).
  • the bottom panel shows representative contour plots of splenocytes gated on CD19 + and stained for immunoglobulin D (IgD) and immunoglobulin M (IgM) from genetically modified control mice (VI3; 1293HO 1460HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci and two human V ⁇ and five human J ⁇ gene segments in the light chain loci (MAID 1912HO 6032 HO; DLC ⁇ UHC). Mature and immature B cells are noted on each of the contour plots.
  • IgD immunoglobulin D
  • IgM immunoglobulin M
  • FIG. 40B shows the total number of CD19 + B cells, mature B cells (CD19 + IgM lo IgD hi ) and immature B cells (CD19 + IgM hi IgD int ) in harvested spleens from genetically modified control mice (VI3; 1293HO 1460HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci and two human V ⁇ and five human J ⁇ gene segments in the light chain loci (MAID 1912HO 6032 HO; DLC ⁇ UHC).
  • FIG. 41A shows representative contour plots of Ig ⁇ + and Ig ⁇ + splenocytes gated on CD19 + from genetically modified control mice (VI3; 1293HO 1460HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci and two human V ⁇ and five human J ⁇ gene segments in the light chain loci (MAID 1912HO 6032 HO; DLC ⁇ UHC).
  • FIG. 41B shows the total number of B cells (CD19 + ), Ig ⁇ + B cells (CD19 + Ig ⁇ + ) and Ig ⁇ + B cells (CD19 + Ig ⁇ + ) in harvested spleens from genetically modified control mice (VI3; 1293HO 1460HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci and two human V ⁇ and five human J ⁇ gene segments in the light chain loci (MAID 1912HO 6032 HO; DLC ⁇ UHC).
  • FIG. 42 shows flow cytometric analyses of IgM surface expression on B cells in harvested spleens from genetically modified control mice (VI3; 1293HO 1460HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci and two human V ⁇ and five human J ⁇ gene segments in the light chain loci (MAID 1912HO 6032 HO; DLC ⁇ UHC). Cells were stained with fluorescent (PE-Cy7 conjugated) antibody against IgM.
  • FIG. 43A shows the peripheral B cell development in genetically modified control mice (VI3; 1293HO 1460HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci and two human V ⁇ and five human J ⁇ gene segments in the light chain loci (MAID 1912HO 6032 HO; DLC ⁇ UHC).
  • the first (far left) contour plot shows CD93 + and B220 + splenocytes gated on CD19 + indicating immature and mature B cells.
  • the second (middle) contour plot shows IgM + and CD23 + expression in immature B cells indicating T1 (IgD ⁇ IgM + CD21 lo CD23 ⁇ ), T2 (IgD hi IgM hi CD21 mid CD23 + ) and T3 B cell populations.
  • the third (right) contour plot shows CD21 + (CD35 + ) and IgM + expression of mature B cells indicating first smaller populations which give rise to marginal zone B cells and second larger populations which gives rise to follicular (FO) B cells. Percentage of cells within each gated region is shown.
  • FIG. 43B shows the peripheral B cell development in genetically modified control mice (VI3; 1293HO 1460HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci and two human V ⁇ and five human J ⁇ gene segments in the light chain loci (MAID 1912HO 6032 HO; DLC ⁇ UHC).
  • the first (left) contour plot shows CD21 + (CD35 + ) and IgM + expression of mature B cells indicating a small population which give rise to marginal zone B cells and a second population which gives rise to follicular (FO) B cells.
  • the second (middle) contour plot shows B220 + and CD23 + expression in mature B cells indicating marginal zone (MZ) and marginal zone precursor (IgM hi IgD hi CD21 hi CD23 + ) B cell populations.
  • the third (right) contour plot shows IgD + and IgM + expression in mature B cells indicating FO-I (IgD hi IgM int CD21 int CD23 + ) and FO-II (IgD hi IgM int CD21 int CD23 + ) B cell populations. Percentage of cells within each gated region is shown.
  • FIG. 44A shows representative contour plots of bone marrow stained for B and T cells (CD19 + and CD3 + , respectively) from a genetically modified control mouse (VI3; 1293HO 1460HO) and a mouse homozygous for a rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci and two human V ⁇ and five human J ⁇ gene segments in the light chain loci (MAID 1912HO 6032 HO; DLC ⁇ UHC).
  • FIG. 44B shows the percentage of lymphocytes, total number of cells/femur and number of CD19+ B cells in bone marrow harvested from the femurs of genetically modified control mice (VI3; 1293HO 1460HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci and two human V ⁇ and five human J ⁇ gene segments in the light chain loci (MAID 1912HO 6032 HO; DLC ⁇ UHC).
  • FIG. 45A shows representative contour plots of bone marrow gated on CD19 + and stained for ckit + and CD43 + from a genetically modified control mouse (VI3; 1293HO 1460HO) and a mouse homozygous for a rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci and two human V ⁇ and five human J ⁇ gene segments in the light chain loci (MAID 1912HO 6032 HO; DLC ⁇ UHC). Pro and Pre B cells are noted on the contour plots.
  • FIG. 45B shows the number of Pre (CD19 + CD43 ⁇ ckit ⁇ ) and Pro (CD19 + CD43 + ckit + ) B cells in bone marrow harvested from the femurs of genetically modified control mice (VI3; 1293HO 1460HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci and two human V ⁇ and five human J ⁇ gene segments in the light chain loci (MAID 1912HO 6032HO; DLC ⁇ UHC).
  • FIG. 46A shows representative contour plots of bone marrow gated on singlets stained for immunoglobulin M (IgM) and B220 from a genetically modified control mouse (VI3; 1293HO 1460HO) and a mouse homozygous for a rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci and two human V ⁇ and five human J ⁇ gene segments in the light chain loci (MAID 1912HO 6032 HO; DLC ⁇ UHC). Immature, mature and pro/pre B cells are noted on each of the contour plots.
  • FIG. 46B shows the total number cell/femur, immature B (B220 int IgM + ) and mature B (B220 hi IgM + ) cells in bone marrow isolated from the femurs of genetically modified control mice (VI3; 1293HO 1460HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci and two human V ⁇ and five human J ⁇ gene segments in the light chain loci (MAID 1912HO 6032 HO; DLC ⁇ UHC).
  • FIG. 47 shows representative contour plots of bone marrow gated on immature (B220 int IgM + ) and mature (B220 hi IgM + ) B cells stained for Ig ⁇ and Ig ⁇ expression isolated from the femurs of a genetically modified control mouse (VI3; 1293HO 1460HO) and a mouse homozygous for a rearranged heavy chain variable region nucleic acid sequence in the heavy chain loci and two human V ⁇ and five human J ⁇ gene segments in the light chain loci (MAID 1912HO 6032 HO; DLC ⁇ UHC).
  • FIG. 48 shows the levels of antigen-specific mIgGs in the mouse sera (Wild type or 1912HO 6031 HET (homozygous DLC ⁇ heterozygous UHC)) before footpad immunization, 23 days following a 1 st round of footpad immunization, 5 weeks following the 1 st round of footpad immunization, and after a 2 nd round of footpad immunization.
  • FIG. 49 illustrates the genomic structure of genetically modified F1 mice containing a rearranged heavy chain variable region nucleic acid sequences in the kappa light chain loci (i.e., a rearranged heavy chain VDJ sequence operably linked to a kappa light chain constant nucleic acid sequence).
  • FIG. 50A in the top panel shows representative contour plots of bone marrow stained for B and T cells (CD19 + and CD3 + , respectively) from a wild type mouse (WT) and a mouse homozygous for a rearranged heavy chain variable region nucleic acid sequence (hV H 3-23/D/J H 4) in the kappa light chain locus.
  • the bottom panel shows representative contour plots of bone marrow gated on CD19 + and stained for ckit + and CD43 + from a wild type mouse (WT) and a mouse homozygous for a rearranged heavy chain variable region nucleic acid sequence (hV H 3-23/D/J H 4) in the kappa light chain locus.
  • Pro and Pre B cells are noted on the contour plots of the bottom panel.
  • FIG. 50B shows the number of Pro (CD19 + CD43 + ckit + ) and Pre (CD19 + CD43 ⁇ ckit ⁇ ) B cells in bone marrow harvested from the femurs of wild type mice (WT) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence (hV H 3-23/D/J H 4) in the kappa light chain locus.
  • FIG. 51A shows representative contour plots of bone marrow gated on singlets stained for immunoglobulin M (IgM) and B220 from a wild type mouse (WT) and a mouse homozygous for a rearranged heavy chain variable region nucleic acid sequence (hV H 3-23/D/J H 4) in the kappa light chain locus. Immature, mature and pro/pre B cells are noted on each of the contour plots.
  • IgM immunoglobulin M
  • WT wild type mouse
  • hV H 3-23/D/J H 4 a rearranged heavy chain variable region nucleic acid sequence
  • FIG. 51B shows the total number of B (CD19 + ) and pro/pre B (IgM ⁇ B220 + ) cells in bone marrow isolated from the femurs of wild type mice (WT) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence (hV H 3-23/D/J H 4) in the kappa light chain locus.
  • FIG. 51C shows the number of immature B (B220 int IgM + ) and mature B (B220 hi IgM + ) cells in bone marrow isolated from the femurs of wild type mice (WT) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence (hV H 3-23/D/J H 4) in the kappa light chain locus.
  • FIG. 52 shows representative contour plots of bone marrow gated on immature (B220 int IgM + ) and mature (B220 hi IgM + ) B cells stained for Ig ⁇ and Ig ⁇ expression isolated from the femurs of wild type mice (WT) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence (hV H 3-23/D/J H 4) in the kappa light chain locus.
  • FIG. 53A in the top panel, shows representative contour plots of splenocytes gated on singlets and stained for B and T cells (CD19 + and CD3 + , respectively) from a wild type mouse (WT) and a mouse homozygous for a rearranged heavy chain variable region nucleic acid sequence (hV H 3-23/D/J H 4) in the kappa light chain locus.
  • WT wild type mouse
  • hV H 3-23/D/J H 4 a rearranged heavy chain variable region nucleic acid sequence
  • the bottom panel shows representative contour plots of splenocytes gated on CD19 + and stained for immunoglobulin D (IgD) and immunoglobulin M (IgM) from a wild type mouse (WT) and a mouse homozygous for a rearranged heavy chain variable region nucleic acid sequence (hV H 3-23/D/J H 4) in the kappa light chain locus.
  • WT wild type mouse
  • hV H 3-23/D/J H 4 a rearranged heavy chain variable region nucleic acid sequence
  • Mature (56.9 for WT, 43 for hV H 3-23/D/J H 4 on kappa) and transitional (26.8 for WT, 34 for hV H 3-23/D/J H 4 on kappa) B cells are noted on each of the contour plots.
  • FIG. 53B shows the total number of CD19 + B cells, mature B cells (CD19 + IgM lo IgD hi ) and transitional B cells (CD19 + IgM hi IgD int ) in harvested spleens from wild type mice (WT) and mice homozygous a rearranged heavy chain variable region nucleic acid sequence (hV H 3-23/D/J H 4) in the kappa light chain locus.
  • FIG. 54A shows representative contour plots of Ig ⁇ + and Ig ⁇ + splenocytes gated on CD19 + from a wild type mouse (WT) and a rearranged heavy chain variable region nucleic acid sequence (hV H 3-23/D/J H 4) in the kappa light chain locus.
  • FIG. 54B shows the total number of B cells (CD19 + ), Ig ⁇ B cells (CD19 + Ig ⁇ + ) and Ig ⁇ + B cells (CD19 + Ig ⁇ + ) in harvested spleens from wild type (WT) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence (hV H 3-23/D/J H 4) in the kappa light chain locus.
  • FIG. 55 shows the peripheral B cell development in the splenic compartment of mice homozygous for a rearranged heavy chain variable region nucleic acid sequence (hV H 3-23/D/J H 4) in the kappa light chain locus compared to wild type mice.
  • the first (left) contour plot shows CD93 + and B220 + splenocytes gated on CD19 + indicating immature and mature B cells.
  • the second (middle) contour plot shows IgM + and CD23 + expression in immature B cells indicating T1, T2 and T3 B cell populations.
  • the third (right) contour plot shows CD21 + (CD35 + ) and IgM + expression of mature B cells indicating a first smaller population that give rise to marginal zone B cells and a second larger population that gives rise to follicular (FO) B cells. Percentage of cells within each gated region is shown.
  • FIG. 56 illustrates the genomic structure of genetically modified F2 mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the kappa light chain locus (MAID 6079HO; homozygous “UHC on kappa mouse”) and homozygous for a kappa light chain variable region nucleic acid sequence in a heavy chain locus (MAID 1994HO; kappa on heavy (“KoH”) mouse).
  • FIG. 57A in the top panel shows representative contour plots of bone marrow stained for B and T cells (CD19 + and CD3 + , respectively) from a VELOCIMMUNE® (VI3) and a mouse homozygous for a rearranged heavy chain variable region nucleic acid sequence in the kappa light chain locus and homozygous for a kappa light chain variable region nucleic acid sequence in a heavy chain locus.
  • VI3 VELOCIMMUNE®
  • the bottom panel shows representative contour plots of bone marrow gated on CD19 + and stained for ckit + and CD43 + from a VELOCIMMUNE® (VI3) and a mouse homozygous for a rearranged heavy chain variable region nucleic acid sequence in the kappa light chain locus and homozygous for a kappa light chain variable region nucleic acid sequence in a heavy chain locus.
  • Pro and Pre B cells are noted on the contour plots of the bottom panel.
  • FIG. 57B shows the total number of B cells (CD19 + ) and the numbers of Pro (CD19 + CD43 + ckit + ) and Pre (CD19 + CD43 ⁇ ckit ⁇ ) B cells in bone marrow harvested from the femurs of VELOCIMMUNE® mice (1242HO 1640HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the kappa light chain locus and homozygous for a kappa light chain variable region nucleic acid sequence in a heavy chain locus (1994HO 6079HO). Numbers are presented as both absolute number of cells per femur and cell percentage.
  • FIG. 58A shows representative contour plots of bone marrow gated on singlets stained for immunoglobulin M (IgM) and B220 from a VELOCIMMUNE® mouse (1242HO 1640HO) and a mouse homozygous for a rearranged heavy chain variable region nucleic acid sequence in the kappa light chain locus and homozygous for a kappa light chain variable region nucleic acid sequence in a heavy chain locus (1994HO 6079HO). Immature, mature and pro/pre B cells are noted on each of the contour plots.
  • FIG. 58B shows the number of immature B (B220 int IgM + ) and mature B (B220 hi IgM + ) cells in bone marrow isolated from the femurs of VELOCIMMUNE® mice (1242HO 1640HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the kappa light chain locus and homozygous for a kappa light chain variable region nucleic acid sequence in a heavy chain locus (1994HO 6079HO). Numbers are presented as both absolute number of cells per femur and cell percentage.
  • FIG. 59 shows representative contour plots of bone marrow gated on immature (B220 int IgM + ) and mature (B220 hi IgM + ) B cells stained for Ig ⁇ and Ig ⁇ expression isolated from the femurs of VELOCIMMUNE® mice (1242HO 1640HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the kappa light chain locus and homozygous for a kappa light chain variable region nucleic acid sequence in a heavy chain locus (1994HO 6079HO).
  • FIG. 60A shows representative contour plots of splenocytes gated on CD19 + and stained for immunoglobulin D (IgD) and immunoglobulin M (IgM) from a VELOCIMMUNE® mouse (VI3; 1242HO 1640HO) and a mouse homozygous for a rearranged heavy chain variable region nucleic acid sequence in the kappa light chain locus and homozygous for a kappa light chain variable region nucleic acid sequence in a heavy chain locus (1994HO 6079HO). Mature and transitional/immature B cells are noted on each of the contour plots.
  • IgD immunoglobulin D
  • IgM immunoglobulin M
  • FIG. 60B shows the total number of CD19 + B cells, mature B cells (CD19 + IgM lo IgD hi ) and transitional B cells (CD19 + IgM hi IgD lo ) in harvested spleens from VELOCIMMUNE® mice (1242HO 1640HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the kappa light chain locus and homozygous for a kappa light chain variable region nucleic acid sequence in a heavy chain locus (1994HO 6079HO).
  • FIG. 61 shows the total number of B cells (CD19 + ), Ig ⁇ + B cells (CD19 + Ig ⁇ + ) and Ig ⁇ + B cells (CD19 + Ig ⁇ + ) in harvested spleens from VELOCIMMUNE® mice (1242HO 1640HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the kappa light chain locus and homozygous for a kappa light chain variable region nucleic acid sequence in a heavy chain locus (1994HO 6079HO). Numbers are presented as both absolute cell number and cell percentage of lymphocytes.
  • FIG. 62 shows the peripheral B cell development in the splenic compartment of VELOCIMMUNE® mice (1242HO 1640HO) and mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the kappa light chain locus and homozygous for a kappa light chain variable region nucleic acid sequence in a heavy chain locus (1994HO 6079HO).
  • the top contour plot shows CD93 + and B220 + splenocytes gated on CD19 + indicating immature and mature B cells.
  • the bottom contour plot shows IgM + and CD23 + expression in immature B cells indicating T1, T2 and T3 B cell populations. Percentage of cells within each gated region is shown.
  • antibody includes immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds.
  • Each heavy chain comprises a heavy chain variable domain and a heavy chain constant region (C H ).
  • the heavy chain constant region comprises three domains, C H 1, C H 2 and C H 3.
  • Each light chain comprises a light chain variable domain and a light chain constant region (C L ).
  • the heavy chain and light chain variable domains can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
  • CDR complementarity determining regions
  • Each heavy and light chain variable domain comprises three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (heavy chain CDRs may be abbreviated as HCDR1, HCDR2 and HCDR3; light chain CDRs may be abbreviated as LCDR1, LCDR2 and LCDR3).
  • the term “high affinity” antibody refers to an antibody that has a K D with respect to its target epitope about of 10 ⁇ 9 M or lower (e.g., about 1 ⁇ 10 ⁇ 9 M, 1 ⁇ 10 ⁇ 10 M, 1 ⁇ 10 ⁇ 11 M, or about 1 ⁇ 10 ⁇ 12 M).
  • K D is measured by surface plasmon resonance, e.g., BIACORETM; in another embodiment, K D is measured by ELISA.
  • bispecific antibody includes an antibody capable of selectively binding two or more epitopes.
  • Bispecific antibodies generally comprise two nonidentical heavy chains, with each heavy chain specifically binding a different epitope—either on two different molecules (e.g., different epitopes on two different immunogens) or on the same molecule (e.g., different epitopes on the same immunogen). If a bispecific antibody is capable of selectively binding two different epitopes (a first epitope and a second epitope), the affinity of the first heavy chain for the first epitope will generally be at least one to two or three or four or more orders of magnitude lower than the affinity of the first heavy chain for the second epitope, and vice versa.
  • bispecific antibodies can be on the same or a different target (e.g., on the same or a different protein).
  • exemplary bispecific antibodies include those with a first heavy chain specific for a tumor antigen and a second heavy chain specific for a cytotoxic marker, e.g., an Fc receptor (e.g., Fc ⁇ RI, Fc ⁇ RII, Fc ⁇ RIII, etc.) or a T cell marker (e.g., CD3, CD28, etc.).
  • the second heavy chain variable domain can be substituted with a heavy chain variable domain having a different desired specificity.
  • a bispecific antibody with a first heavy chain specific for a tumor antigen and a second heavy chain specific for a toxin can be paired so as to deliver a toxin (e.g., saporin, vinca alkaloid, etc.) to a tumor cell.
  • a toxin e.g., saporin, vinca alkaloid, etc.
  • Other exemplary bispecific antibodies include those with a first heavy chain specific for an activating receptor (e.g., B cell receptor, Fc ⁇ RI, Fc ⁇ RIIA, Fc ⁇ RIIIA, Fc ⁇ RI, T cell receptor, etc.) and a second heavy chain specific for an inhibitory receptor (e.g., Fc ⁇ RIIB, CD5, CD22, CD72, CD300a, etc.).
  • bispecific antibodies can be constructed for therapeutic conditions associated with cell activation (e.g. allergy and asthma).
  • Bispecific antibodies can be made, for example, by combining heavy chains that recognize different epitopes of the same immunogen.
  • nucleic acid sequences encoding heavy chain variable sequences that recognize different epitopes of the same immunogen can be fused to nucleic acid sequences encoding the same or different heavy chain constant regions, and such sequences can be expressed in a cell that expresses an immunoglobulin light chain.
  • a typical bispecific antibody has two heavy chains each having three heavy chain CDRs, followed by (N-terminal to C-terminal) a C H 1 domain, a hinge, a C H 2 domain, and a C H 3 domain, and an immunoglobulin light chain that either does not confer epitope-binding specificity but that can associate with each heavy chain, or that can associate with each heavy chain and that can bind one or more of the epitopes bound by the heavy chain epitope-binding regions, or that can associate with each heavy chain and enable binding of one or both of the heavy chains to one or both epitopes.
  • the term “trispecific antibody” includes an antibody capable of selectively binding three or more epitopes.
  • cell includes any cell that is suitable for expressing a recombinant nucleic acid sequence.
  • Cells include those of prokaryotes and eukaryotes (single-cell or multiple-cell), bacterial cells (e.g., strains of E. coli, Bacillus spp., Streptomyces spp., etc.), mycobacteria cells, fungal cells, yeast cells (e.g., S. cerevisiae, S. pombe, P. pastoris, P.
  • the cell is a human, monkey, ape, hamster, rat, or mouse cell.
  • the cell is eukaryotic and is selected from the following cells: CHO (e.g., CHO K1, DXB-11 CHO, Veggie-CHO), COS (e.g., COS-7), retinal cell, Vero, CV1, kidney (e.g., HEK293, 293 EBNA, MSR 293, MDCK, HaK, BHK), HeLa, HepG2, WI38, MRC 5, Colo205, HB 8065, HL-60, (e.g., BHK21), Jurkat, Daudi, A431 (epidermal), CV-1, U937, 3T3, L cell, C127 cell, SP2/0, NS-0, MMT 060562, Sertoli cell, BRL 3A cell, HT1080 cell, myeloma cell, tumor cell, and a cell line derived from an aforementioned cell.
  • the cell comprises one or more viral genes, e.g. a retinal cell that expresses a viral gene
  • CDR complementarity determining region
  • a CDR includes an amino acid sequence encoded by a nucleic acid sequence of an organism's immunoglobulin genes that normally (i.e., in a wild-type animal) appears between two framework regions in a variable region of a light or a heavy chain of an immunoglobulin molecule (e.g., an antibody or a T cell receptor).
  • a CDR can be encoded by, for example, a germline sequence or a rearranged or unrearranged sequence, and, for example, by a naive or a mature B cell or a T cell.
  • a CDR can be somatically mutated (e.g., vary from a sequence encoded in an animal's germline), humanized, and/or modified with amino acid substitutions, additions, or deletions.
  • CDRs can be encoded by two or more sequences (e.g., germline sequences) that are not contiguous (e.g., in an unrearranged nucleic acid sequence) but are contiguous in a B cell nucleic acid sequence, e.g., as the result of splicing or connecting the sequences (e.g., V-D-J recombination to form a heavy chain CDR3).
  • conservative amino acid substitution when used to describe a conservative amino acid substitution, includes substitution of an amino acid residue by another amino acid residue having a side chain R group with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of interest of a protein, for example, the ability of a variable region to specifically bind a target epitope with a desired affinity.
  • groups of amino acids that have side chains with similar chemical properties include aliphatic side chains such as glycine, alanine, valine, leucine, and isoleucine; aliphatic-hydroxyl side chains such as serine and threonine; amide-containing side chains such as asparagine and glutamine; aromatic side chains such as phenylalanine, tyrosine, and tryptophan; basic side chains such as lysine, arginine, and histidine; acidic side chains such as aspartic acid and glutamic acid; and, sulfur-containing side chains such as cysteine and methionine.
  • aliphatic side chains such as glycine, alanine, valine, leucine, and isoleucine
  • aliphatic-hydroxyl side chains such as serine and threonine
  • amide-containing side chains such as asparagine and glutamine
  • aromatic side chains such as phenylalanine, tyrosine, and trypto
  • Conservative amino acids substitution groups include, for example, valine/leucine/isoleucine, phenylalanine/tyrosine, lysine/arginine, alanine/valine, glutamate/aspartate, and asparagine/glutamine.
  • a conservative amino acid substitution can be substitution of any native residue in a protein with alanine, as used in, for example, alanine scanning mutagenesis.
  • a conservative substitution is made that has a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Exhaustive Matching of the Entire Protein Sequence Database, Science 256:1443-45, hereby incorporated by reference.
  • the substitution is a moderately conservative substitution wherein the substitution has a nonnegative value in the PAM250 log-likelihood matrix.
  • residue positions in an immunoglobulin light chain or heavy chain differ by one or more conservative amino acid substitutions.
  • residue positions in an immunoglobulin light chain or functional fragment thereof e.g., a fragment that allows expression and secretion from, e.g., a B cell
  • residue positions in an immunoglobulin light chain or functional fragment thereof are not identical to a light chain whose amino acid sequence is listed herein, but differs by one or more conservative amino acid substitutions.
  • epitope-binding protein includes a protein having at least one CDR and that is capable of selectively recognizing an epitope, e.g., is capable of binding an epitope with a K D that is at about one micromolar or lower (e.g., a K D that is about 1 ⁇ 10 ⁇ 6 M, 1 ⁇ 10 ⁇ 7 M, 1 ⁇ 10 ⁇ 9 M, 1 ⁇ 10 ⁇ 9 M, 1 ⁇ 10 ⁇ 10 M, 1 ⁇ 10 ⁇ 11 M, or about 1 ⁇ 10 ⁇ 12 M).
  • Therapeutic epitope-binding proteins e.g., therapeutic antibodies
  • the phrase “functional fragment” includes fragments of epitope-binding proteins that can be expressed, secreted, and specifically bind to an epitope with a K D in the micromolar, nanomolar, or picomolar range. Specific recognition includes having a K D that is at least in the micromolar range, the nanomolar range, or the picomolar range.
  • germline in reference to an immunoglobulin nucleic acid sequence includes a nucleic acid sequence that can be passed to progeny.
  • heavy chain or “immunoglobulin heavy chain” includes an immunoglobulin heavy chain sequence, including immunoglobulin heavy chain constant region sequence, from any organism.
  • Heavy chain variable domains include three heavy chain CDRs and four FR regions, unless otherwise specified. Fragments of heavy chains include CDRs, CDRs and FRs, and combinations thereof.
  • a typical heavy chain has, following the variable domain (from N-terminal to C-terminal), a C H 1 domain, a hinge, a C H 2 domain, and a C H 3 domain.
  • a functional fragment of a heavy chain includes a fragment that is capable of specifically recognizing an epitope (e.g., recognizing the epitope with a K D in the micromolar, nanomolar, or picomolar range), that is capable of expressing and secreting from a cell, and that comprises at least one CDR.
  • a heavy chain variable domain is encoded by a variable region gene sequence, which generally comprises V H , D H , and J H segments derived from a repertoire of V H , D H , and J H segments present in the germline. Sequences, locations and nomenclature for V, D, and J heavy chain segments for various organisms can be found in IMGT database, www.imgt.org.
  • identity when used in connection with a sequence, includes identity as determined by a number of different algorithms known in the art that can be used to measure nucleotide and/or amino acid sequence identity. In some embodiments described herein, identities are determined using a ClustalW v. 1.83 (slow) alignment employing an open gap penalty of 10.0, an extend gap penalty of 0.1, and using a Gonnet similarity matrix (MACVECTORTM 10.0.2, MacVector Inc., 2008).
  • ClustalW v. 1.83 (slow) alignment employing an open gap penalty of 10.0, an extend gap penalty of 0.1, and using a Gonnet similarity matrix (MACVECTORTM 10.0.2, MacVector Inc., 2008).
  • the length of the sequences compared with respect to identity of sequences will depend upon the particular sequences, but in the case of a light chain constant domain, the length should contain sequence of sufficient length to fold into a light chain constant domain that is capable of self-association to form a canonical light chain constant domain, e.g., capable of forming two beta sheets comprising beta strands and capable of interacting with at least one C H 1 domain of a human or a mouse. In the case of a C H 1 domain, the length of sequence should contain sequence of sufficient length to fold into a C H 1 domain that is capable of forming two beta sheets comprising beta strands and capable of interacting with at least one light chain constant domain of a mouse or a human.
  • immunoglobulin molecule includes two immunoglobulin heavy chains and two immunoglobulin light chains.
  • the heavy chains may be identical or different, and the light chains may be identical or different.
  • light chain includes an immunoglobulin light chain sequence from any organism, and unless otherwise specified includes human kappa and lambda light chains and a VpreB, as well as surrogate light chains.
  • Light chain variable domains typically include three light chain CDRs and four framework (FR) regions, unless otherwise specified.
  • FR framework
  • a full-length light chain includes, from amino terminus to carboxyl terminus, a variable domain that includes FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, and a light chain constant region.
  • a light chain variable domain is encoded by a light chain variable region gene sequence, which generally comprises V L and J L segments, derived from a repertoire of V and J segments present in the germline.
  • Light chains include those, e.g., that do not selectively bind either a first or a second epitope selectively bound by the epitope-binding protein in which they appear. Light chains also include those that bind and recognize, or assist the heavy chain with binding and recognizing, one or more epitopes selectively bound by the epitope-binding protein in which they appear. Common or universal light chains include those derived from a human V ⁇ 1-39J ⁇ 5 gene or a human V ⁇ 3-20J ⁇ 1 gene, and include somatically mutated (e.g., affinity matured) versions of the same.
  • Dual light chains include those derived from a light chain locus comprising no more than two human V ⁇ segments, e.g., a human V ⁇ 1-39 gene segment and a human V ⁇ 3-20 gene segment, and include somatically mutated (e.g., affinity matured) versions of the same.
  • the phrase “somatically hypermutated” includes reference to a nucleic acid sequence from a B cell that has undergone class-switching, wherein the nucleic acid sequence of an immunoglobulin variable region (e.g., nucleotide sequence encoding a heavy chain variable domain or including a heavy chain CDR or FR sequence) in the class-switched B cell is not identical to the nucleic acid sequence in the B cell prior to class-switching, such as, for example, a difference in a CDR or framework nucleic acid sequence between a B cell that has not undergone class-switching and a B cell that has undergone class-switching.
  • an immunoglobulin variable region e.g., nucleotide sequence encoding a heavy chain variable domain or including a heavy chain CDR or FR sequence
  • “Somatically mutated” includes reference to nucleic acid sequences from affinity-matured B cells that are not identical to corresponding immunoglobulin variable region sequences in B cells that are not affinity-matured (i.e., sequences in the genome of germline cells).
  • the phrase “somatically mutated” also includes reference to an immunoglobulin variable region nucleic acid sequence from a B cell after exposure of the B cell to an epitope of interest, wherein the nucleic acid sequence differs from the corresponding nucleic acid sequence prior to exposure of the B cell to the epitope of interest.
  • mutated refers to sequences from antibodies that have been generated in an animal, e.g., a mouse having human immunoglobulin variable region nucleic acid sequences, in response to an immunogen challenge, and that result from the selection processes inherently operative in such an animal.
  • nucleic acid sequences that exist in the germline of an animal cell.
  • variable domain includes an amino acid sequence of an immunoglobulin light or heavy chain (modified as desired) that comprises the following amino acid regions, in sequence from N-terminal to C-terminal (unless otherwise indicated): FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • operably linked refers to a relationship wherein the components operably linked function in their intended manner.
  • a nucleic acid sequence encoding a protein may be operably linked to regulatory sequences (e.g., promoter, enhancer, silencer sequence, etc.) so as to retain proper transcriptional regulation.
  • a nucleic acid sequence of an immunoglobulin variable region (or V(D)J segments) may be operably linked to a nucleic acid sequence of an immunoglobulin constant region so as to allow proper recombination between the sequences into an immunoglobulin heavy or light chain sequence.
  • a functional immunoglobulin gene segment may include a variable gene segment that is capable of productive rearrangement to generate a rearranged immunoglobulin gene sequence.
  • Neutral pH includes pH between about 7.0 and about 8.0, e.g., pH between about 7.0 and about 7.4, e.g., between about 7.2 and about 7.4, e.g., physiological pH.
  • Acidic pH includes pH of 6.0 or lower, e.g., pH between about 5.0 and about 6.0, pH between about 5.75 and about 6.0, e.g., pH of endosomal or lysosomal compartments.
  • polymorphic variant includes a sequence in which one or more nucleotides or amino acids have been substituted by a different nucleotides or amino acid as compared to the given sequence.
  • Polymorphic alleles of the human immunoglobulin heavy chain variable gene segments (V H genes) have largely been the result of insertion/deletion of gene segments and single nucleotide differences within coding regions, both of which have the potential to have functional consequences on the immunoglobulin molecule. Examples of common polymorphic alleles of the human immunoglobulin V H genes are well known in the art (see, for example, U.S. Ser. No. 13/653,456, incorporated by reference herein in its entirety).
  • substantially all when used to refer to an amount of gene segments (e.g., “substantially all” V, D, or J gene segments) includes both functional and non-functional gene segments and includes, in various embodiments, e.g., 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more of all V, D, or J gene segments.
  • “substantially all” gene segments include, e.g., at least 95%, 96%, 97%, 98%, or 99% of functional (i.e., non-pseudogene) gene segments).
  • Non-Human Animals Comprising a Rearranged Heavy Chain Variable Region Gene Sequence and Optionally a Limited Repertoire of Unrearranged Light Chain Variable Gene Segments
  • bispecific antibodies While a variety of bispecific antibodies with dual antigen binding properties have been developed, the specificity and affinity of the light chain or heavy chain variable regions in conventional bispecific antibodies had to be sacrificed to some extent because, in conventional bispecific antibodies, either a heavy chain or a light chain variable region alone contributes to binding each separate antigenic determinant, whereas in regular antibodies, both light and heavy chain variable regions can contribute to binding the same antigenic determinant.
  • V L s light chain variable domains
  • antigen-binding molecules e.g., bispecific binding molecules that comprise a heavy chain constant region (e.g., selected from a C H 1, a hinge, a C H 2, a C H 3, and a combination thereof) fused with V L ), particularly those that do not comprise a heavy chain variable domain, including heterodimers having the same or similar heavy chain constant region but V L s with different specificities and/or affinities.
  • One approach to produce such light chain variable domains that can bind to an antigen independently from a heavy chain variable region is to apply a selective pressure on nucleotide sequences that encode a variable region or domain of a light chain (V L ) to generate light chain CDR3s with more diverse antigenic binding repertoire.
  • V L variable region or domain of a light chain
  • this can be achieved by generating a genetically modified non-human animal that contains, in its genome, a rearranged human immunoglobulin heavy chain variable region nucleotide sequence.
  • the heavy chain sequence is restricted to a common or universal (i.e., the same or a very similar) sequences in these animals
  • the light chain variable region nucleotide sequences i.e., genes
  • the precise replacement of germline variable region gene segments allows for making animals (e.g., mice) that have partly human immunoglobulin loci.
  • the partly human immunoglobulin loci rearrange, hypermutate, and somatically mutate (e.g., class switch) normally, the partly human immunoglobulin loci generate antibodies in the animal that comprise human variable regions. These animals exhibit a humoral immune system that is substantially similar to wild type animals, and display normal cell populations and normal lymphoid organ structures—even where the animals lack a full repertoire of human variable region gene segments. Immunizing these animals (e.g., mice) results in robust humoral responses that display a wide diversity of variable gene segment usage.
  • Nucleotide sequences that encode the variable regions can be identified and cloned, then fused (e.g., in an in vitro system) with any sequences of choice, e.g., any immunoglobulin isotype suitable for a particular use, resulting in an antibody or antigen-binding protein derived wholly from human sequences.
  • mice or rats that have a restricted (limited) light chain variable region gene segment repertoire, e.g., a restricted light chain variable segment repertoire comprising one or more but less than the wild type number of human V L gene segments (e.g., a dual light chain or “DLC,” US Patent Application Publication No. 2013/0198880, incorporated by reference herein in its entirety) in combination with the rearranged human immunoglobulin heavy chain variable region nucleotide sequence described above, an immunoglobulin light chain variable domain that can more efficiently pair with an immunoglobulin heavy chain variable domain can be produced.
  • animals e.g., mice or rats
  • a restricted light chain variable region gene segment repertoire e.g., a restricted light chain variable segment repertoire comprising one or more but less than the wild type number of human V L gene segments (e.g., a dual light chain or “DLC,” US Patent Application Publication No. 2013/0198880, incorporated by reference herein in its entirety) in combination with the rearranged human immunoglobulin heavy
  • histidine codons e.g., via addition of one or more histidine codons or substitution of one or more non-histidine codons with histidine codons
  • light chain variable region amino acid sequences that can confer improved pH-dependent recyclability to the antigen-binding proteins (e.g., bispecific or trispecific antibodies) can be generated.
  • the genetically modified non-human animals as described herein provide a greater yield of antibodies, while limiting diversity at the same time, thereby increasing the probability of successful pairing of light chains with heavy chains generated in a non-human animal comprising a single rearranged light chain variable region (e.g., a Universal Light Chain (“ULC”) mouse; see, e.g., U.S. pre-grant publication 2013/0185821, incorporated by reference herein).
  • the light chains may themselves exhibit antigen-binding properties.
  • the non-human animal may be induced to produce antigen-binding proteins exhibiting antigen specificity that resides in their light chains (e.g., by limiting a mouse or rat's immunoglobulin heavy chain repertoire; e.g., by replacing the mouse or rat heavy chain locus with a locus comprising a single rearranged human immunoglobulin heavy chain variable region nucleotide sequence).
  • antigen-binding proteins produced in such animals will be specific for a particular first epitope (e.g., effector antigens, cytotoxic molecules, Fc receptors, toxins, activating or inhibitory receptors, T cell markers, immunoglobulin transporters, etc.) through their light chain binding.
  • first epitope e.g., effector antigens, cytotoxic molecules, Fc receptors, toxins, activating or inhibitory receptors, T cell markers, immunoglobulin transporters, etc.
  • Such epitope-specific human light chains derived from these non-human animals may be co-expressed with human heavy chains derived from a mouse with a limited light chain repertoire, e.g., a ULC mouse or rat, wherein the heavy chain is selected based on its ability to bind a second epitope (e.g., a second epitope on a different antigen).
  • a non-human animal comprising in its germline genome an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (i.e., a rearranged heavy chain VDJ sequence).
  • a rearranged human immunoglobulin heavy chain variable region nucleotide sequence i.e., a rearranged heavy chain VDJ sequence.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a human or a non-human heavy chain constant region sequence.
  • an immunoglobulin heavy chain variable domain encoded by the rearranged heavy chain variable region nucleotide sequence is not immunogenic to the non-human animal.
  • the non-human animal is modified to comprise a nucleotide sequence that encodes two copies, three copies, four copies or more of the rearranged heavy chain variable domain operably linked to a heavy chain constant domain.
  • the nucleotide sequence encodes a plurality of copies of the rearranged human immunoglobulin heavy chain variable region nucleotide sequence.
  • the nucleotide sequence can encode at least one, two, three, four, five copies of the rearranged human immunoglobulin heavy chain variable region nucleotide sequence.
  • the nucleotide sequence encodes 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies of the rearranged human immunoglobulin heavy chain variable region nucleotide sequence.
  • the locus comprises a plurality of copies of the rearranged human immunoglobulin heavy chain variable region nucleotide sequence operably linked to a heavy chain constant domain gene sequence.
  • a non-human animal is provided that is genetically engineered to contain an immunoglobulin light chain locus that encodes a rearranged heavy chain variable domain (i.e., a light chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence) operably linked to a human or a non-human light chain constant region gene sequence.
  • an immunoglobulin light chain locus that encodes a rearranged heavy chain variable domain (i.e., a light chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence) operably linked to a human or a non-human light chain constant region gene sequence.
  • a rearranged human immunoglobulin heavy chain variable region nucleotide sequence i.e., a pre-designed VDJ region; i.e., a common or universal heavy chain sequence
  • a rearranged heavy chain variable domain nucleotide sequence can be operably linked to a light chain constant region gene sequence by targeting the rearranged heavy chain sequence into a mouse or rat light chain loci, either kappa or lambda.
  • the nucleotide sequence encoding the rearranged heavy chain variable domain is present in the germline genome of the non-human animal.
  • the rearranged heavy chain variable domain expressed by the genetically modified non-human animal is not immunogenic to the non-human animal.
  • the non-human animal is modified to comprise a nucleotide sequence that encodes two copies, three copies, four copies or more of the rearranged human immunoglobulin heavy chain variable region nucleotide sequence operably linked to a light chain constant domain.
  • the nucleotide sequence can encode a plurality of copies of the rearranged human immunoglobulin heavy chain variable region nucleotide sequence.
  • the nucleotide sequence encodes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies of the rearranged human immunoglobulin heavy chain variable region nucleotide sequence.
  • the locus comprises a plurality of copies of the rearranged human immunoglobulin heavy chain variable region nucleotide sequence operably linked to a light chain constant domain gene sequence.
  • the immunoglobulin light chain locus of the non-human animals described herein comprises a limited repertoire of light chain variable gene segments, e.g., one or more but less than the wild type number of human V L gene segments; and one or more human J L gene segments, operably linked to a non-human light chain constant region nucleic acid sequence.
  • genetically modified non-human animals comprising in their genomes: (i) an immunoglobulin heavy chain locus that comprises a rearranged human heavy chain variable region nucleic acid sequence operably linked to a human or non-human heavy chain constant region nucleic acid sequence; and (ii) an immunoglobulin light chain locus comprising two or more but less than the wild type number of human immunoglobulin light chain variable V L and J L gene segments operably linked to a light chain constant region nucleic acid sequence.
  • the light chain constant region is a rat or a mouse constant region, e.g., a rat or a mouse CK constant region.
  • the human variable region gene segments are capable of rearranging and encoding human variable domains of an antibody, and the non-human animal does not comprise an endogenous V L gene segment.
  • the non-human animal comprises five human J ⁇ gene segments, e.g., J ⁇ 1, J ⁇ 2, J ⁇ 3, J ⁇ 4, and J ⁇ 5 gene segments.
  • the immunoglobulin light chain locus comprises two human V L gene segments, V ⁇ 1-39 and V ⁇ 3-20.
  • one or more (e.g., 2, 3, 4, or 5) human V L gene segments and two or more human J L gene segments are present at an endogenous light chain locus, e.g., at an endogenous kappa light chain locus.
  • the mouse comprises a functional ⁇ light chain locus. In some embodiments, the mouse comprises a non-functional ⁇ light chain locus. In some embodiments, the one or more human V H , one or more human D H , and one or more human J H gene segments are operably linked to a mouse or a rat heavy chain constant region sequence.
  • genetically modified mice comprising in their genomes (i) an immunoglobulin heavy chain locus that comprises a rearranged human heavy chain variable region nucleic acid sequence operably linked to a human or non-human heavy chain constant region nucleic acid sequence, and (ii) an immunoglobulin light chain locus comprising two or more but less than the wild type number of human immunoglobulin light chain variable V L and J L gene segments operably linked to a light chain constant region nucleic acid sequence, demonstrate CD19+ B cell numbers and mature B cell numbers that are substantially the same as the numbers observed in wild type mice or mice containing other modifications of their immunoglobulin loci (i.e., genetically modified control mice; e.g., VELOCIMMUNE® mice, in which the humoral immune system of the mouse functions like that of a wild type mouse).
  • genetically modified control mice e.g., VELOCIMMUNE® mice
  • such mice demonstrate an increase in immature B cell numbers in the spleen compared to genetically modified control mice. In specific embodiments, such mice demonstrate about a 2-fold, about a 3-fold, about a 4-fold, or about a 5-fold or greater fold increase in immature B cell numbers in the spleen compared to genetically modified control mice. In some embodiments, such mice are also substantially similar to wild type mice or genetically modified control mice with respect to kappa and gamma light chain usage in splenic B cells. In some embodiments, such mice demonstrate increased surface IgM on splenic B cells (i.e., more IgM surface expression per cell) as compared to genetically modified control mice.
  • such mice demonstrate altered peripheral B cell development through various stages of B cell development in the splenic compartment compared to genetically modified control mice, for example an increase in immature, T1 and/or marginal zone B cells.
  • such mice demonstrate numbers of CD19+ B cells in the bone marrow compartment that are substantially similar to the numbers demonstrated in genetically modified control mice.
  • such mice demonstrate fewer pro-B cells in the bone marrow compared to genetically modified control mice.
  • the numbers of pro-B cells in the bone marrow compartment are reduced by about 2-fold, about 5-fold, about 10-fold, about 15-fold, about 20-fold, about 25-fold or more compared to genetically modified control mice.
  • such mice demonstrate about 2-fold, about 3-fold, about 4-fold, about 5-fold, etc. fewer immature and/or mature B cells in the bone marrow compared to genetically modified control mice. In some embodiments, such mice exhibit a slight preference (e.g., 2-fold increase) in the bone marrow compartment for usage of lambda light chain genes compared to genetically modified control mice.
  • a non-human animal comprising a genetically modified immunoglobulin locus comprising: (a) a first nucleotide sequence that encodes a rearranged heavy chain variable domain (i.e., where the first nucleotide sequence is a rearranged human immunoglobulin heavy chain variable region nucleotide sequence), wherein the first nucleotide sequence is operably linked to a light chain constant region gene sequence; and (b) a second nucleotide sequence that encodes a human light chain variable domain (i.e., where the second nucleotide sequence is an unrearranged human immunoglobulin light chain variable region nucleotide sequence), wherein the second nucleotide sequence is operably linked to a heavy chain constant region gene sequence.
  • a rearranged heavy chain from a pre-designed VDJ region i.e., a rearranged human immunoglobulin heavy chain variable region nucleotide sequence; i.e., a common or universal heavy chain sequence
  • a rearranged heavy chain sequence i.e., a common or universal heavy chain sequence
  • this genetically engineered immunoglobulin locus may be present in the germline genome of the non-human animal. Genetically modified non-human animals comprising a human immunoglobulin light chain variable region nucleotide sequences in operable linkage with a heavy chain constant region gene sequences are described in U.S.
  • the first nucleotide sequence that encodes the rearranged heavy chain variable domain is operably linked to a ⁇ light chain constant region gene sequence. In some embodiments, the first nucleotide sequence that encodes the rearranged heavy chain variable domain is operably linked to a mouse or rat ⁇ light chain constant region gene sequence. In some embodiments, the first nucleotide sequence that encodes the rearranged heavy chain variable domain is operably linked to a human ⁇ light chain constant region gene sequence. In some embodiments, the first nucleotide sequence that encodes the rearranged heavy chain variable domain is operably linked to a ⁇ light chain constant region gene sequence.
  • the first nucleotide sequence that encodes the rearranged heavy chain variable domain is operably linked to a mouse or rat ⁇ light chain constant region gene sequence. In some embodiments, the first nucleotide sequence that encodes the rearranged heavy chain variable domain is operably linked to a human ⁇ light chain constant region gene sequence.
  • a genetically modified mouse comprising an immunoglobulin light chain locus containing a rearranged human immunoglobulin heavy chain variable region nucleotide sequence and an immunoglobulin heavy chain locus containing unrearranged human immunoglobulin light chain variable domain sequences (e.g., kappa light chain genes) presents CD19+ and pre-B cell frequencies in the bone marrow that are altered relative to a wild type mouse or a genetically modified mouse with other modifications at an immunoglobulin locus (i.e., genetically modified control mice; e.g., VELOCIMMUNE® mice, in which the humoral immune system of the mouse functions like that of a wild type mouse).
  • genetically modified control mice e.g., VELOCIMMUNE® mice
  • the CD19+ B cell and pre-B cell numbers in the bone marrow are 2-fold lower, 3-fold lower, 4-fold lower or 5-fold lower compared to a wild type mouse or a genetically modified immunoglobulin locus control mouse.
  • the number of immature B cells in the bone marrow is 2-fold less, 3-fold less, 4-fold less or 5-fold less compared to a wild type mouse or a genetically modified immunoglobulin locus control mouse.
  • a genetically modified mouse comprising an immunoglobulin light chain locus containing a rearranged human immunoglobulin heavy chain variable region nucleotide sequence and an immunoglobulin heavy chain locus containing unrearranged human immunoglobulin light chain variable domain sequences (e.g., kappa light chain genes) does not express or essentially does not express lambda light chain genes in the bone marrow cells.
  • a genetically modified mouse comprising an immunoglobulin light chain locus containing a rearranged human immunoglobulin heavy chain variable region nucleotide sequence and an immunoglobulin heavy chain locus containing unrearranged human immunoglobulin light chain variable domain sequences (e.g., kappa light chain genes) has reduced levels of splenic B cells compared to a wild type mouse or a genetically modified immunoglobulin locus control mouse.
  • the levels of splenic B cells and mature B cells are 2-fold lower, 3-fold lower, 4-fold lower or 5-fold lower compared to a wild type mouse or a genetically modified immunoglobulin locus control mouse.
  • a genetically modified mouse comprising an immunoglobulin light chain locus containing a rearranged human immunoglobulin heavy chain variable region nucleotide sequence and an immunoglobulin heavy chain locus containing unrearranged human immunoglobulin light chain variable domain sequences (e.g., kappa light chain genes) does not express or essentially does not express lambda light chain genes in splenic B cells.
  • a genetically modified mouse comprising an immunoglobulin light chain locus containing a rearranged human immunoglobulin heavy chain variable region nucleotide sequence and an immunoglobulin heavy chain locus containing unrearranged human immunoglobulin light chain variable domain sequences (e.g., kappa light chain genes) has an increased frequency of cells in the T1 phase in the spleen compared to a wild type mouse or a genetically modified immunoglobulin locus control mouse.
  • the non-human animal is a mammal.
  • a rearranged human heavy chain variable domain in a mouse i.e., a mouse with an immunoglobulin locus comprising a rearranged human immunoglobulin heavy chain variable region nucleotide sequence
  • other non-human animals that comprise a genetically modified immunoglobulin locus encoding a rearranged human heavy chain variable domain are also provided.
  • non-human animals include any of those which can be genetically modified to express the rearranged human immunoglobulin heavy chain variable region nucleotide sequence as disclosed herein, including, e.g., mammals, e.g., mouse, rat, rabbit, pig, bovine (e.g., cow, bull, buffalo), deer, sheep, goat, chicken, cat, dog, ferret, primate (e.g., marmoset, rhesus monkey), etc.
  • mammals e.g., mouse, rat, rabbit, pig, bovine (e.g., cow, bull, buffalo), deer, sheep, goat, chicken, cat, dog, ferret, primate (e.g., marmoset, rhesus monkey), etc.
  • suitable genetically modifiable ES cells are not readily available, other methods are employed to make a non-human animal comprising the genetic modification.
  • Such methods include, e.g., modifying a non-ES cell genome (e.g., a fibroblast or an induced pluripotent cell) and employing somatic cell nuclear transfer (SCNT) to transfer the genetically modified genome to a suitable cell, e.g., an enucleated oocyte, and gestating the modified cell (e.g., the modified oocyte) in a non-human animal under suitable conditions to form an embryo.
  • SCNT somatic cell nuclear transfer
  • genomes include, e.g., employing a zinc finger nuclease (ZFN) or a transcription activator-like effector nuclease (TALEN) to modify a genome to include a rearranged human immunoglobulin heavy chain variable region nucleotide sequence.
  • ZFN zinc finger nuclease
  • TALEN transcription activator-like effector nuclease
  • the non-human animal is a small mammal, e.g., of the superfamily Dipodoidea or Muroidea.
  • the genetically modified animal is a rodent.
  • the rodent is selected from a mouse, a rat, and a hamster.
  • the rodent is selected from the superfamily Muroidea.
  • the genetically modified animal is from a family selected from Calomyscidae (e.g., mouse-like hamsters), Cricetidae (e.g., hamster, New World rats and mice, voles), Muridae (true mice and rats, gerbils, spiny mice, crested rats), Nesomyidae (climbing mice, rock mice, with-tailed rats, Malagasy rats and mice), Platacanthomyidae (e.g., spiny dormice), and Spalacidae (e.g., mole rates, bamboo rats, and zokors).
  • Calomyscidae e.g., mouse-like hamsters
  • Cricetidae e.g., hamster, New World rats and mice, voles
  • Muridae true mice and rats, gerbils, spiny mice, crested rats
  • Nesomyidae climbing mice, rock mice, with
  • the genetically modified rodent is selected from a true mouse or rat (family Muridae), a gerbil, a spiny mouse, and a crested rat.
  • the genetically modified mouse is from a member of the family Muridae.
  • the animal is a rodent.
  • the rodent is selected from a mouse and a rat.
  • the non-human animal is a mouse.
  • the non-human animal is a rodent that is a mouse of a C57BL strain selected from C57BL/A, C57BL/An, C57BL/GrFa, C57BL/KaLwN, C57BL/6, C57BL/6J, C57BL/6ByJ, C57BL/6N, C57BL/6NJ, C57BL/10, C57BL/10ScSn, C57BL/10Cr, and C57BL/Ola.
  • the mouse is a 129 strain.
  • the 129 strain is selected from the group consisting of 129P1, 129P2, 129P3, 129X1, 129S1 (e.g., 129S1/SV, 129S1/Svlm), 129S2, 129S4, 129S5, 129S9/SvEvH, 129S6 (129/SvEvTac), 129S7, 129S8, 129T1, 129T2 (see, e.g., Festing et al. (1999) Revised nomenclature for strain 129 mice, Mammalian Genome 10:836, see also, Auerbach et al.
  • the genetically modified mouse is a mix of an aforementioned 129 strain and an aforementioned C57BL strain (e.g., a C57BL/6 strain).
  • the mouse is a mix of aforementioned 129 strains, or a mix of aforementioned C57BL/6 strains.
  • the 129 strain of the mix is a 129S6 (129/SvEvTac) strain.
  • the mouse is a mix of a 129/SvEv- and a C57BL/6-derived strain.
  • the mouse is a mix of a 129/SvEv- and a C57BL/6-derived strain as described in Auerbach et al. 2000 BioTechniques 29:1024-1032.
  • the mouse is a BALB strain, e.g., BALB/c strain.
  • the mouse is a mix of a BALB strain (e.g., BALB/c strain) and another aforementioned strain.
  • the non-human animal is a rat.
  • the rat is selected from a Wistar rat, an LEA strain, a Sprague Dawley strain, a Fischer strain, F344, F6, ACI, and Dark Agouti (DA).
  • the rat strain is a mix of two or more of a strain selected from the group consisting of Wistar, LEA, Sprague Dawley, Fischer, F344, F6, ACI and Dark Agouti (DA).
  • a genetically modified mouse comprising in its germline genome an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence generates splenic mature and immature B cell populations that are essentially normal relative to a wild type mouse.
  • such a genetically modified mouse has a slight decrease in the usage of light chain lambda gene sequences relative to wild type in splenic B cells.
  • such a genetically modified mouse uses light chain lambda gene sequences with a 2-fold, 3-fold, 4-fold or 5-fold lower frequency than wild type in splenic B cells.
  • such a genetically modified mouse has a slight decrease in T1 population splenic B cells and an increase in marginal zone splenic B cells relative to wild type. In some embodiments, such a genetically modified mouse has near normal B cell populations in the bone marrow. In some embodiments, such a genetically modified mouse uses lambda gene sequences with a frequency that is half or less than half of the frequency that lambda gene sequences are used in wild type.
  • the rearranged heavy chain variable domain (e.g., the rearranged human immunoglobulin heavy chain variable region nucleotide sequence) is derived from a human V, D, and J gene sequence or segment.
  • the rearranged heavy chain variable domain is derived from a human germline V segment, a human germline D segment, and a human germline J segment.
  • the human V H segment corresponds to observed variants in the human population.
  • the human V gene segment is selected from the group consisting of V H 1-2, V H 1-3, V H 1-8, V H 1-18, V H 1-24, V H 1-45, V H 1-46, V H 1-58, V H 1-69, V H 2-5, V H 2-26, V H 2-70, V H 3-7, V H 3-9, V H 3-11, V H 3-13, V H 3-15, V H 3-16, V H 3-20, V H 3-21, V H 3-23, V H 3-30, V H 3-30-3, V H 3-30-5, V H 3-33, V H 3-35, V H 3-38, V H 3-43, V H 3-48, V H 3-49, V H 3-53, V H 3-64, V H 3-66, V H 3-72, V H 3-73, V H 3-74, V H 4-4, V H 4-28, V H 4-30-1, V H 4-30-2, V H 4-30-4, V H 4-31, V H 4-34, V H 4-39, V H 4-59, V H
  • the human V segment is V H 3-23 or polymorphic variant thereof.
  • the human D gene segment is selected from the group consisting of D1-1, D1-7, D1-14, D1-20, D1-26, D2-2, D2-8, D2-15, D2-21, D3-3, D3-9, D3-10, D3-16, D3-22, D4-4, D4-11, D4-17, D4-23, D5-12, D5-5, D5-18, D5-24, D6-6, D6-13, D6-19, D6-25, D7-27, and a polymorphic variant thereof.
  • the human or non-human animal heavy chain constant region sequence comprises a sequence selected from a C H 1, a hinge, a C H 2, a C H 3, and a combination thereof.
  • the constant region sequence comprises a C H 1, a hinge, a C H 2, and a C H 3.
  • the human J gene segment is selected from the group consisting of J H 1, J H 2, J H 3, J H 4, J H 5, J H 6, and a polymorphic variant thereof.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence encodes the sequence of human V H 3-23/GY/J H 4-4 (SEQ ID NO: 137).
  • the rearranged heavy chain variable domain encoded by and expressed from the rearranged human immunoglobulin heavy chain variable region nucleotide sequence comprises the sequence of human V H 3-23/X 1 X 2 /J (wherein X1 is any amino acid, and X2 is any amino acid).
  • X 1 is Gly and X 2 is Tyr.
  • the rearranged heavy chain variable domain comprises the sequence of human V H 3-23/X 1 X 2 /J H 4-4 (wherein X1 is any amino acid, and X 2 is any amino acid).
  • X 2 is an amino acid comprising a phenyl group. In specific embodiments, X 2 is selected from Tyr and Phe.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence comprises a human D segment that is not autoreactive (non-immunogenic) in the animal.
  • the nucleotide sequence comprises a human D segment that is capable of being expressed in a heavy chain variable sequence of a mature B cell of a mouse.
  • the D segment is a segment that has been expressed in a mouse that comprises a humanized immunoglobulin locus comprising a human V H , a human D, and a human J H segment.
  • VELOCIMMUNE® humanized mice contain a precise, large-scale replacement of germline variable regions of mouse immunoglobulin heavy chain (IgH) and immunoglobulin light chain (e.g., ⁇ light chain, Ig ⁇ ) with corresponding human immunoglobulin variable regions, at the endogenous loci (see, e.g., U.S. Pat. No. 6,596,541 and U.S. Pat. No. 8,502,018, the entire contents of which are incorporated herein by reference). In total, about six megabases of mouse loci are replaced with about 1.5 megabases of human genomic sequence.
  • IgH immunoglobulin heavy chain
  • Ig ⁇ immunoglobulin light chain
  • VELOCIMMUNE® humanized mice are possible because immunoglobulin gene segments for heavy and ⁇ light chains rearrange similarly in humans and mice. Although the loci are not identical, they are similar enough that humanization of the heavy chain variable gene locus can be accomplished by replacing about three million base pairs of contiguous mouse sequence that contains all the V H , D, and J H gene segments with about one million bases of contiguous human genomic sequence covering basically the equivalent sequence from a human immunoglobulin locus.
  • the D segment is derived from a heavy chain expressed in a mature B cell of a VELOCIMMUNE® humanized mouse immunized with an antigen, wherein the D segment contributes no more than two amino acids to the heavy chain CDR3 sequence.
  • a VELOCIMMUNE® mouse comprising an immunoglobulin heavy chain locus encoding a rearranged heavy chain variable domain (i.e., comprising an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence) is provided.
  • a VELOCIMMUNE® mouse so modified comprises a replacement of mouse immunoglobulin heavy chain variable gene segments with a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (i.e., a Universal Heavy Chain sequence at an endogenous heavy chain locus), and a replacement of mouse immunoglobulin ⁇ light chain variable gene segments with at least 40 human V ⁇ gene segments and five human J ⁇ gene segments.
  • the human V ⁇ gene segments are selected from the group consisting of V ⁇ 1-5, V ⁇ 1-6, V ⁇ 1-8, V ⁇ 1-9, V ⁇ 1-12, V ⁇ 1-13, V ⁇ 1-16, V ⁇ 1-17, V ⁇ 1-22, V ⁇ 1-27, V ⁇ 1-32, V ⁇ -1-33, V ⁇ 1-35, V ⁇ 1-37, V ⁇ 1-39, V ⁇ 1D-8, V ⁇ 1D-12, V ⁇ 1D-13, V ⁇ 1D-16, V ⁇ 1D-17, V ⁇ 1D-22, V ⁇ 1D-27, V ⁇ 1D-32, V ⁇ 1D-33, V ⁇ 1D-35, V ⁇ 1D-37, V ⁇ 1D-39, V ⁇ 1D-42, V ⁇ 1D-43, V ⁇ 1-NL1, V ⁇ 2-4, V ⁇ 2-10, V ⁇ 2-14, V ⁇ 2-18, V ⁇ 2-19, V ⁇ 2-23, V ⁇ 2-24, V ⁇ 2-26, V ⁇ 2-28, V ⁇ 2-29, V ⁇ 2-30, V ⁇ 2-36, V ⁇ 2-38, V ⁇ 2-40, V ⁇ 2
  • the human V ⁇ gene segments comprise V ⁇ 4-1, V ⁇ 5-2, V ⁇ 7-3, V ⁇ 2-4, V ⁇ 1-5, and V ⁇ 1-6.
  • the V ⁇ gene segments comprise V ⁇ 3-7, V ⁇ 1-8, V ⁇ 1-9, V ⁇ 2-10, V ⁇ 3-11, V ⁇ 1-12, V ⁇ 1-13, V ⁇ 2-14, V ⁇ 3-15 and V ⁇ 1-16.
  • the human V ⁇ gene segments comprise V ⁇ 1-17, V ⁇ 2-18, V ⁇ 2-19, V ⁇ 3-20, V ⁇ 6-21, V ⁇ 1-22, V ⁇ 1-23, V ⁇ 2-24, V ⁇ 3-25, V ⁇ 2-26, V ⁇ 1-27, V ⁇ 2-28, V ⁇ 2-29, and V ⁇ 2-30.
  • the human V ⁇ gene segments comprise V ⁇ 3-31, V ⁇ 1-32, V ⁇ 1-33, V ⁇ 3-34, V ⁇ 1-35, V ⁇ 2-36, V ⁇ 1-37, V ⁇ 2-38, V ⁇ 1-39, and V ⁇ 2-40.
  • the V ⁇ gene segments comprise contiguous human immunoglobulin K gene segments spanning the human immunoglobulin ⁇ light chain locus from V ⁇ 4-1 through V ⁇ 2-40
  • the J ⁇ gene segments comprise contiguous gene segments spanning the human immunoglobulin ⁇ light chain locus from J ⁇ 1 through J ⁇ 5.
  • the rearranged human heavy chain variable domain nucleotide sequence is operably linked to a mouse heavy chain constant region sequence.
  • a VELOCIMMUNE® mouse comprising an immunoglobulin heavy chain locus encoding a rearranged heavy chain variable domain (i.e., comprising an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence) can be used in any of the aspects, embodiments, methods, etc. described herein.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a human or mouse heavy chain constant region gene sequence (e.g., a heavy chain constant region gene sequence that encodes an immunoglobulin isotype selected from IgM, IgD, IgA, IgE, IgG, and combinations thereof).
  • a human or mouse heavy chain constant region gene sequence e.g., a heavy chain constant region gene sequence that encodes an immunoglobulin isotype selected from IgM, IgD, IgA, IgE, IgG, and combinations thereof.
  • genetically modified non-human animals comprising immunoglobulin loci in which: (a) a first nucleotide sequence encodes a rearranged heavy chain variable domain (i.e., where the first nucleotide sequence is a rearranged human immunoglobulin heavy chain variable region nucleotide sequence), wherein the first nucleotide sequence is operably linked to a human or non-human heavy chain constant region gene sequence; and (b) a second nucleotide sequence encodes a light chain variable domain (i.e., where the second nucleotide sequence is an unrearranged human immunoglobulin light chain variable nucleotide sequence), wherein the second nucleotide sequence is operably linked to a human or non-human light chain constant region gene sequence.
  • the human heavy chain constant region gene sequence is selected from a C H 1, a hinge, a C H 2, a C H 3, and combinations thereof.
  • a mouse heavy chain constant region gene sequence is selected from a C H 1, a hinge, a C H 2, a C H 3, and combinations thereof.
  • further replacement of certain non-human animal constant region gene sequences with human gene sequences results in genetically modified non-human animals with hybrid immunoglobulin loci that make antibodies that have human variable regions and partly human constant regions, suitable for, e.g., making fully human antibody fragments, e.g., fully human Fab's.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a rat heavy chain constant region gene sequence.
  • the rat heavy chain constant region gene sequence is selected from a C H 1, a hinge, a C H 2, a C H 3, and combinations thereof.
  • the genetically modified immunoglobulin heavy chain locus of the non-human animal comprises two copies, three copies, four copies or more of the rearranged human immunoglobulin heavy chain variable region nucleotide sequence operably linked to a heavy chain constant domain gene sequence.
  • the locus comprises a plurality of copies of the rearranged human immunoglobulin heavy chain variable region nucleotide sequence operably linked to a heavy chain constant domain gene sequence.
  • the heavy chain constant region nucleotide sequence comprises a modification in a C H 2 or a C H 3, wherein the modification increases the affinity of the heavy chain constant region amino acid sequence to FcRn in an acidic environment (e.g., in an endosome where pH ranges from about 5.5 to about 6.0).
  • the heavy chain constant region nucleotide sequence encodes a human heavy chain constant region amino acid sequence comprising a modification at position 250 by EU numbering (263 by Kabat numbering) (e.g., E or Q); 250 by EU numbering (263 by Kabat numbering) and 428 by EU numbering (459 by Kabat numbering) (e.g., L or F); 252 by EU numbering (265 by Kabat numbering) (e.g., L/Y/F/W or T), 254 by EU numbering (267 by Kabat numbering) (e.g., S or T), and 256 by EU numbering (269 by Kabat numbering) (e.g., S/R/Q/E/D or T); or a modification at position 428 by EU numbering (459 by Kabat numbering) and/or 433 by EU numbering (464 by Kabat numbering) (e.g., L/R/S/P/Q or K) and/or 434 by EU numbering (465 by Kabat numbering)
  • the modification comprises a 428L (e.g., M428L) and 434S (e.g., N434S) modification by EU numbering (a 459, e.g., M459L, and 465S (e.g., N465S) modification by Kabat numbering); a 428L, 2591 (e.g., V2591), and 308F (e.g., V308F) modification by EU numbering (a 459L, 2721 (e.g., V2721), and 327F (e.g., V327F) modification by Kabat numbering; a 433K (e.g., H433K) and a 434 (e.g., 434Y) modification by EU numbering (a 464K (e.g., H464K) and a 465 (e.g., 465Y) modification by Kabat numbering; a 252, 254, and 256 (e.g., 252Y, 254T
  • the heavy chain constant region nucleotide sequence encodes a human C H 2 amino acid sequence comprising at least one modification between amino acid residues at positions 252 and 257 by EU numbering (i.e., at least one modification between amino acid positions 265 and 270 by Kabat numbering), wherein the modification increases the affinity of the human C H 2 amino acid sequence to FcRn in an acidic environment (e.g., in an endosome where pH ranges from about 5.5 to about 6.0).
  • the heavy chain constant region nucleotide sequence encodes a human C H 2 amino acid sequence comprising at least one modification between amino acid residues at positions 307 and 311 (i.e., at least one modification between amino acid positions 326 and 330 by Kabat numbering), wherein the modification increases the affinity of the C H 2 amino acid sequence to FcRn in an acidic environment (e.g., in an endosome where pH ranges from about 5.5 to about 6.0).
  • the heavy chain constant region nucleotide sequence encodes a human C H 3 amino acid sequence, wherein the C H 3 amino acid sequence comprises at least one modification between amino acid residues at positions 433 and 436 by EU numbering (i.e., at least one modification between amino acid residues at positions 464 and 467 by Kabat numbering), wherein the modification increases the affinity of the C H 3 amino acid sequence to FcRn in an acidic environment (e.g., in an endosome where pH ranges from about 5.5 to about 6.0).
  • EU numbering i.e., at least one modification between amino acid residues at positions 464 and 467 by Kabat numbering
  • the heavy chain constant region nucleotide sequence encodes a human heavy chain constant region amino acid sequence comprising a mutation selected from the group consisting of M428L by EU numbering (459 by Kabat numbering), N434S by EU numbering (465 by Kabat numbering), and a combination thereof.
  • the heavy chain constant region nucleotide sequence encodes a human heavy chain constant region amino acid sequence comprising a mutation selected from the group consisting of M428L by EU numbering (M459L by Kabat numbering), V259I by EU numbering (V272I by Kabat numbering), V308F by EU numbering (V327 by Kabat numbering), and a combination thereof.
  • the heavy chain constant region nucleotide sequence encodes a human heavy chain constant region amino acid sequence comprising an N434A mutation by EU numbering (an N465A mutation by Kabat numbering). In some embodiments, the heavy chain constant region nucleotide sequence encodes a human heavy chain constant region amino acid sequence comprising a mutation selected from the group consisting of M252Y by EU numbering (M265Y by Kabat numbering), S254T by EU numbering (S267T by Kabat numbering), T256E by EU numbering (T269E by Kabat numbering), and a combination thereof.
  • the heavy chain constant region nucleotide sequence encodes a human heavy chain constant region amino acid sequence comprising a mutation selected from the group consisting of T250Q by EU numbering (T263Q by Kabat numbering), M428L by EU numbering (M459L by Kabat numbering), or both. In some embodiments, the heavy chain constant region nucleotide sequence encodes a human heavy chain constant region amino acid sequence comprising a mutation selected from the group consisting of H433K by EU numbering (H464K by Kabat numbering), N434Y by EU numbering (N465Y by Kabat numbering), or both.
  • a genetically modified immunoglobulin locus comprises: (1) a first allele, wherein the rearranged human immunoglobulin heavy chain variable region nucleotide sequence as described herein is operably linked to a first heavy chain constant region nucleotide sequence encoding a first CH 3 amino acid sequence of a human IgG selected from IgG1, IgG2, IgG4, and a combination thereof; and (2) a second allele, wherein the rearranged human immunoglobulin heavy chain variable region nucleotide sequence as described herein is operably linked to a second heavy chain constant region nucleotide sequence encoding a second C H 3 amino acid sequence of the human IgG selected from IgG1, IgG2, IgG4, and a combination thereof, and wherein the second CH 3 amino acid sequence comprises a modification that reduces or eliminates binding for the second CH 3 amino acid sequence to Protein A (see, for example, U.S.
  • the second CH 3 amino acid sequence comprises an H95R modification (by IMGT exon numbering; H435R by EU numbering). In one embodiment the second CH 3 amino acid sequence further comprises an Y96F modification (by IMGT exon numbering; H436F by EU). In another embodiment, the second CH 3 amino acid sequence comprises both an H95R modification (by IMGT exon numbering; H435R by EU numbering) and an Y96F modification (by IMGT exon numbering; H436F by EU).
  • the second CH 3 amino acid sequence is from a modified human IgG1 and further comprises a mutation selected from the group consisting of D16E, L18M, N44S, K52N, V57M, and V82I (IMGT; D356E, L38M, N384S, K392N, V397M, and V422I by EU).
  • the second CH 3 amino acid sequence is from a modified human IgG2 and further comprises a mutation selected from the group consisting of N44S, K52N, and V82I (IMGT: N384S, K392N, and V422I by EU).
  • the second CH 3 amino acid sequence is from a modified human IgG4 and further comprises a mutation selected from the group consisting of Q15R, N44S, K52N, V57M, R69K, E79Q, and V82I (IMGT: Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I by EU).
  • the heavy chain constant region amino acid sequence is a non-human constant region amino acid sequence, and the heavy chain constant region amino acid sequence comprises one or more of any of the types of modifications described above.
  • Fc domains are modified to have altered Fc receptor binding, which in turn affects effector function.
  • an engineered heavy chain constant region which includes the Fc domain, is chimeric.
  • a chimeric C H region combines C H domains derived from more than one immunoglobulin isotype.
  • a chimeric C H region comprises part or all of a C H 2 domain derived from a human IgG1, human IgG2 or human IgG4 molecule, combined with part or all of a C H 3 domain derived from a human IgG1, human IgG2 or human IgG4 molecule.
  • a chimeric C H region contain a chimeric hinge region.
  • a chimeric hinge may comprise an “upper hinge” amino acid sequence (amino acid residues from positions 216 to 227 according to EU numbering; amino acid residues from positions 226 to 240 according to Kabat numbering) derived from a human IgG1, a human IgG2 or a human IgG4 hinge region, combined with a “lower hinge” sequence (amino acid residues from positions 228 to 236 according to EU numbering; amino acid positions from positions 241 to 249 according to Kabat numbering) derived from a human IgG1, a human IgG2 or a human IgG4 hinge region.
  • the chimeric hinge region comprises amino acid residues derived from a human IgG1 or a human IgG4 upper hinge and amino acid residues derived from a human IgG2 lower hinge.
  • the Fc domain may be engineered to activate all, some, or none of the normal Fc effector functions, without affecting the Fc-containing protein's (e.g. antibody's) desired pharmacokinetic properties.
  • Fc-containing protein's e.g. antibody's
  • the genome of the non-human animals is modified (i) to delete or render nonfunctional (e.g., via insertion of a nucleotide sequence (e.g., an exogenous nucleotide sequence)) in the immunoglobulin locus or via non-functional rearrangement or inversion of all, or substantially all, endogenous functional immunoglobulin V H , D, J H segments; and (ii) to comprise a rearranged human immunoglobulin heavy chain variable region nucleotide sequence, wherein the nucleotide sequence is present at an endogenous locus (i.e., where the nucleotide sequence is located in a wild type non-human animal).
  • a nucleotide sequence e.g., an exogenous nucleotide sequence
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is at an ectopic locus in the genome (e.g., at a locus different from the endogenous immunoglobulin chain locus in its genome, or within its endogenous locus, e.g., within an immunoglobulin variable locus, wherein the endogenous locus is placed or moved to a different location in the genome).
  • e.g., about 80% or more, about 85% or more, about 90% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more of all endogenous functional heavy chain V, D, or J gene segments are deleted or rendered non-functional.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a human or non-human heavy chain constant region gene sequence. In some embodiments, the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a human or non-human light chain constant region gene sequence, either kappa or lambda.
  • the genetically modified non-human animal comprises a modification that deletes or renders non-functional endogenous functional V H , D, and J H heavy chain variable gene segments and endogenous functional light chain variable V L and J L gene segments; and comprises (i) a rearranged human immunoglobulin heavy chain variable region nucleotide sequence and (ii) a nucleotide sequence encoding unrearranged human immunoglobulin light chain V gene segments (V L ) and unrearranged human immunoglobulin light chain J gene segments (J L ) (i.e., where the nucleotide sequence is located in a wild-type non-human animal) or at an ectopic location (e.g., at a locus different from the endogenous immunoglobulin chain locus in its genome, or within its endogenous locus, e.g., within an immunoglobulin variable region locus, wherein the endogenous locus is placed or moved to a different location in the genome).
  • V L unrearranged human immunoglobul
  • the genetically modified non-human animal comprises a modification that deletes or renders non-functional endogenous functional V H , D, and J H heavy chain variable gene segments and endogenous functional light chain variable V L and J L gene segments; and comprises (i) a rearranged human immunoglobulin heavy chain variable region nucleotide sequence and (ii) one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments (V L and J L ) at an endogenous location (i.e., where the nucleotide sequence is located in a wild-type non-human animal) or at an ectopic location (e.g., at a locus different from the endogenous immunoglobulin chain locus in its genome, or within its endogenous locus, e.g., within an immunoglobulin variable region locus, wherein the endogenous locus is placed or moved to a different location in the genome).
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a human or non-human heavy chain constant region gene sequence. In some embodiments, the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a human or non-human light chain constant region gene sequence, either kappa or lambda.
  • Nucleic acid sequences encoding light chain variable domains may be used in making the genetically modified non-humans described herein, may be expressed by such animals, and/or may encode amino acids present in antibodies bodied produced by (or derived from sequences diversified by) such animals.
  • the light chain variable domain is a human ⁇ light chain variable domain.
  • the light chain variable domain is a mouse ⁇ light chain variable domain.
  • the light chain variable domain is a rat ⁇ light chain variable domain.
  • the light chain variable domain is a human ⁇ light chain variable domain.
  • the light chain variable domain is a mouse ⁇ light chain variable domain.
  • the light chain variable domain is a rat ⁇ light chain variable domain.
  • the light chain variable domains produced by the genetically modified non-human animals described herein are encoded by one or more mouse or human immunoglobulin ⁇ light chain variable gene segments.
  • the one or more mouse immunoglobulin ⁇ light chain variable gene segments comprises about three megabases of the mouse immunoglobulin ⁇ light chain locus.
  • the one or more mouse immunoglobulin ⁇ light chain variable gene segments comprises at least 137 V ⁇ gene segments, at least five J ⁇ gene segments or a combination thereof of the mouse immunoglobulin ⁇ light chain locus.
  • the one or more human immunoglobulin ⁇ light chain variable gene segments comprises about one-half megabase of a human immunoglobulin ⁇ light chain locus.
  • the one or more human immunoglobulin ⁇ light chain variable gene segments comprises the proximal repeat (with respect to the immunoglobulin ⁇ constant region) of a human immunoglobulin ⁇ light chain locus. In some embodiments, the one or more human immunoglobulin ⁇ light chain variable gene segments comprises at least 40V ⁇ gene segments, at least five J ⁇ gene segments or a combination thereof of a human immunoglobulin ⁇ light chain locus.
  • the genetically modified non-human animals further comprise a nucleotide sequence encoding an unrearranged human immunoglobulin light chain (V L ) gene segment and an unrearranged human immunoglobulin light chain (J L ) gene segment.
  • V L human immunoglobulin light chain
  • J L human immunoglobulin light chain
  • the nucleotide sequence encoding the unrearranged light chain V gene segment and the unrearranged light chain J gene segment is operably linked to an immunoglobulin light chain constant region gene sequence.
  • the nucleotide sequence encoding the unrearranged light chain V gene segment and the unrearranged light chain J gene segment is operably linked to an immunoglobulin heavy chain constant region gene sequence.
  • the unrearranged human immunoglobulin light chain V (V L ) gene segment and the unrearranged human immunoglobulin J (J L ) gene segment are operably linked, at an endogenous rodent locus, to a rodent immunoglobulin light chain constant region gene; e.g., a ⁇ or ⁇ light chain constant region gene.
  • a rodent immunoglobulin light chain constant region gene e.g., a ⁇ or ⁇ light chain constant region gene.
  • the unrearranged human variable region gene segments are capable of rearranging and encoding human variable domains of an antibody.
  • the non-human animal does not comprise an endogenous V L gene segment.
  • the human V ⁇ gene segments expressed by the non-human animals are selected from the group consisting of V ⁇ 1-5, V ⁇ 1-6, V ⁇ 1-8, V ⁇ 1-9, V ⁇ 1-12, V ⁇ 1-13, V ⁇ 1-16, V ⁇ 1-17, V ⁇ 1-22, V ⁇ 1-27, V ⁇ 1-32, V ⁇ 1-33, V ⁇ 1-35, V ⁇ 1-37, V ⁇ 1-39, V ⁇ 1D-8, V ⁇ 1D-12, V ⁇ 1D-13, V ⁇ 1D-16, V ⁇ 1D-17, V ⁇ 1D-22, V ⁇ 1D-27, V ⁇ 1D-32, V ⁇ 1D-33, V ⁇ 1D-35, V ⁇ 1D-37, V ⁇ 1D-39, V ⁇ 1D-42, V ⁇ 1D-43, V ⁇ 1-NL1, V ⁇ 2-4, V ⁇ 2-10, V ⁇ 2-14, V ⁇ 2-18, V ⁇ 2-19, V ⁇ 2-23, V ⁇ 2-24, V ⁇ 2-26, V ⁇ 2-28, V ⁇ 2-29, V ⁇ 2-30, V ⁇ 2-36, V ⁇ 2-38, V ⁇
  • the genetically modified non-human animals described herein express all functional human V ⁇ genes.
  • the human V ⁇ gene segments comprise V ⁇ 4-1, V ⁇ 5-2, V ⁇ 7-3, V ⁇ 2-4, V ⁇ 1-5, and V ⁇ 1-6.
  • the V ⁇ gene segments comprise V ⁇ 3-7, V ⁇ 1-8, V ⁇ 1-9, V ⁇ 2-10, V ⁇ 3-11, V ⁇ 1-12, V ⁇ 1-13, V ⁇ 2-14, V ⁇ 3-15 and V ⁇ 1-16.
  • the human V ⁇ gene segments comprise V ⁇ 1-17, V ⁇ 2-18, V ⁇ 2-19, V ⁇ 3-20, V ⁇ 6-21, V ⁇ 1-22, V ⁇ 1-23, V ⁇ 2-24, V ⁇ 3-25, V ⁇ 2-26, V ⁇ 1-27, V ⁇ 2-28, V ⁇ 2-29, and V ⁇ 2-30.
  • the human V ⁇ gene segments comprise V ⁇ 3-31, V ⁇ 1-32, V ⁇ 1-33, V ⁇ 3-34, V ⁇ 1-35, V ⁇ 2-36, V ⁇ 1-37, V ⁇ 2-38, V ⁇ 1-39, and V ⁇ 2-40.
  • the non-human animal comprises five human J ⁇ gene segments, e.g., J ⁇ 1, J ⁇ 2, J ⁇ 3, J ⁇ 4, and J ⁇ 5 gene segments.
  • the V ⁇ gene segments comprise contiguous human immunoglobulin ⁇ gene segments spanning the human immunoglobulin K light chain locus from V ⁇ -4-1 through V ⁇ 2-40
  • the J ⁇ gene segments comprise contiguous gene segments spanning the human immunoglobulin ⁇ light chain locus from J ⁇ 1 through J ⁇ 5.
  • the immunoglobulin light chain locus comprises two human V L gene segments, V ⁇ 1-39 and V ⁇ 3-20.
  • one or more (e.g., 2, 3, 4, or 5) human V L gene segments and two or more human J L gene segments are present at an endogenous light chain locus, e.g., at an endogenous kappa light chain locus.
  • the genetically modified non-human animal is a mouse that comprises a functional ⁇ light chain locus. In other embodiments, the mouse comprises a non-functional ⁇ light chain locus.
  • the one or more human V H , one or more human D H , and one or more human J H gene segments are operably linked to a mouse or a rat heavy chain constant region sequence (i.e., the one or more human V L gene segments and two or more human J L gene segments are present at an endogenous heavy chain locus).
  • a genetically modified non-human animal e.g., mouse or rat
  • expresses a rearranged human immunoglobulin heavy chain variable region nucleotide sequence i.e., produces an antigen-binding protein comprising a rearranged heavy chain variable domain
  • V ⁇ genes selected from the group consisting of V ⁇ 1-5, V ⁇ 1-6, V ⁇ 1-8, V ⁇ 1-9, V ⁇ 1-12, V ⁇ 1-13, V ⁇ 1-16, V ⁇ 1-17, V ⁇ 1-22, V ⁇ 1-27, V ⁇ 1-32, V ⁇ 1D-33, V ⁇ 1-35, V ⁇ 1-37, V ⁇ 1-39, V ⁇ 1D-8, V ⁇ 1D-12, V ⁇ 1D-13, V ⁇ 1D-16, V ⁇ 1D-17, V ⁇ 1D-22, V ⁇ 1D-27, V ⁇ 1D-32, V ⁇ 1D-33, V ⁇ 1D-35, V ⁇ 1D-37, V ⁇ 1D-39, V ⁇ 1D-42, V ⁇ 1D-43, V ⁇ 1-NL1, V ⁇ 2-4, V ⁇ 2-10, V ⁇ 2-14, V ⁇ 2-18, V ⁇ 2-19, V ⁇ 2-23, V ⁇ 2-24, V ⁇ 2-26, V ⁇ 2-28, V ⁇ 2-29, V ⁇ 2-30, V ⁇ 2-36, V ⁇ 2-38, V ⁇ 2-40, V ⁇
  • the light chain variable region gene segments encode one or more histidine codons that are not encoded by a corresponding human germline light chain variable gene segment.
  • the light chain variable domain as described herein exhibits a decrease in dissociative half-life (t 1/2 ) at an acidic pH as compared to neutral pH of at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, or at least about 30-fold.
  • the decrease in t 1/2 at an acidic pH as compared to a neutral pH is about 30 fold or more.
  • At least one of the V L gene segments comprises a substitution of at least one non-histidine codon encoded by the corresponding human germline V L segment sequence with a histidine codon.
  • the substitution is of one, two, three, or four codons (e.g., three or four codons).
  • the substitution is in the CDR3 codon(s).
  • the human V L gene segments are human V ⁇ 1-39 and V ⁇ 3-20 gene segments, and each of the human V ⁇ 1-39 and V ⁇ 3-20 gene segments comprises a substitution of at least one non-histidine codon encoded by a corresponding human germline V L gene segment with the histidine codon.
  • each of the human V ⁇ 1-39 and V ⁇ 3-20 gene segments comprises a substitution of three or four histidine codons.
  • the three or four substitutions are in the CDR3 region.
  • the substitution is of three non-histidine codons of the human V ⁇ 1-39 gene segment, wherein the substitution is designed to express histidines at positions 106, 108, and 111.
  • the substitution is of four non-histidine codons of the human V ⁇ 1-39 gene segment, and the substitution is designed to express histidines at positions 105, 106, 108, and 111 (see, e.g., US 2013/0247234A1 and WO 2013/138680, incorporated by reference herein).
  • the substitution is of three non-histidine codons of the human V ⁇ 3-20 gene segment, and the substitution is designed to express histidines at positions 105, 106, and 109.
  • the substitution is of four non-histidine codons of the human V ⁇ 3-20 gene segment, and the substitution is designed to express histidines at positions 105, 106, 107, and 109.
  • the immunoglobulin light chain locus comprises one or more but less than the wild type number of human V L gene segments and one or more, e.g., two or more, human J L gene segments, wherein each of the human V L gene segments comprises at least one histidine codon that is not encoded by the corresponding human germline V L gene segment.
  • the non-human animal comprising the genetically modified immunoglobulin loci as described herein, upon stimulation by an antigen of interest, expresses an antigen-binding protein comprising an amino acid sequence derived from the human V L gene segments, wherein the antigen-binding protein retains at least one histidine residue at an amino acid position encoded by the at least one histidine codon introduced into the human V L gene segment.
  • the animal expresses a population of antigen-binding proteins in response to an antigen, wherein all antigen-binding proteins in the population comprise (a) immunoglobulin light chain variable domains derived from a rearrangement of the human V L gene segments and the J L gene segments, wherein at least one of the human V L gene segments encodes one or more histidine codons that are not encoded by the corresponding human germline V L gene segment, and (b) immunoglobulin heavy chains comprising human heavy chain variable domains encoded by the rearranged human immunoglobulin heavy chain variable region nucleotide sequence.
  • a first nucleotide sequence that encodes the rearranged heavy chain variable domain i.e., where the first nucleotide sequence is a rearranged human immunoglobulin heavy chain variable region nucleotide sequence
  • a second nucleotide sequence that encodes the human light chain variable domain i.e., where the second nucleotide sequence is an unrearranged human immunoglobulin light chain variable nucleotide sequence
  • a first nucleotide sequence that encodes the rearranged heavy chain variable domain i.e., where the first nucleotide sequence is a rearranged human immunoglobulin heavy chain variable region nucleotide sequence
  • a second nucleotide sequence that encodes the human light chain variable domain i.e., where the second nucleotide sequence is an unrearranged human immunoglobulin light chain variable nucleotide sequence
  • a first nucleotide sequence that encodes the rearranged heavy chain variable domain i.e., where the first nucleotide sequence is a rearranged human immunoglobulin heavy chain variable region nucleotide sequence
  • a second nucleotide sequence that encodes the human light chain variable domain i.e., where the second nucleotide sequence is an unrearranged human immunoglobulin light chain variable nucleotide sequence
  • the light chain constant region sequence operably linked to the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is a human ⁇ light chain constant region sequence.
  • the light chain constant region sequence operably linked to the rearranged heavy chain variable domain is a mouse ⁇ light chain constant region sequence. In some embodiments, the light chain constant region sequence operably linked to the rearranged heavy chain variable domain is a rat ⁇ light chain constant region sequence. In some embodiments, the light chain constant region sequence operably linked to the rearranged heavy chain variable domain is a human ⁇ light chain constant region sequence. In some embodiments, the light chain constant region sequence operably linked to the rearranged heavy chain variable domain is a mouse ⁇ light chain constant region sequence. In some embodiments, the light chain constant region sequence operably linked to the rearranged heavy chain variable domain is a rat ⁇ light chain constant region sequence.
  • non-human animals comprising a genetically modified immunoglobulin locus that encodes a rearranged heavy chain variable domain (i.e., where an immunoglobulin locus comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence), wherein the rearranged heavy chain variable domain comprises a heavy chain variable (V H ) sequence that is operably linked, via a spacer, to a heavy chain J segment (J H ) sequence, wherein the spacer comprises at least one amino acid residue.
  • V H heavy chain variable
  • J H heavy chain J segment
  • the spacer comprises at least one amino acid residue.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a non-human heavy chain constant region gene sequence.
  • the non-human heavy chain constant region gene sequence is a mouse or a rat constant region gene sequence.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a human heavy chain constant region gene sequence.
  • the heavy chain constant region comprises a sequence selected from a C H 1, a hinge, a C H 2, a C H 3, and a combination thereof.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a non-human light chain constant region gene sequence.
  • the non-human light chain constant region gene sequence is a mouse or a rat constant region gene sequence.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a human light chain constant region gene sequence.
  • the spacer is a single amino acid residue. In some embodiments, the spacers are two amino acid residues. In some embodiments, the spacers are three amino acid residues. In some embodiments, the spacers are four amino acid residues. In some embodiments, the spacers are five amino acid residues. In some embodiments, the spacers are six amino acid residues.
  • genetically modified non-human animals and methods for making said animals are provided in which the animals comprise a functional universal light chain (“ULC”) immunoglobulin locus.
  • such animals further comprise a rearranged heavy chain variable domain locus (i.e., a heavy chain variable domain immunoglobulin locus comprising a rearranged human immunoglobulin heavy chain variable region nucleotide sequence).
  • a ULC is a common light chain that can be used in a bispecific format that contains a function, e.g., a modification that affects FcRn binding to improve a half-life, e.g., a bispecific that comprises a heavy chain that binds an antigen and a light chain that binds FcRn.
  • the genetically modified mice as described herein are immunized with FcRN, to obtain antibodies that bind FcRN solely through the light chains.
  • These light chains produced by the genetically modified non-human animal are used as ULCs that assist the bispecific antibody to associate with an FcRn, thereby helping to increase half-life.
  • the remainder of the antibody e.g., either a second, different light chain, or a heavy chain that binds an antigen different than FcRn
  • a ULC as used in the embodiments described herein can also be used to generate antibody variable chain sequences whose diversity results primarily from the processes of somatic mutation (e.g., hypermutation), thereby elucidating antibody variable chain sequences whose antigen-binding capacity benefits from post-genomic events.
  • somatic mutation e.g., hypermutation
  • Various aspects include genetically modified non-human animals comprising in their genomes a rearranged human heavy chain variable region nucleic acid sequence, and further comprising in their genomes a nucleic acid encoding a light chain variable domain as described herein cloned onto a constant region nucleic acid sequence selected from a kappa constant region, a lambda constant region, a heavy chain constant region (e.g., selected from the group consisting of a CH1, a hinge, a CH2, a CH3, and a combination thereof).
  • a constant region nucleic acid sequence selected from a kappa constant region, a lambda constant region, a heavy chain constant region (e.g., selected from the group consisting of a CH1, a hinge, a CH2, a CH3, and a combination thereof).
  • the light chain variable region nucleic acid sequence is cloned onto a first human heavy chain constant region nucleic acid sequence, and a second light chain variable domain is cloned onto a second human heavy chain constant region nucleic acid sequence; wherein the first and the second human heavy chain constant region nucleic acid sequence are the same, the first light chain variable domain specifically binds a first antigen, and the second light chain variable domain specifically binds a second antigen.
  • a dimer of two polypeptides is formed, wherein each of the light chain variable domains fused to the heavy chain constant region exhibit distinct antigen-binding specificity.
  • a genetically modified non-human animal e.g., mouse
  • a genetically modified non-human animal e.g., mouse
  • a receptor or other moiety that traverses the blood-brain barrier, e.g., the transferrin receptor.
  • Previous studies have shown that low affinity antibodies directed against the transferrin receptor will traverse the blood-brain barrier and be released due to low affinity.
  • the genetically modified animals e.g., mice
  • a low affinity antibody to a moiety that is capable of traversing the blood-brain barrier (e.g., a transferrin receptor), wherein the low affinity antibody is bispecific and comprises a second binding specificity to a desired target (i.e., the antibody binds the traversing moiety, and also binds a different target than the traversing moiety).
  • a desired target i.e., the antibody binds the traversing moiety, and also binds a different target than the traversing moiety.
  • Methods of making and using the genetically modified non-human animals described herein are provided. Methods are provided for placing a rearranged human heavy chain variable region nucleic acid sequence in operable linkage with an immunoglobulin heavy or light chain constant region nucleic acid sequence in the genome of a non-human animal.
  • the constant region nucleic acid sequence is human or non-human, and the non-human animal is a rodent.
  • the methods comprise making a non-human animal that further comprises an immunoglobulin light chain locus comprising one or more but less than the wild type number of human light chain variable region gene segments, e.g., two human V ⁇ gene segments and one or more human J ⁇ gene segments, operably linked to a human or non-human light chain constant region nucleic acid sequence.
  • an immunoglobulin light chain locus comprising one or more but less than the wild type number of human light chain variable region gene segments, e.g., two human V ⁇ gene segments and one or more human J ⁇ gene segments, operably linked to a human or non-human light chain constant region nucleic acid sequence.
  • the methods comprise placing the aforementioned sequences in the germline of a non-human animal, e.g., a rodent, employing, e.g., transgenic technology including, e.g., employing modified pluripotent or totipotent donor cells (e.g., ES cells or iPS cells) with host embryos, germ cells (e.g., oocytes), etc.
  • a non-human animal e.g., a rodent
  • transgenic technology including, e.g., employing modified pluripotent or totipotent donor cells (e.g., ES cells or iPS cells) with host embryos, germ cells (e.g., oocytes), etc.
  • embodiments include a non-human immunoglobulin heavy chain locus in a genome of a non-human germ cell comprising a rearranged human immunoglobulin heavy chain variable region nucleotide sequence operably linked to a heavy chain constant region gene sequence, wherein the constant region gene sequence comprises a non-human sequence, a human sequence, or a combination thereof.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to an endogenous non-human immunoglobulin constant region gene sequence.
  • the endogenous non-human immunoglobulin constant region gene sequence is a mouse or a rat heavy chain constant region gene sequence.
  • a method of making a non-human animal that comprises a genetically modified immunoglobulin locus comprises: (a) modifying a genome of a non-human animal to delete or render non-functional endogenous functional immunoglobulin heavy chain V, D, and J gene segments; and (b) placing in the genome a rearranged human immunoglobulin heavy chain variable region nucleotide sequence.
  • a method for making a non-human animal that expresses a single immunoglobulin heavy chain from a rearranged heavy chain gene sequence in the germline of the non-human animal, the method comprising a step of genetically modifying a non-human animal such that its entire antibody-expressing mature B cell population expresses a heavy chain derived from (i) a single V H gene segment; (ii) an amino acid spacer of one, two, three, four, five, or six amino acids; and (iii) a single J H gene segment.
  • the method comprises inactivating or replacing an endogenous heavy chain immunoglobulin variable locus with a single rearranged heavy chain gene as described herein.
  • methods of making a non-human animal that comprises a genetically modified immunoglobulin heavy chain locus comprising: (a) modifying a genome of a non-human animal to delete or render non-functional endogenous functional immunoglobulin heavy chain V, D, and J gene segments; and (b) placing in the genome a rearranged human immunoglobulin heavy chain variable region nucleotide sequence.
  • substantially all endogenous functional V H , D, and J H gene segments are deleted from the immunoglobulin heavy chain locus of the non-human animal or rendered non-functional (e.g., via insertion of a nucleotide sequence (e.g., an exogenous nucleotide sequence in the immunoglobulin locus or via non-functional rearrangement, or inversion of, endogenous V H , D, J H segments).
  • a nucleotide sequence e.g., an exogenous nucleotide sequence in the immunoglobulin locus or via non-functional rearrangement, or inversion of, endogenous V H , D, J H segments.
  • the method comprises inserting a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (i.e., a nucleotide sequence that encodes the rearranged heavy chain variable domain) into an endogenous location (i.e., targeted to where the nucleotide sequence is located in a wild type non-human animal).
  • a rearranged human immunoglobulin heavy chain variable region nucleotide sequence i.e., a nucleotide sequence that encodes the rearranged heavy chain variable domain
  • an endogenous location i.e., targeted to where the nucleotide sequence is located in a wild type non-human animal.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is present ectopically (e.g., at a locus different from the endogenous immunoglobulin chain locus in its genome, or within its endogenous locus, e.g., within an immunoglobulin variable locus, wherein the endogenous locus is placed or moved to a different location in the genome).
  • e.g., about 80% or more, about 85% or more, about 90% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more of all endogenous functional V, D, or J gene segments are deleted or rendered non-functional.
  • at least 95%, 96%, 97%, 98%, or 99% of endogenous functional heavy chain V, D, or J gene segments are deleted or rendered non-functional.
  • methods for making a non-human animal that comprises a genetically modified immunoglobulin locus, comprising: (a) modifying a genome of a non-human animal to delete or render non-functional endogenous functional immunoglobulin light chain V and J gene segments; and (b) placing in an endogenous immunoglobulin light chain locus a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (i.e., a nucleotide sequence that encodes a rearranged heavy chain variable domain), wherein the nucleotide sequence is operably linked to a light chain constant region gene sequence.
  • the genetically engineered immunoglobulin locus is present in the germline genome of the non-human animal.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a ⁇ light chain constant region gene sequence. In some embodiments, the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a mouse or rat ⁇ light chain constant region gene sequence. In some embodiments, the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a human ⁇ light chain constant region gene sequence. In some embodiments, the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a ⁇ light chain constant region gene sequence.
  • rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a mouse or rat ⁇ light chain constant region gene sequence. In some embodiments, the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a human ⁇ light chain constant region gene sequence.
  • methods for making a non-human animal that comprises a genetically modified immunoglobulin locus comprising: (a) modifying a genome of a non-human animal to delete or render non-functional: (i) endogenous functional immunoglobulin heavy chain V, D, and J gene segments, and (ii) endogenous functional immunoglobulin light chain V and J gene segments; and (b) placing in the genome: (i) a first nucleotide sequence that encodes a rearranged heavy chain variable domain (i.e., where the first nucleotide sequence is a rearranged human immunoglobulin heavy chain variable region nucleotide sequence), wherein the first nucleotide sequence is operably linked to a light chain constant region gene sequence, and (ii) a second nucleotide sequence that encodes a human immunoglobulin light chain variable domain (i.e., where the second nucleotide sequence is an unrearranged human immunoglobulin light chain variable region nucleotide sequence
  • the genetically engineered immunoglobulin locus is present in the germline genome of the non-human animal.
  • the first nucleotide sequence that encodes the rearranged heavy chain variable domain is operably linked to a K light chain constant region gene sequence.
  • the first nucleotide sequence that encodes the rearranged heavy chain variable domain is operably linked to a mouse or rat ⁇ light chain constant region gene sequence.
  • the first nucleotide sequence that encodes the rearranged heavy chain variable domain is operably linked to a human ⁇ light chain constant region gene sequence.
  • the first nucleotide sequence that encodes the rearranged heavy chain variable domain is operably linked to a ⁇ light chain constant region gene sequence. In some embodiments, the first nucleotide sequence that encodes the rearranged heavy chain variable domain is operably linked to a mouse or rat ⁇ light chain constant region gene sequence. In some embodiments, the first nucleotide sequence that encodes the rearranged heavy chain variable domain is operably linked to a human ⁇ light chain constant region gene sequence. In some embodiments, the human immunoglobulin light chain variable domain is a ⁇ light chain variable domain.
  • the second nucleotide sequence is a human kappa light chain variable region nucleotide sequence.
  • the human immunoglobulin light chain variable domain is a ⁇ light chain variable domain.
  • the second nucleotide sequence is a human lambda light chain variable region nucleotide sequence.
  • the heavy chain constant region gene sequence is a non-human immunoglobulin heavy chain constant region gene sequence.
  • the non-human immunoglobulin heavy chain constant region gene sequence is a mouse or a rat heavy chain constant region gene sequence.
  • methods for making a non-human animal that comprises a genetically modified immunoglobulin locus comprising: (a) modifying a genome of a non-human animal to delete or render non-functional: (i) endogenous functional immunoglobulin heavy chain V, D, and J gene segments, and (ii) endogenous functional immunoglobulin light chain V and J gene segments; and (b) placing in the genome: (i) a first nucleotide sequence that encodes a rearranged heavy chain variable domain (i.e., where the first nucleotide sequence is a rearranged human immunoglobulin heavy chain variable region nucleotide sequence), wherein the first nucleotide sequence is operably linked to a heavy chain constant region gene sequence, and (ii) a second nucleotide sequence that encodes a human immunoglobulin light chain variable domain (i.e., where the second nucleotide sequence is an unrearranged human immunoglobulin light chain variable region nucleotide sequence
  • the light chain constant region gene sequence is a ⁇ light chain constant region gene sequence. In some embodiments, the light chain constant region gene sequence is a mouse or rat ⁇ light chain constant region gene sequence. In some embodiments, the light chain constant region gene sequence is a human ⁇ light chain constant region gene sequence. In some embodiments, the light chain constant region gene sequence is a ⁇ light chain constant region gene sequence. In some embodiments, the light chain constant region gene sequence is a mouse or rat ⁇ light chain constant region gene sequence. In some embodiments, the light chain constant region gene sequence is a human ⁇ light chain constant region gene sequence. In some embodiments, the human immunoglobulin light chain variable domain is a ⁇ light chain variable domain.
  • the human immunoglobulin light chain variable domain is a ⁇ light chain variable domain.
  • the heavy chain constant region gene sequence is a non-human immunoglobulin heavy chain constant region gene sequence.
  • the non-human immunoglobulin heavy chain constant region gene sequence is a mouse or a rat heavy chain constant region gene sequence.
  • a method of making a non-human animal that comprises a genetically modified immunoglobulin heavy chain locus comprising: (a) modifying a genome of a non-human animal to delete or render non-functional endogenous functional immunoglobulin heavy chain V, D, and J gene segments; and (b) placing in the genome a rearranged human immunoglobulin heavy chain variable region nucleotide sequence, wherein the rearranged human immunoglobulin heavy chain variable region nucleotide sequence comprises a heavy chain V gene segment (V H ) sequence that is operably linked, via spacer, to a heavy chain J gene segment (J H ) sequence, wherein the spacer comprises at least one amino acid residue.
  • V H heavy chain V gene segment
  • J H heavy chain J gene segment
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a non-human immunoglobulin heavy chain constant region gene sequence.
  • the non-human immunoglobulin heavy chain constant region gene sequence is a mouse or rat immunoglobulin heavy chain constant region gene sequence.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a non-human immunoglobulin light chain constant region gene sequence.
  • the non-human immunoglobulin light chain constant region gene sequence is a mouse or rat immunoglobulin light chain constant region gene sequence.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is present at an endogenous location (i.e., where the nucleotide sequence is located in a wild-type non-human animal). In some embodiments the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is present ectopically (e.g., at a locus different from the endogenous immunoglobulin chain locus in its genome, or within its endogenous locus, e.g., within an immunoglobulin variable locus, wherein the endogenous locus is placed or moved to a different location in the genome). In some embodiments, the spacers are a single amino acid residue.
  • the spacers are two amino acid residues. In some embodiments, the spacers are three amino acid residues. In some embodiments, the spacers are four amino acid residues. In some embodiments, the spacers are five amino acid residues. In some embodiments, the spacers are six amino acid residues.
  • the nucleotide sequences encodes two copies, three copies, four copies, or more of the rearranged human immunoglobulin heavy chain variable region nucleotide sequence operably linked to a heavy chain constant domain gene sequence. In some embodiments, the nucleotide sequence encodes a plurality of copies of the rearranged human immunoglobulin heavy chain variable region nucleotide sequence operably linked to a heavy chain constant domain gene sequence.
  • Methods are provided for making a non-human animal, comprising: (a) modifying a genome of a non-human animal to delete or render non-functional (i) endogenous functional immunoglobulin heavy chain V H , D, and/or J H gene segments, and (ii) endogenous functional immunoglobulin light chain V and J gene segments; and (b) placing (i) a rearranged heavy chain variable region nucleic acid sequence at a heavy chain locus, wherein the rearranged heavy chain variable region nucleic acid sequence comprises a heavy chain V gene segment (V H ) sequence that is operably linked, via spacer, to a heavy chain J gene segment (J H ) sequence, wherein the spacer comprises at least one amino acid residue; and (ii) one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments (e.g., two human V ⁇ gene segments and at least one human J ⁇ gene segments) operably linked to a human or non-human light chain constant region nucleic acid sequence
  • a method for making a non-human animal comprising a genetically modified immunoglobulin locus comprising:
  • the non-human animal is a rodent, e.g., a mouse, a rat, or a hamster.
  • the rodent is a mouse.
  • the light chain constant region is a rat or a mouse constant region, e.g., a rat or a mouse CK constant region.
  • a method for making a non-human animal comprising a genetically modified immunoglobulin locus comprising:
  • a method for making a non-human animal that comprises a genetically modified immunoglobulin locus comprising:
  • a method for making a non-human animal that comprises a genetically modified immunoglobulin locus comprising:
  • a method of making a non-human animal that comprises a genetically modified immunoglobulin heavy chain locus comprising: (a) modifying a genome of a non-human animal to delete or render non-functional endogenous functional immunoglobulin heavy chain V, D, and/or J gene segments; and (b) placing in the genome rearranged human immunoglobulin heavy chain variable region nucleotide sequence, wherein the rearranged human immunoglobulin heavy chain variable region nucleotide sequence comprises a heavy chain V gene segment (V H ) sequence that is operably linked, via spacer, to a heavy chain J gene segment (J H ) sequence, wherein the spacer comprises at least one amino acid residue.
  • V H heavy chain V gene segment
  • J H heavy chain J gene segment
  • a method for making a non-human animal comprising a genetically modified immunoglobulin locus comprising:
  • a method for making a non-human animal comprising a genetically modified immunoglobulin locus comprising:
  • nucleic acid sequences encoding a rearranged heavy chain variable domain i.e., nucleotide sequences that are rearranged human immunoglobulin heavy chain variable region nucleotide sequences; i.e., a pre-rearranged variable heavy chain VDJ nucleotide sequence
  • the nucleic acid sequence is derived from a human V, D, and J gene sequence or segment.
  • the nucleic acid sequence is derived from a human germline V segment, a human germline D segment, and a human germline J segment.
  • the human V H segment corresponds to observed variants in the human population.
  • the nucleic acid sequence comprises a human V gene selected from the group consisting of V H 1-2, V H 1-3, V H 1-8, V H 1-18, V H 1-24, V H 1-45, V H 1-46, V H 1-58, V H 1-69, V H 2-5, V H 2-26, V H 2-70, V H 3-7, V H 3-9, V H 3-11, V H 3-13, V H 3-15, V H 3-16, V H 3-20, V H 3-21, V H 3-23, V H 3-30, V H 3-30-3, V H 3-30-5, V H 3-33, V H 3-35, V H 3-38, V H 3-43, V H 3-48, V H 3-49, V H 3-53, V H 3-64, V H 3-66, V H 3-72, V H 3-73, V H 3-74, V H 4-4, V H 4-28, V H 4-30-1, V H 4-30-2, V H 4-30-4, V H 4-31, V H 4-34, V H 4-39, V H 4-59, V
  • the human V segment is V H 3-23 or polymorphic variant thereof.
  • the nucleic acid sequence comprises a human D gene segment selected from the group consisting of D1-1, D1-7, D1-14, D1-20, D1-26, D2-2, D2-8, D2-15, D2-21, D3-3, D3-9, D3-10, D3-16, D3-22, D4-4, D4-11, D4-17, D4-23, D5-12, D5-5, D5-18, D5-24, D6-6, D6-13, D6-19, D6-25, D7-27, and a polymorphic variant thereof.
  • the nucleic acid sequence comprises a human D segment that is not autoreactive (non-immunogenic) in the animal. In some embodiments, the nucleic acid sequence comprises a human D segment that is capable of being expressed in a heavy chain variable sequence of a mature B cell of a mouse. In some embodiments, the nucleic acid sequence further comprises a human or non-human animal heavy chain constant region gene sequence selected from a C H 1, a hinge, a C H 2, a C H 3, and a combination thereof. In specific embodiments, the nucleic acid comprises a constant region gene sequence comprising a C H 1, a hinge, a C H 2, and a C H 3.
  • the nucleic acid sequence comprises a human J gene segment is selected from the group consisting of J H 1, J H 2, J H 3, 44, J H 5, J H 6, and a polymorphic variant thereof.
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence encodes the sequence of human V H 3-23/GY/J H 4-4 (SEQ ID NO: 137).
  • the nucleic acid sequence encodes a rearranged heavy chain variable domain comprising the sequence of human V H 3-23/X 1 X 2 /J (wherein X1 is any amino acid, and X2 is any amino acid).
  • X 1 is Gly and X 2 is Tyr.
  • the nucleic acid sequence encodes a rearranged heavy chain variable domain comprising the sequence of human V H 3-23/X 1 X 2 /J H 4-4 (wherein X1 is any amino acid, and X 2 is any amino acid).
  • X 2 is an amino acid comprising a phenyl group.
  • X 2 is selected from Tyr and Phe.
  • the nucleic acid sequence further comprises a human or non-human animal light chain constant region gene sequence.
  • a nucleic acid construct comprising a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (i.e., a pre-rearranged heavy chain VDJ sequence) as described herein.
  • the nucleic acid construct is designed in such a way that the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a human or non-human animal heavy chain constant region gene sequence.
  • the nucleic acid construct contains two copies, three copies, four copies, or more of the rearranged human immunoglobulin heavy chain variable region nucleotide sequence operably linked to a heavy chain constant region gene sequence.
  • the nucleic acid construct is a targeting vector.
  • the targeting vector comprises an Adam6a gene, an Adam6b gene, or both, in order to prevent fertility problems associated with the deletion of the Adam6a/6b genes (see, for example, US 2012-0322108A1, incorporated by reference in its entirety).
  • the Adam6a and the Adam6b genes are placed at 5′ upstream of the transcriptional unit of the universal heavy chain sequence.
  • the targeting vector comprises a selection cassette flanked by recombination sites.
  • the targeting vector comprises one or more site-specific recombination sites (e.g., a loxP or a FRT site).
  • methods for obtaining a light chain variable region (V L ) amino acid sequence capable of binding an antigen independently from a heavy chain variable region amino acid sequence, comprising: (a) immunizing a genetically modified non-human animal as described herein (e.g., a genetically modified animal comprising a rearranged human heavy chain variable region nucleic acid sequence in operable linkage to a heavy or light chain constant region nucleic acid sequence) with an antigen of interest, wherein the non-human animal mounts an immune response to the antigen; and (b) obtaining a rearranged light chain (VJ) nucleic acid sequence of a light chain variable domain that specifically binds the antigen from a cell (e.g., mature B cell) of the genetically modified non-human animal.
  • VJ rearranged light chain
  • methods for obtaining a nucleic acid sequence that encodes an immunoglobulin light chain variable region (V L ) domain capable of binding an antigen independently from a heavy chain variable region comprising: (a) immunizing a non-human animal with an antigen of interest or an immunogen thereof, wherein the non-human animal comprises in its genome (i) a rearranged human immunoglobulin heavy chain variable region nucleic acid sequence operably linked to a heavy chain constant region nucleic acid sequence, (b) allowing the non-human animal to mount an immune response, (c) isolating from the immunized non-human animal a cell comprising a nucleic acid sequence that encodes a light chain variable domain that can bind the antigen, and (d) obtaining from the cell a nucleic acid sequence that encodes the light chain variable domain (V L domain) that can bind the antigen.
  • the heavy chain constant region gene sequence is a mouse or rat heavy chain constant region gene sequence. In some embodiments, the heavy chain constant region gene sequence is a human heavy chain constant region gene sequence. In some embodiments, the rearranged heavy chain variable domain expressed by the genetically modified locus is not autoreactive, i.e., non-immunogenic to the non-human animal. In some embodiments, the non-human animal further comprises in its genome two or more but less than the wild type number of human immunoglobulin light chain variable region gene segments (V L and J L ). In some embodiments, the human immunoglobulin light chain variable region gene segments (V L and J L ) are operably linked to a light chain constant region nucleic acid sequence.
  • the isolating step (c) is carried out via fluorescence-activated cell sorting (FACS) or flow cytometry.
  • the cell comprising the nucleic acid sequence that encodes the light chain variable domain that bind the antigen is a lymphocyte.
  • the lymphocyte comprises natural killer cells, T cells, or B cells.
  • the method further comprises a step of (c)′ fusing the lymphocyte with a cancer cell.
  • the cancer cell is a myeloma cell.
  • V L immunoglobulin light chain variable domain
  • V L immunoglobulin light chain variable domain
  • V L immunoglobulin light chain variable domain
  • V L immunoglobulin light chain variable domain
  • V L immunoglobulin light chain variable domain
  • V L immunoglobulin light chain variable region
  • V L immunoglobulin light chain variable domain
  • V L immunoglobulin light chain variable region
  • V L immunoglobulin light chain variable region
  • the light chain variable domain described herein is an effector light chain variable domain.
  • the effector light chain variable domain specifically binds FcRn in order to improve a half-life of multispecific antibodies.
  • a bispecific antibody comprises a heavy chain variable domain that binds an antigen and a light chain variable domain that binds FcRn.
  • the genetically modified mice as described herein are immunized with FcRN, to obtain antibodies that bind FcRN solely through the light chains. These light chains produced by the genetically modified non-human animal are used as universal or common light chains that assist the bispecific antibody to associate with an FcRn, thereby helping to increase half-life.
  • the remainder of the antibody e.g., either a second, different light chain, or a heavy chain that binds an antigen different than FcRn is selected to perform a second function.
  • a genetically modified immunoglobulin locus obtainable by any of the methods as described herein is provided.
  • the light chain variable regions produced by the methods as described herein and the nucleic acid sequence encoding such light chain variable regions are also provided.
  • an immunoglobulin locus in a germline genome of a non-human animal comprising (1) a rearranged human immunoglobulin heavy chain variable region nucleotide sequence that is operably linked to a heavy chain constant region gene sequence, and (2) an unrearranged human immunoglobulin light chain variable region nucleotide sequence that is operably linked to a light chain constant region gene sequence.
  • an immunoglobulin locus in a germline genome of a non-human animal comprising (1) a rearranged human immunoglobulin heavy chain variable region nucleotide sequence that is operably linked to a light chain constant region gene sequence, and (2) an unrearranged human immunoglobulin light chain variable region nucleotide sequence that is operably linked to a heavy chain constant region gene sequence.
  • an immunoglobulin locus in a germline genome of a non-human animal comprising (1) a rearranged human immunoglobulin heavy chain variable region nucleotide sequence that is operably linked to a heavy chain constant region gene sequence, and (2) a nucleotide sequence that encodes two or more but less than the wild type number of human immunoglobulin light chain variable region gene segments (V L and J L ).
  • the light chain constant region gene sequence is a ⁇ light chain constant region gene sequence.
  • the light chain constant region gene sequence is a ⁇ light chain constant region gene sequence.
  • the light chain constant region gene sequence is a mouse or rat light chain constant region gene sequence.
  • the light chain variable region nucleotide sequence is a ⁇ light chain variable region gene sequence. In some embodiments, the light chain variable region nucleotide sequence is a ⁇ light chain variable region gene sequence. In some embodiments, the light chain variable region nucleotide sequence is a mouse or rat light chain variable region gene sequence.
  • antigen-binding proteins e.g. antibodies
  • antigen-binding proteins e.g., recombinant antibodies
  • V L light chain variable region
  • the antigen-binding proteins produced by the methods as described herein comprise a heavy chain and a light chain, wherein the heavy chain does not interfere with the binding of the light chain to the antigen, and/or the heavy chain does not bind the antigen in the absence of the light chain.
  • the light chain variable domain binds an antigen of interest with a K D that is no more than one order of magnitude higher in the absence of heavy chain than in the presence of heavy chain (e.g., K D ⁇ 10 ⁇ 10 in the presence of heavy chain or K D ⁇ 10 ⁇ 9 in the absence of heavy chain).
  • the antigen-binding proteins as described herein include an immunoglobulin light chain that can specifically bind an antigen of interest with an affinity (K D ) lower than 10 ⁇ 6 , 10 ⁇ 7 , 10 ⁇ 8 , 10 ⁇ 9 or 10 ⁇ 10 .
  • the immunoglobulin light chain produced by the methods are capable of specifically binding an antigen of interest in the absence of a heavy chain variable region with an affinity (K D ) lower than 10 ⁇ 6 , 10 ⁇ 7 , 10 ⁇ 8 , 10 ⁇ 9 , or 10 ⁇ 10 .
  • the light chain variable domains generated as described herein specifically bind a target molecule (“T”).
  • a target molecule is any protein, polypeptide, or other macromolecule whose activity or extracellular concentration is desired to be attenuated, reduced or eliminated.
  • the target molecule to which a light chain variable region binds is a protein or polypeptide (i.e., a “target protein”); however, also provided are embodiments wherein the target molecule (“T”) is a carbohydrate, glycoprotein, lipid, lipoprotein, lipopolysaccharide, or other non-protein polymer or molecule to which a light chain variable region binds.
  • T can be a cell surface-expressed target protein or a soluble target protein.
  • Target binding by the antigen-binding molecule may take place in an extracellular or cell surface context.
  • the antigen-binding molecule binds a target molecule inside the cell, for example within an intracellular component such as the endoplasmic reticulum, Golgi, endosome, lysosome, etc.
  • cell surface-expressed target molecules include cell surface-expressed receptors, membrane-bound ligands, ion channels, and any other monomeric or multimeric polypeptide component with an extracellular portion that is attached to or associated with a cell membrane.
  • Non-limiting, exemplary cell surface-expressed target molecules that may be targeted by the multispecific antigen-binding molecules provided herein include, e.g., cytokine receptors (e.g., receptors for IL-1, IL-4, IL-6, IL-13, IL-22, IL-25, IL-33, etc.), as well as cell surface targets including other type 1 transmembrane receptors such as PRLR, G-protein coupled receptors such as GCGR, ion channels such as Nav1.7, ASIC1 or ASIC2, non-receptor surface proteins such as MHC-I (e.g., HLA-B*27), etc.
  • cytokine receptors e.g., receptors for IL-1, IL-4, IL-6, IL-13, IL-22, IL-25, IL-33, etc.
  • cell surface targets including other type 1 transmembrane receptors such as PRLR, G-protein coupled receptors such as GCGR, ion channels such as Nav1.7
  • the D1 component of the multispecific antigen-binding molecule can be, e.g., an antibody or antigen-binding fragment of an antibody that specifically binds T, or a ligand or portion of a ligand that specifically interacts with the cell surface-expressed target protein.
  • T is IL-4R
  • the D1 component can comprise or consist of IL-4 or a receptor-binding portion thereof.
  • soluble target molecules include cytokines, growth factors, and other ligands and signaling proteins.
  • Non-limiting exemplary soluble target protein that may be targeted by the multispecific antigen-binding molecules provided herein include, e.g., IL-1, IL-4, IL-6, IL-13, IL-22, IL-25, IL-33, SOST, DKK1, etc.
  • Soluble targets molecules also include, e.g., non-human target molecules such as allergens (e.g., Fel D1, Betv1, CryJ1), pathogens (e.g., Candida albicans, S. aureus , etc.), and pathogenic molecules (e.g., lipopolysaccharide (LPS), lipotechoic acid (LTA), Protein A., toxins, etc.).
  • allergens e.g., Fel D1, Betv1, CryJ1
  • pathogens e.g., Candida albicans, S. aureus , etc.
  • pathogenic molecules e.g., lipopolysaccharide (LPS), lip
  • the D1 component of the multispecific antigen-binding molecule can be, e.g., an antibody or antigen-binding fragment of an antibody that specifically binds T, or a receptor or portion of a receptor that specifically interacts with the soluble target molecule.
  • the D1 component can comprise or consist of IL-4R or a ligand-binding portion thereof.
  • Target molecules also include tumor-associated antigens.
  • antigen-binding proteins e.g., bispecific or trispecific antibodies
  • antigen-specific light chain variable domains derived from (i.e., with human light chain variable region (V L ) sequences generated by) a non-human animal comprising an immunoglobulin locus with a rearranged human heavy chain variable region nucleic acid sequence (i.e., an animal comprising a predesigned, rearranged heavy chain VDJ sequence).
  • V L human light chain variable region
  • Such antigen-specific, reverse chimeric (e.g., human variable/mouse constant) light chains can be used to derive antigen-specific light chain variable region sequences that can be cloned in-frame into an expression vector with a suitable human light chain constant region sequence.
  • An antigen-specific human heavy chain variable region(s) (specific for a different epitope on the same or different antigen than the antigen-specific light chain) from an animal comprising an immunoglobulin locus with a rearranged human heavy chain variable region nucleic acid sequence (i.e., a mouse comprising a predesigned, rearranged heavy chain VDJ sequence), can be cloned in-frame into an expression vector comprising human heavy chain constant region sequence, and the antigen-specific human light and heavy chains can be co-expressed in a suitable cell to obtain an antigen-binding protein (e.g., bispecific or trispecific human antibody).
  • an antigen-binding protein e.g., bispecific or trispecific human antibody
  • a previously selected antigen-specific heavy chain e.g., a heavy chain from an antibody that comprises a light chain derived from the same variable region gene segment as the one used in the rearranged human heavy chain variable region nucleic acid sequence may be cloned in-frame into an expression vector comprising human heavy chain constant region sequence, and the antigen-specific human light and heavy chains can be co-expressed in a suitable cell to obtain an antigen-binding protein (e.g., bispecific or trispecific human antibody).
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a non-human heavy chain constant region gene sequence (e.g., mouse or rat, kappa or lambda).
  • the rearranged human immunoglobulin heavy chain variable region nucleotide sequence is operably linked to a non-human light chain constant region gene sequence (e.g., mouse or rat, kappa or lambda).
  • a non-human light chain constant region gene sequence e.g., mouse or rat, kappa or lambda.
  • the human light chain variable region (V L ) sequences are kappa gene sequences.
  • a method for making a multispecific antigen-binding protein comprising:
  • a method for making a multispecific antigen-binding protein comprising:
  • a method for making a multispecific antigen-binding protein comprising:
  • a method for making a multispecific antigen-binding protein comprising:
  • a method for making a multispecific antigen-binding protein comprising:
  • methods are provided for making an antigen-binding protein that comprises an immunoglobulin light chain variable domain that can bind an antigen independently from a heavy chain variable domain. Such methods comprise
  • methods are provided for making an antigen-binding protein that comprises an immunoglobulin light chain variable domain that can bind an antigen independently from a heavy chain variable domain. Such methods comprise
  • methods are provided for making an antigen-binding protein that comprises an immunoglobulin light chain variable domain that can bind an antigen independently from a heavy chain variable domain. Such methods comprise
  • one of the heavy chains is modified to omit a Protein A-binding determinant, resulting in a differential Protein A-binding affinity of a homodimeric binding protein from a heterodimeric binding protein.
  • Compositions and methods that address this issue are described in U.S. Pat. No. 8,586,713, granted 19 Nov. 2013, entitled “Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format,” hereby incorporated by reference.
  • this bispecific antigen binding protein can be screened to confirm the retention of its pH-dependent antigen binding property.
  • a pluripotent cell, induced pluripotent, or totipotent stem cells derived from a non-human animal comprising the various genomic modifications herein are provided.
  • the pluripotent or totipotent cell is derived from a non-human animal.
  • the non-human animal is a rodent, e.g., a mouse, a rat, or a hamster.
  • the rodent is a mouse.
  • the pluripotent cell is an embryonic stem (ES) cell.
  • the pluripotent cell comprises in its genome: (i) an immunoglobulin heavy chain locus that comprises a rearranged human heavy chain variable region nucleic acid sequence operably linked to a heavy chain constant region nucleic acid sequence; and (ii) an immunoglobulin light chain locus comprising one or more but less than the wild type number of human immunoglobulin light chain variable V L and J L gene segments, operably linked to a light chain constant region nucleic acid sequence.
  • the pluripotent, induced pluripotent, or totipotent stem cells are mouse or rat embryonic stem (ES) cells.
  • the pluripotent, induced pluripotent, or totipotent stem cells have an XX karyotype or an XY karyotype.
  • Cells that comprise a nucleus containing a genetic modification as described herein are also provided, e.g., a modification introduced into a cell by pronuclear injection.
  • a hybridoma or quadroma is provided, derived from a cell of the non-human animal as described herein.
  • the non-human animal is a rodent, such as a mouse, a rat, or a hamster.
  • a lymphocyte isolated from a genetically modified non-human animal as described herein is provided.
  • the lymphocyte is a B cell, wherein the B cell comprises an immunoglobulin genomic locus comprising a rearranged human immunoglobulin heavy chain variable region nucleotide sequence operably linked to a human or a non-human animal (e.g., mouse or rat) heavy chain or light chain constant region gene sequence.
  • the B cell is capable of producing antibodies wherein the rearranged heavy chain variable domain as described herein is operably linked to a heavy chain or light chain constant domain.
  • a non-human animal embryo comprising a cell whose genome comprises: (i) an immunoglobulin heavy chain locus comprising a rearranged human heavy chain variable region nucleic acid sequence operably linked to a constant region nucleic acid sequence; and (ii) an immunoglobulin light chain locus comprising two or more but less than the wild type number of human immunoglobulin light chain variable region gene segments, operably linked to a light chain constant region nucleic acid sequence.
  • the genetically modified non-human animals express an antibody repertoire (e.g., an IgG repertoire) that is derived from the nucleotide sequence that encodes the rearranged heavy chain variable domain, and a plurality of light chain V segments (and a plurality of light chain J segments).
  • the genetically modified locus produces an antibody population that comprises an immunoglobulin light chain that is capable of specifically binding an antigen of interest with an affinity (K D ) lower than 10 ⁇ 6 , 10 ⁇ 7 , 10 ⁇ 8 , 10 ⁇ 9 or 10 ⁇ 10 .
  • the immunoglobulin light chain expressed by the genetically modified locus is capable of specifically binding an antigen of interest in the absence of a heavy chain variable region with an affinity (K D ) lower than 10 ⁇ 6 , 10 ⁇ 7 , 10 ⁇ 8 , 10 ⁇ 9 , or 10 ⁇ 10 .
  • the genetic modifications described herein do not affect fertility of the non-human animal (see, for example, US 2012-0322108A1, incorporated by reference in its entirety).
  • the heavy chain locus comprises an endogenous Adam6a gene, Adam6b gene, or both, and the genetic modification does not affect the expression and/or function of the endogenous Adam6a gene, Adam6b gene, or both.
  • the genome of the genetically modified non-human animal comprises an ectopically located Adam6a gene, Adam6b gene, or both.
  • an Adam6a and/or Adam6b gene is placed 5′ upstream of the transcriptional unit of the rearranged heavy chain variable region nucleic acid sequence.
  • the Adam6a and/or the Adam6b gene is placed 3′ downstream of the transcriptional unit of the rearranged heavy chain variable region nucleic acid sequence.
  • the genetically modified heavy chain locus does not comprise an Intergenic Control Region 1 (IGCR1) nucleic acid sequence.
  • the genetically modified heavy chain locus comprises an IGCR1 sequence downstream of the rearranged heavy chain variable region nucleic acid sequence.
  • the IGCR1 nucleic acid sequence is present between the rearranged heavy chain variable region nucleic acid sequence and the most V-proximal D H gene segment.
  • the immunoglobulin light chain locus of the non-human animals described herein comprises a limited repertoire of light chain variable gene segments, e.g., (i) one, two or more but less than the wild type number of human V L gene segments.
  • the non-human animal is a mouse; and the immunoglobulin light chain variable domain is generated from a rearrangement of one of two human V ⁇ gene segments and one of 1, 2, 3, 4, or 5 human J ⁇ gene segments.
  • the mouse exhibits a ratio of (a) B cells in the bone marrow that express an immunoglobulin having a ⁇ light chain to (b) B cells in the bone marrow that express an immunoglobulin having a ⁇ light chain, of about 1 to about 15.
  • the rearrangement includes a human V ⁇ 1-39 gene segment.
  • the rearrangement includes a human V ⁇ 3-20 gene segment.
  • the two human V ⁇ gene segments is at an endogenous immunoglobulin V ⁇ locus, and, in some embodiments, the two human V ⁇ gene segments replace all or substantially all mouse immunoglobulin V ⁇ gene segments.
  • the two human V ⁇ gene segments are at an endogenous immunoglobulin V ⁇ locus, and, in some embodiments, the two human V ⁇ gene segments replace all or substantially all mouse immunoglobulin V ⁇ and J ⁇ gene segments.
  • the two human V ⁇ gene segments are operably linked to two or more (e.g., 2, 3, 4, 5) human J ⁇ gene segments.
  • the light chain variable domain of the mouse is generated through a rearrangement of a human V ⁇ 1-39 gene segment or a human V ⁇ 3-20 gene segment and one of two or more (e.g., 2, 3, 4, or 5) human J ⁇ gene segments.
  • the ratio of immature B cells in the bone marrow that express an immunoglobulin having a ⁇ light chain to immature B cells that express an immunoglobulin having a ⁇ light chain is about 1 to about 13.
  • the light chain variable domain of the mouse is generated through a rearrangement of a human V ⁇ 1-39 gene segment or a human V ⁇ 3-20 gene segment and one of two or more (e.g., 2, 3, 4, or 5) human J ⁇ gene segments, and the ratio of mature B cells in the bone marrow that express an immunoglobulin having a ⁇ light chain to immature B cells that express an immunoglobulin having a ⁇ light chain is about 1 to about 7.
  • the light chain variable domain of a genetically modified mouse as described herein is generated through a rearrangement of a human V ⁇ 1-39 gene segment or a human V ⁇ 3-20 gene segment and one of two or more (e.g., 2, 3, 4, or 5) human J ⁇ gene segments, and has a pro B cell population in the bone marrow within in the range of about 2.5 ⁇ 10 4 to about 1.5 ⁇ 10 5 cells, inclusive, for example about 2.5 ⁇ 10 4 , 3.0 ⁇ 10 4 , 3.5 ⁇ 10 4 , 4.0 ⁇ 10 4 , 4.5 ⁇ 10 4 , 5.0 ⁇ 10 4 , 5.5 ⁇ 10 4 , 6.0 ⁇ 10 4 , 6.5 ⁇ 10 4 , 7.0 ⁇ 10 4 , 7.5 ⁇ 10 4 , 8.0 ⁇ 10 4 , 8.5 ⁇ 10 4 , 9.0 ⁇ 10 4 , 9.5 ⁇ 10 4 , 1.0 ⁇ 10 5 , or 1.5 ⁇ 10 5 cells; in some embodiments, a modified rodent (e.g., a mouse) described herein comprises a pro
  • Exemplary pro B cells in the bone marrow of genetically modified rodents are characterized by expression of CD19, CD43, c-kit and/or a combination thereof (e.g., CD19 + , CD43 + , c-kit + ).
  • a rodent e.g., mouse
  • a modified rodent e.g., a mouse
  • a modified rodent comprises a pre B cell population in the bone marrow of about 1.25 ⁇ 10 6 cells; in some embodiments, a modified rodent (e.g.,
  • Exemplary pre B cells in the bone marrow of genetically modified rodents are characterized by expression of CD19, CD43, c-kit and/or a combination thereof (e.g., CD19 + , CD43 ⁇ , c-kit ⁇ ).
  • a genetically modified mouse as described herein expresses a light chain generated through a rearrangement of a human V ⁇ 1-39 gene segment or a human V ⁇ 3-20 gene segment and one of two or more (e.g., 2, 3, 4, or 5) human J ⁇ gene segments, and has an immature B cell population in the bone marrow within the range of about 5 ⁇ 10 5 to about 7 ⁇ 10 5 cells, inclusive, for example, about 5.0 ⁇ 10 5 , 5.1 ⁇ 10 5 , 5.2 ⁇ 10 5 , 5.3 ⁇ 10 5 , 5.4 ⁇ 10 5 , 5.5 ⁇ 10 5 , 5.6 ⁇ 10 5 , 5.7 ⁇ 10 5 , 5.8 ⁇ 10 5 , 5.9 ⁇ 10 5 , 6.0 ⁇ 10 5 , 6.1 ⁇ 10 5 , 6.2 ⁇ 10 5 , 6.3 ⁇ 10 5 , 6.4 ⁇ 10 5 , 6.5 ⁇ 10 5 , 6.6 ⁇ 10 5 , 6.7 ⁇ 10 5 , 6.8 ⁇ 10 5 , 6.9 ⁇ 10 5 , or 7.0 ⁇
  • Exemplary immature B cells in the bone marrow of genetically modified rodents are characterized by expression of IgM, B220 and/or a combination thereof (e.g., IgM + , B220 int ).
  • a genetically modified mouse as described herein expresses a light chain generated through a rearrangement of a human V ⁇ 1-39 gene segment or a human V ⁇ 3-20 gene segment and one of two or more (e.g., 2, 3, 4, or 5) human J ⁇ gene segments, and has a mature B cell population in the bone marrow within the range of about 3 ⁇ 10 4 to about 1.5 ⁇ 10 5 cells, inclusive, for example about 3.0 ⁇ 10 4 , 3.5 ⁇ 10 4 , 4.0 ⁇ 10 4 , 4.5 ⁇ 10 4 , 5.0 ⁇ 10 4 , 5.5 ⁇ 10 4 , 6.0 ⁇ 10 4 , 6.5 ⁇ 10 4 , 7.0 ⁇ 10 4 , 7.5 ⁇ 10 4 , 8.0 ⁇ 10 4 , 8.5 ⁇ 10 4 , 9.0 ⁇ 10 4 , 9.5 ⁇ 10 4 , 1.0 ⁇ 10 5 , or 1.5 ⁇ 10 5 cells; in some embodiments, a modified rodent (e.g., a mouse) described herein comprises a mature B cell population in the bone
  • Exemplary mature B cells in the bone marrow of genetically modified rodents are characterized by expression of IgM, B220 and/or a combination thereof (e.g., IgM + , B220 hi ).
  • a genetically modified rodent expresses a light chain generated through a rearrangement of a human V ⁇ 1-39 gene segment or a human V ⁇ 3-20 gene segment and one of two or more (e.g., 2, 3, 4, or 5) human J ⁇ gene segments, and has a total B cell population in the bone marrow within the range of about 1 ⁇ 10 6 to about 3 ⁇ 10 6 cells, inclusive, for example about 1.0 ⁇ 10 6 , 1.1 ⁇ 10 6 , 1.2 ⁇ 10 6 , 1.3 ⁇ 10 6 , 1.4 ⁇ 10 6 , 1.5 ⁇ 10 6 , 1.6 ⁇ 10 6 , 1.7 ⁇ 10 6 , 1.8 ⁇ 10 6 , 1.9 ⁇ 10 6 , 2.0 ⁇ 10 6 , 2.1 ⁇ 10 6 , 2.2 ⁇ 10 6 , 2.3 ⁇ 10 6 , 2.4 ⁇ 10 6 , 2.5 ⁇ 10 6 , 2.6 ⁇ 10 6 , 2.7 ⁇ 10 6 , 2.8 ⁇ 10 6 , 2.9 ⁇ 10 6 or 2.0
  • a genetically modified rodent as described herein comprises an immunoglobulin ⁇ light chain locus that comprises two unrearranged human immunoglobulin V ⁇ gene segments and two or more (e.g., 2, 3, 4, or 5) unrearranged human J ⁇ gene segments, wherein the rodent (e.g., mouse) comprises a peripheral splenic B cell population comprising transitional (e.g., T1, T2 and T3) B cell populations that are about the same as a rodent (e.g., a mouse) that comprises a wild type complement of immunoglobulin ⁇ light chain V and J gene segments.
  • the rodent e.g., mouse
  • transitional e.g., T1, T2 and T3
  • Exemplary transitional B cell populations (e.g., T1, T2 and T3) in the spleen of a genetically modified rodent (e.g., a mouse) as described herein are characterized by expression of IgM, CD23, CD93, B220 and/or a combination thereof.
  • a genetically modified rodent as described herein comprises a T1 B cell population in the spleen (e.g., CD93 + , B220 + , IgM hi , CD23 ⁇ ) within the range of about 2 ⁇ 10 6 to about 7 ⁇ 10 6 cells, inclusive, for example about 2.0 ⁇ 10 6 , 2.5 ⁇ 10 6 , 3.0 ⁇ 10 6 , 3.5 ⁇ 10 6 , 4.0 ⁇ 10 6 , 4.5 ⁇ 10 6 , 5.0 ⁇ 10 6 , 5.5 ⁇ 10 6 , 6.0 ⁇ 10 6 , 6.5 ⁇ 10 6 , or 7.0 ⁇ 10 6 cells; in some embodiments, a modified rodent (e.g., a mouse) as described herein comprises a T1 B cell population in the spleen of about 2.16 ⁇ 10 6 cells; in some embodiments, a rodent (e.g., a mouse) as described herein comprises a T1 B cell population in the spleen of about 3.63
  • a genetically modified rodent as described herein comprises a T2 B cell population in the spleen (e.g., CD93 + , B220 + , IgM hi , CD23 + ) within the range of about 1 ⁇ 10 6 to about 7 ⁇ 10 6 cells, inclusive, for example about 1.0 ⁇ 10 6 , 1.5 ⁇ 10 6 , 2.0 ⁇ 10 6 , 2.5 ⁇ 10 6 , 3.0 ⁇ 10 6 , 3.5 ⁇ 10 6 , 4.0 ⁇ 10 6 , 4.5 ⁇ 10 6 , 5.0 ⁇ 10 6 , 5.5 ⁇ 10 6 , 6.0 ⁇ 10 6 , 6.5 ⁇ 10 6 , or 7.0 ⁇ 10 6 cells; in some embodiments, a modified rodent (e.g., a mouse) described herein comprises a T2 B cell population in the spleen of about 1.30 ⁇ 10 6 cells; in some embodiments, a modified rodent (e.g., a mouse) described herein comprises a T2 B cell
  • a genetically modified rodent as described herein a T3 B cell population in the spleen (e.g., CD93 + , B220 + , IgM lo , CD23 + ) within the range of about 1 ⁇ 10 6 to about 4 ⁇ 10 6 cells, inclusive, for example about 1.0 ⁇ 10 6 , 1.5 ⁇ 10 6 , 2.0 ⁇ 10 6 , 2.5 ⁇ 10 6 , 3.0 ⁇ 10 6 , 3.5 ⁇ 10 6 , or 4.0 ⁇ 10 6 cells; in some embodiments, a modified rodent (e.g., a mouse) described herein comprises a T3 B cell population in the spleen of about 1.08 ⁇ 10 6 cells; in some embodiments, a modified rodent (e.g., a mouse) described herein comprises a T3 B cell population in the spleen of about 1.35 ⁇ 10 6 cells; in some embodiments, a modified rodent (e.g., a mouse) described herein comprises a T3 B cell population in the spleen of about 1.35
  • Marginal zone B cells are noncirculating mature B cells that segregate anatomically into the marginal zone (MZ) of the spleen.
  • MZ B cells are sessile and reside in the outer white pulp of the spleen between the marginal sinus and the red pulp. This region contains multiple subtypes of macrophages, dendritic cells, and the MZ B cells; it is not fully formed until 2 to 3 weeks after birth in rodents and 1 to 2 years in humans.
  • the MZ B cells within this region typically express high levels of sIgM, CD21, CD1, CD9 with low to negligible levels of sIgD, CD23, CD5, and CD11b that help to distinguish them phenotypically from follicular (FO) B cells and B1 B cells. Similar to B1 B cells, MZ B cells can be rapidly recruited into the early adaptive immune responses in a T cell independent manner.
  • the MZ B cells are especially well positioned as a first line of defense against systemic blood-borne antigens that enter the circulation and become trapped in the spleen. It is believed they are especially reactive to bacterial cell wall components and are an important source of lipid-specific antibodies. MZ B cells also display a lower activation threshold than their FO B cell counterparts with heightened propensity for plasma cell differentiation that contributes further to the accelerated primary antibody response.
  • a genetically modified rodent e.g., a mouse as described herein comprising a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (e.g., V H 3-23/D/J H 4) has increased levels of marginal zone B cells relative to wild type rodents (e.g., wild type mice).
  • marginal zone B cells in a genetically modified rodent (e.g., mouse) comprising a rearranged human immunoglobulin heavy chain variable region nucleotide sequence are increased by 10%, 20%, 30%, 40%, 50% or more relative to wild type rodents (e.g., wild type mice).
  • a genetically modified rodent as described herein comprises an immunoglobulin ⁇ light chain locus that comprises two unrearranged human immunoglobulin V ⁇ gene segments and 1, 2, 3, 4, or 5 unrearranged human immunoglobulin J ⁇ gene segments, and wherein the rodent (e.g., mouse) comprises a peripheral splenic B cell population comprising marginal zone and marginal zone precursor B cell populations that are about the same as a rodent (e.g., mouse) that comprises a wild type complement of immunoglobulin V ⁇ and J ⁇ gene segments.
  • Exemplary marginal zone B cell populations in the spleen of a genetically modified rodent as described herein are characterized by expression of IgM, CD21/35, CD23, CD93, B220 and/or a combination thereof.
  • a genetically modified rodent as described herein comprises marginal zone B cell population in the spleen (e.g., CD93 ⁇ , B220 + , IgM hi , CD21/35 hi , CD23 ⁇ ) within the range of about 1 ⁇ 10 6 to about 3 ⁇ 10 6 cells, inclusive, for example, about 1.0 ⁇ 10 6 , 1.5 ⁇ 10 6 , 2.0 ⁇ 10 6 , 2.5 ⁇ 10 6 , or 3.0 ⁇ 10 6 cells; in some embodiments, a modified rodent (e.g., a mouse) described herein comprises a marginal zone B cell population in the spleen of about 1.47 ⁇ 10 6 cells; in some embodiments, a modified rodent (e.g., a mouse) described herein comprises a marginal zone B cell population in the spleen of about 1.49 ⁇ 10 6 cells; in some embodiments, a modified rodent (e.g., a mouse) described herein comprises a marginal zone B cell population in the spleen (e.g., a mouse
  • a genetically modified rodent e.g., mouse
  • the rodent comprises an immunoglobulin ⁇ light chain locus that comprises two unrearranged human immunoglobulin V ⁇ gene segments and 1, 2, 3, 4, or 5 unrearranged human immunoglobulin J ⁇ gene segments
  • the rodent comprises a peripheral splenic B cell population comprising follicular (e.g., FO-I and FO-II) B cell population(s) that are about the same as a rodent (e.g., mouse) that comprises a wild type complement of immunoglobulin V ⁇ and J ⁇ gene segments.
  • Exemplary follicular B cell populations in the spleen of a genetically modified rodent (e.g., mouse) as described herein are characterized by expression of IgM, IgD, CD21/35, CD93, B220 and/or a combination thereof.
  • a genetically modified rodent as described herein comprises a follicular type 1 B cell population in the spleen (e.g., CD93 ⁇ , B220 + , CD21/35 int , IgM lo , IgD hi ) within the range of about 3 ⁇ 10 6 to about 1.5 ⁇ 10 7 cells, inclusive, for example about 3.0 ⁇ 10 6 , 3.5 ⁇ 10 6 , 4.0 ⁇ 10 6 , 4.5 ⁇ 10 6 , 5.0 ⁇ 10 6 , 5.5 ⁇ 10 6 , 6.0 ⁇ 10 6 , 6.5 ⁇ 10 6 , 7.0 ⁇ 10 6 , 7.5 ⁇ 10 6 , 8.0 ⁇ 10 6 , 8.5 ⁇ 10 6 , 9.0 ⁇ 10 6 , 9.5 ⁇ 10 6 , 1.0 ⁇ 10 7 , or 1.5 ⁇ 10 7 cells; in some embodiments, a modified rodent (e.g., mouse) as described herein comprises a follicular type 1 B cell population in the spleen of
  • a genetically modified rodent as described herein comprises a follicular type 2 B cell population in the spleen (e.g., CD93 ⁇ , B220 + , CD21/35 int , IgM int , IgD hi ) within the range of about 1 ⁇ 10 6 to about 2 ⁇ 10 6 cells, inclusive, for example, 1.0 ⁇ 10 6 , 1.25 ⁇ 10 6 , 1.5 ⁇ 10 6 , 1.75 ⁇ 10 6 , or 2.0 ⁇ 10 6 cells; in some embodiments, a modified rodent (e.g., a mouse) described herein comprises a follicular type 2 B cell population in the spleen of about 1.14 ⁇ 10 6 cells; in some embodiments, a modified rodent (e.g., a mouse) described herein comprises a follicular type 2 B cell population in the spleen of about 1.45 ⁇ 10 6 cells; in some embodiments, a modified rodent (e.g., a)
  • variable light chain gene sequences e.g., light chain CDR3s
  • the rearranged heavy chain variable domain gene sequences disclosed herein can be paired with one or more genetic modifications of a light chain locus and/or the insertion of nucleotide sequences encoding light chain variable domains into a heavy chain locus.
  • genetically modified non-human animals comprising an immunoglobulin locus with a rearranged heavy chain variable domain gene sequence may further comprise (e.g., via cross-breeding or multiple gene targeting strategies) one or more modifications as described in WO 2011/072204, WO 2011/163311, WO 2011/163314, WO 2012/018764, WO 2012/141798, U.S. 2013/0185821, WO 2013/022782, WO 2013/096142, WO2013/116609; these publications are incorporated herein by reference in their entirety.
  • a genetically modified mouse comprising a rearranged heavy chain variable region nucleic acid sequence in a light chain locus (i.e, a rearranged heavy chain variable domain gene sequence operably linked to a human or non-human ⁇ light chain constant region gene sequence) is crossed to a genetically modified mouse comprising an immunoglobulin heavy chain locus comprising human light chain variable region gene segments (e.g., 40 human V ⁇ genes and all human J ⁇ genes inserted into a mouse heavy chain locus; see, e.g., U.S. pre-grant publication 2012/0096572, incorporated herein by reference).
  • a genetically modified mouse comprising a rearranged heavy chain variable region nucleic acid sequence in a light chain locus (i.e, a rearranged heavy chain variable domain gene sequence operably linked to a human or non-human ⁇ light chain constant region gene sequence) is crossed to a genetically modified mouse comprising an immunoglobulin heavy chain locus comprising one or more (e.g., two) but less than the wild type number of human light chain variable region gene segments.
  • mice are able to produce kappa+ B cells with variable heavy chains derived from genomic light chain variable sequence, thus facilitating the identification of kappa VJ sequences that bind to specific targets, which can then be reformatted back to a light chain and paired with a variety of heavy chains to produce bi or tri specific antibodies.
  • hV H 3-23 is a thermostable human variable heavy chain gene segment and is also one of the most commonly used variable segments in the human repertoire.
  • codon-optimized human V H 3-23, D4-4 (reading frame 2 or 3), and J H 4 (or J H 6) gene segments were selected for designing a rearranged heavy chain variable sequence (hereinafter “Universal Heavy Chain” or “UHC”).
  • VDJ sequences were synthesized de novo (by IDT) and cloned into CMV expression vectors (e.g., pRG1301 or pRG1368): (1) hV H 3-23(D4-4_RF2)J H 4 (SEQ ID NO: 148); (2) hV H 3-23(D4-4_RF2)J H 6 (SEQ ID NO: 146); (3) hV H 3-23(D4-4_RF3)J H 4 (SEQ ID NO: 147); (4) hV H 3-23(D4-4_RF3)J H 6 (SEQ ID NO: 145).
  • CMV expression vectors e.g., pRG1301 or pRG1368
  • the ASAP antibody database of Regeneron Pharmaceuticals which was generated from the antibodies produced by VELOCIMMUNE® humanized mice, was searched for antibodies containing an amino acid sequence that is similar to hV H 3-23(D4-4)J H 4 ( FIG. 5 ). More specifically, the criteria that were used to identify non-autoreactive antibodies included the amino acid sequence of DYSNY (SEQ ID NO: 144) or sequences similar to DYSNY (SEQ ID NO: 144). Expression studies in CHO cells, however, revealed that UHC sequences containing DYSNY (SEQ ID NO: 144) did not express well in mammalian cells.
  • the expression levels of the peptide AKGYYFDY derived from the rearranged VDJ sequence (V H 3-23/GY/J H 4; HIH2002B) in CHO cells were compared with the peptide derived from of V H 3-23/D4-4 (reading frame 2)/J H 4 (SEQ ID NO: 148), with respect to expression with five human ⁇ chains, three human ⁇ chains, and other rearranged VDJ sequences (i.e., V H 3-20 and V H 1-39).
  • the selected rearranged VDJ sequence (V H 3-23/GY/J H 4) showed expression levels equivalent to those of the controls.
  • V H 3-23/GY/J H 4 (SEQ ID NO: 137; HIH2002B) was selected as a rearranged heavy chain variable domain sequence for creating a genetically modified mouse.
  • Detailed targeting strategies for generating a mouse containing a genetically modified immunoglobulin locus that encodes a rearranged heavy chain variable domain i.e., a mouse that comprises an immunoglobulin locus comprising a rearranged human immunoglobulin heavy chain variable region
  • FIGS. 1-9 are illustrated in FIGS. 1-9 and as described below.
  • targeting vectors were designed to introduce a rearranged human immunoglobulin heavy chain variable region nucleotide sequence (i.e., hV H 3-23(D)J H 4; SEQ ID NO: 136) into a genetically modified mouse in which all or substantially all endogenous functional immunoglobulin heavy chain V, D, J gene segments have been deleted.
  • the targeting vectors included a genomic region comprising Adam6a and Adam6b genes in order to prevent fertility problems associated with the deletion of the genomic region comprising Adam6a/6b genes in mice (see, for example, US 2012-0322108A1, incorporated by reference herein in its entirety).
  • a BHR donor for modifying a mouse BAC clone comprising a leader sequence (which guides the heavy chain through the endoplasmic reticulum), a rearranged heavy chain variable region nucleotide sequence (V H 3-23(D)J H 4; SEQ ID NO: 136) and an intron of hJ H 4 (SEQ ID NO: 140) that are operably linked to a 2239-bp V H 3-23 promoter (SEQ ID NO: 139), was constructed. Additionally, the genomic locus was flanked 5′ and 3′ by mouse IgH homology boxes for homologous recombination with the MAID1115 BAC clone ( FIG. 1 ).
  • a spectinomycin selection cassette was introduced into the upstream of the V H 3-23 promoter (between the I-CeuI and SpeI sites) to generate pJSh0038 (UHC mini-locus; SEQ ID NO: 142) ( FIG. 1 , 1. I-CeuI/SpeI Ligation (Amp+Spec)).
  • the UHC mini-locus contains: (1) a spectinomycin (Spec) cassette with I-CeuI/AscI sites for ligation; (2) 2239-bp hV H 3-23 promoter (SEQ ID NO: 139); (3) a rearranged hV H 3-23(D)J H 4 nucleotide sequence (SEQ ID NO: 136); (4) an hJ H 4 intron (SEQ ID NO: 140); and (5) mouse homology boxes for BHR (MAID 1115).
  • Spec spectinomycin
  • a hygromycin selection cassette (EM7-HYG) was targeted into the 5′ end of the genomic region of the MAID 1115 BAC clone, which contains a loxP-flanked neomycin cassette (Pgk-Neo) in the upstream of the IgM genomic region. Insertion of the hygromycin cassette deleted the loxP site located at the 5′ end of the MAID 1115 clone.
  • the bacterial cells containing the genetically modified BAC clone (VI432) were selected via hygromycin/kanamycin selection ( FIG. 2 , 2. BHR (Hyg+Kan)).
  • the UHC mini-locus which was constructed in Step 1, was targeted into the upstream of the IgM locus of the VI432 BAC clone.
  • the introduction of the UHC mini-locus replaced the floxed neomycin selection cassette with a new spectinomycin cassette (VI443).
  • Bacterial cells containing the genetically modified BAC clones (VI443) were selected via spectinomycin and hygromycin selection ( FIG. 2 ; 3. BHR (Spec+Hyg)).
  • the VI421 BAC clone which comprises, from 5′ to 3′, (1) an Adam6a gene (present in a 3′ to 5′ direction); (2) a neomycin cassette (present in a 3′ to 5′ direction) flanked by FRT sites; (3) an Adam6b gene (present in a 3′ to 5′ direction); (4) Intergenic Control Region 1 (IGCR1; i.e., a key V(D)J recombination regulatory region); and (5) a spectinomycin cassette (present in a 5′ to 3′ direction), were targeted with the pDBa0049 construct, which contains a chloramphenicol (Cm) cassette; an AscI restriction site upstream of the chloramphenicol gene; and 5′ and 3′ homology arms.
  • IGCR1 Intergenic Control Region 1
  • a spectinomycin cassette present in a 5′ to 3′ direction
  • the targeting of the pDBa0049 construct removed IGCR1 and the spectinomycin cassette from the VI421 clone; and introduced a new AscI restriction site and a chloramphenicol cassette to the downstream of the Adam6b gene.
  • Bacterial cells containing the successfully targeted clone (VI444) were selected via chloramphenicol and kanamycin selection ( FIG. 3 ; 4. BHR (Cm+Kan)).
  • the genomic region of the VI444 BAC clone containing the Adam6a and/or 6b genes were introduced into the upstream of the universal heavy chain genomic locus in the VI443 BAC clone between the I-CeuI and the AscI sites via restriction digestion and ligation ( FIG. 3 ).
  • This modification introduces Adam6a and/or 6b genes into the clone and replaces the spectinomycin cassette with a neomycin cassette, yielding a final targeting construct (MAID6031; VI445).
  • the bacterial cells (BHR) containing the final targeting construct (MAID 6031; VI445) were selected based on hygromycin and kanamycin selection ( FIG. 3 , 5. I-CeuI/AscI ligation (Hyg+Kan)).
  • the final targeting construct (MAID6031) for the creation of a genomic locus containing a rearranged human heavy chain variable domain sequence contains, from 5′ to 3′, (1) a 5′ homology arm containing about 20000 bp of a mouse genomic sequence upstream of the endogenous Ig heavy chain locus; (2) an Adam6a gene; (3) a 5′ FRT site; (4) a neomycin cassette; (5) a 3′ FRT site, (6) an Adam6b gene; (7) 2239 bp of hVH3-23 promoter (SEQ ID NO: 139); (8) a rearranged human immunoglobulin heavy chain nucleotide sequence (hVH3-23(D)J H 4; SEQ ID NO: 136); (9) an hJ H 4 intron (SEQ ID NO: 140); and (10) a 3′ homology arm containing about 7400 bp of a mouse genomic sequence downstream of the mouse J H gene segments.
  • the final targeting construct MAID6031 BAC DNA, was linearized and electroporated into ES cells isolated from the 1661 heterozygous mouse ( FIG. 4 .), which contain a wild-type Ig heavy chain VDJ genomic loci and a mutated VDJ genomic loci in which all V H , D, J H genes have been deleted.
  • Successfully targeted mouse ES cells were screened using the primers and probes set forth in FIGS. 6-8 .
  • the successfully targeted mouse ES cells were introduced into host mouse embryos using VELOCIMOUSE® technology to produce a genetically modified heterozygous F0 mouse.
  • mice MAID 6032 het
  • the successfully targeted ES cells were electroporated with a plasmid that expresses Flp recombinase prior to introducing into host embryos.
  • MAID6031 heterozygous male mice harboring the selection cassette were bred to female mice that express Flp recombinase in order to remove the cassette.
  • Heterozygous mice bearing the modification were bred to each other to generate homozygotes (MAID 6032 HO) that are capable of making immunoglobulin heavy chains only from the genetically modified locus.
  • mice All mice were housed and bred in specific pathogen-free conditions at Regeneron Pharmaceuticals.
  • WT wild type
  • FACS fluorescence-activated cell sorting
  • Bone marrow cells, spleen cells, and blood cells isolated from a wild type or F0 6032 heterozygous mouse were gated on singlets and sorted based on CD19 expression (a B cell marker) or CD3 expression (a T cell marker).
  • CD19+-gated B cells were sorted based on the presence of IgM b antibodies (IgM antibodies produced from a wild type allele (B6 allele)) or IgM a antibodies (antibodies produced from the genetically modified allele (129 allele) comprising a rearranged heavy chain variable region nucleotide sequence (hV H 3-23(D)J H 4;).
  • IgM b antibodies IgM antibodies produced from a wild type allele (B6 allele)
  • IgM a antibodies antibodies produced from the genetically modified allele (129 allele) comprising a rearranged heavy chain variable region nucleotide sequence (hV H 3-23(D)J H 4;).
  • mice heterozygous with respect to the targeted allele i.e., containing one copy of the rearranged heavy chain variable sequence; MAID 6032 het
  • IgM a genetically modified 129
  • FACS fluorescence-activated cell sorting
  • B lymphocytes Only mature B lymphocytes can enter the lymphoid follicles of spleen and lymph nodes and thus efficiently participate in the immune response.
  • Mature, long-lived B lymphocytes derive from short-lived precursors generated in the bone marrow. Selection into the mature pool is an active process and takes place in the spleen.
  • Two populations of splenic B cells have been identified as precursors for mature B cells.
  • Transitional B cells of type 1 (T1) are recent immigrants from the bone marrow. They develop into the transitional B cells of type 2 (T2), which are cycling and found exclusively in the primary follicles of the spleen.
  • Mature B cells can be generated from T1 or T2 B cells. Loder, F. et al., J. Exp. Med., 190(1): 75-89, 1999.
  • FIGS. 13A and 13B The FACS analysis ( FIGS. 13A and 13B ) suggested that the mice homozygous with the respect to the targeted allele (i.e., containing two copies of the rearranged heavy chain variable sequence: MAID 6032 HO) were able to produce normal splenic mature and immature B cell populations, albeit with a slight decrease in the lambda sequences relative to wild type ( FIGS. 13C and 13D ). Also in the spleen, the MAID 6032HO mice demonstrated a slight decrease in T1 population B cells and an increase in marginal zone B cells ( FIG. 13E ).
  • the MAID6032 HO mice produced near normal B cell populations ( FIGS. 14A-14E ) with a usage of lambda sequences that was half of wild type ( FIG. 14F ).
  • mice Five WT (75% C57BL6/25% 129 background) and three to four MAID 6032 HET mice were immunized in the footpad with 0.025 ml of a mixture containing 2.35 ⁇ g of an antigen X, 10 ⁇ g CpG oligonucleotide (ODN 1826, InvivoGen, cat# tlrl-1826), and 25 ⁇ g Aluminum Phosphate Gel Adjuvant (Brenntag cat#7784-30-7). Mice were boosted six times with the same dosage. On days 15 and 24 post primary immunization, blood was collected from anaesthetized mice using a retro-orbital bleed into BD serum separator tubes (BD, cat #365956), and serum was collected as per manufacturer's directions.
  • BD BD serum separator tubes
  • ELISA plates (Nunc) were coated with either 1 ⁇ g/ml of an antigen X incubated overnight at 4 deg C. Excess antigen was washed off before blocking with PBS+1% BSA for 1 hr at RT. Serial dilutions of serum were applied and plates were incubated for 1 hr at RT before washing. Plates were incubated with horseradish peroxidase (HRP)-conjugated anti-IgG (cat #1030-05, Southern Biotech) antibody for 1 hr at RT. Following washing, plates were developed with TMB substrate (cat#555214, BD).
  • HRP horseradish peroxidase
  • the genetically modified F0 and F1 mice which are heterozygous with respect to the targeted allele (i.e., containing one copy of the rearranged V H 3-23/D/J H 4 nucleotide sequence), were able to produce antigen-specific IgG antibodies at levels comparable to those produced by wild type mice at both Days 15 and 24 post primary immunization.
  • Two engineered light chain loci containing two human V ⁇ gene segments (e.g., a human V ⁇ 1-39 and human V ⁇ 3-20 gene segment; i.e., a dual light chain (“DLC”)) were constructed ( FIG. 20 ).
  • One engineered light chain locus contained two human V ⁇ gene segments and five human J ⁇ gene segments in unrearranged configuration (DLC-5J).
  • the second engineered light chain locus contained two human V ⁇ gene segments and one human J ⁇ gene segment in unrearranged configuration (DLC-1J).
  • the human gene segments were flanked 3′ with recombination signal sequences to allow for in vivo rearrangement of the human gene segments in B cells.
  • FIG. 21 Engineering steps that result in generation of a light chain locus comprising two human V ⁇ gene segments (V ⁇ 1-39 and V ⁇ 3-20) and one human J ⁇ gene segment (J ⁇ 5), otherwise termed as DLC-1J, are depicted in FIG. 21 .
  • human V ⁇ 1-39 and V ⁇ 3-20 sequences were amplified by PCR from BAC templates (Invitrogen), and together with an amplified sequence containing recombination signal sequence (rss) and human J ⁇ 5 segment, cloned via a four-way ligation into a plasmid containing a UB-hygromycin selection cassette ( FIG. 21A ). 5′ and 3′ arms were attached as depicted in FIGS. 21B and 21C .
  • FIG. 21C bottom diagram; DLC-1J
  • RSS recombination signal sequences
  • ES cells bearing the engineered light chain locus may be transfected with a construct that expresses FLP in order to remove the FRTed neomycin cassette introduced by the targeting construct (see FIG. 21E ).
  • the neomycin cassette is removed by breeding to mice that express FLP recombinase (e.g., U.S. Pat. No. 6,774,279).
  • the neomycin cassette is retained in the mice.
  • a 2000 base pair amplified sequence comprising all 5 human J ⁇ 's was ligated into a vector comprising two human V ⁇ gene segments and one human J ⁇ , depicted in FIG. 21B (middle) (see FIG. 23A ).
  • Subsequent engineering steps involved attachment of 3′ and 5′ arms as depicted in FIG. 23B .
  • FIG. 23B bottom diagram; DLC-5J
  • RSS recombination signal sequences
  • ES cells bearing the engineered light chain locus may be transfected with a construct that expresses FLP in order to remove the FRTed neomycin cassette introduced by the targeting construct (see FIG. 23D ).
  • the neomycin cassette is removed by breeding to mice that express FLP recombinase (e.g., U.S. Pat. No. 6,774,279).
  • the neomycin cassette is retained in the mice.
  • mice B cell populations and B cell development in DLC mice were validated by flow cytometry analysis of splenocyte and bone marrow preparations.
  • DLC-5J mice demonstrate normal B cell populations within the splenic and bone marrow compartments ( FIG. 25A-31 ). DLC-5J mice demonstrated immature, mature and pre/pro B cell populations within the bone marrow compartment that are substantially the same as observed in wild-type littermates. In fact, the DLC-5J locus was capable of competing with the endogenous lambda light chain locus to yield a kappa:lambda ratio that is substantially the same as that observed in wild-type mice ( FIG. 27B ).
  • DLC-5J mice demonstrate a normal peripheral B cell development as progression of B cells through various stages in the splenic compartment (e.g., immature, mature, T1, T2 T3, marginal zone precursor, marginal zone, follicular-I, follicular-II, etc.) occurs in a manner substantially the same as observed in wild type mice ( FIG. 30A-31 ).
  • DLC-1J mice demonstrated a lower overall number of B cells and an increased lambda light chain usage as compared to the engineered kappa light chain (data not shown).
  • DLC-1J mice demonstrated about two-fold higher expression of human V ⁇ 3-20-derived light chains over DLC-5J mice in the bone marrow compartment.
  • Human V ⁇ 1-39-derived light chain expression was observed at about six-fold (DLC-5J) to thirteen-fold (DLC-1J) higher than in HK mice.
  • DLC-1J mice demonstrated about two-fold higher expression of human V ⁇ 1-39-derived light chains over DLC-5J mice in the bone marrow compartment.
  • mice homozygous for two unrearranged human V ⁇ gene segments and five unrearranged human J ⁇ gene segments were analyzed for human V ⁇ /J ⁇ gene segment usage in splenic B cells by reverse-transcriptase polymerase chain reaction (RT-PCR).
  • Splenocytes were pelleted with a centrifuge (1200 rpm for five minutes) and red blood cells were lysed in 5 mL of ACK lysing buffer (GIBCO) for three minutes.
  • Splenocytes were diluted with PBS (Irvine Scientific), filtered with a 0.7 ⁇ m cell strainer and centrifuged again to pellet cells, which was followed by resuspension in 1 mL of PBS.
  • PCR products were gel-purified and cloned into pCR®2.1-TOPO® vector (TOPO® TA Cloning® Kit, Invitrogen) and sequenced with M13 Forward (GTAAAACGAC GGCCAG; SEQ ID NO: 92) and M13 Reverse (CAGGAAACAG CTATGAC; SEQ ID NO: 93) primers located within the vector at locations flanking the cloning site.
  • M13 Forward GTAAAACGAC GGCCAG
  • SEQ ID NO: 92 M13 Reverse primers located within the vector at locations flanking the cloning site.
  • Ten clones from each spleen sample were sequenced. Sequences were compared to the mouse and human immunoglobulin sets from the IMGT/V-QUEST reference directory sets to determine V ⁇ /J ⁇ usage.
  • Table 10 sets forth the V ⁇ /J ⁇ combinations for selected clones observed in RT-PCR clones from each splenocyte sample.
  • Table 11 sets forth the amino acid sequence of the human V ⁇ /human J ⁇ and human J ⁇ /mouse C ⁇ junctions of selected RT-PCR clones from DLC-5J homozygous mice. Lower case letters indicate mutations in the amino acid sequence of the variable region or non-template additions resulting from N and/or P additions during recombination.
  • mice homozygous for two unrearranged human V ⁇ gene segments and five unrearranged human J ⁇ gene segments (DLC-5J) operably linked to the mouse C ⁇ gene are able to productively recombine both human V ⁇ gene segments to multiple human J ⁇ gene segments to produce a limited immunoglobulin light chain repertoire.
  • DLC-5J unrearranged human J ⁇ gene segments
  • unique human V ⁇ /J ⁇ rearrangements were observed for V ⁇ 1-39/J ⁇ 2 (1), V ⁇ 1-39/J ⁇ 3 (1), V ⁇ 3-20/J ⁇ 1 (7), V ⁇ 3-20/J ⁇ 2 (4) and V ⁇ 3-20/J ⁇ 3 (1).
  • mice engineered to present a choice of no more than two human V ⁇ gene segments, both of which are capable of rearranging (e.g., with one or more and, in some embodiments, up to five human J ⁇ gene segments) and encoding a human V L domain of an immunoglobulin light chain have B cell numbers and development that is nearly wild-type in all aspects.
  • Such mice produce a collection of antibodies having immunoglobulin light chains that have one of two possible human V L gene segments present in the collection.
  • the mouse produces this collection of antibodies in response to antigen challenge and, and the collection of antibodies is associated with a diversity of reverse chimeric (human variable/mouse constant) heavy chains.
  • Histidine substitutions were introduced into the dual light chain locus as described above for V ⁇ 1-39 and V ⁇ 3-20 ULC mice. Briefly, the DLC sequence depicted in FIG. 23A (bottom) was subjected to site-directed mutagenesis, first modifying the V ⁇ 1-39 sequence, and subsequently modifying the V ⁇ 3-20 sequence, using primers depicted in FIG. 34 .
  • the resultant dual light chain sequence contained V ⁇ 1-39 segment with histidines introduced into the germline sequence at positions 105, 106, 108, and 111, V ⁇ 3-20 segment with histidines introduced into the germline sequence at positions 105, 106, 107, and 109, as well as all five J ⁇ segments (J ⁇ 1, J ⁇ 2, J ⁇ 3, J ⁇ 4, and J ⁇ 5).
  • a subsequent engineering step involved attachment of a 5′ arm carrying an FRT-UB-NEO-FRT cassette, and a 3′ arm carrying a mouse Ig ⁇ enhancers and constant region.
  • This targeting vector was electroporated into ES cells comprising deletion of the mouse Ig ⁇ variable locus (comprising K variable and joining gene segments), as depicted in FIG. 35A (recombination signal sequences, RSS, are omitted in this figure).
  • Targeted ES cells were screened by a modification of allele assay as described above, using primers and probes that detected the regions described above in Tables 1, 5, 8, and 9 (specifically, 1633h2, 1635h2, neo, Jxn 1-39/3-20, mIgKd2, and mIgKp15), as well as two additional sets of primers and probes listed in Table 12 below. The sequences of these two additional sets of primers and probes are included in the Sequence Listing.
  • a confirmed ES cell clone is then used to implant female mice to give rise to a litter of pups comprising DLC-5J light chain locus with four histidine modifications at each of the two present V L segment sequences, and expressing a human light chain variable domain fused with a mouse C ⁇ domain.
  • ES cells bearing the engineered light chain locus may be transfected with a construct that expresses FLP (e.g., FLPo) in order to remove the FRTed neomycin cassette introduced by the targeting construct (see FIG. 35B , RSS are omitted in this figure).
  • FLP FLP
  • the neomycin cassette is removed by breeding to mice that express FLP recombinase (e.g., U.S. Pat. No. 6,774,279).
  • the neomycin cassette is retained in the mice.
  • V ⁇ 1-39 and V ⁇ 3-20 of the dual light chain mice Three histidine substitutions were introduced into each V ⁇ 1-39 and V ⁇ 3-20 of the dual light chain mice. Briefly, the DLC sequence depicted in FIG. 23A (bottom) was subjected to site-directed mutagenesis, first modifying the V ⁇ 1-39 sequence, and subsequently modifying the V ⁇ 3-20 sequence, using primers depicted in FIG. 36 .
  • the resultant dual light chain sequence contained V ⁇ 1-39 segment with histidines introduced into the germline sequence at positions 106, 108, and 111, V ⁇ 3-20 segment with histidines introduced into the germline sequence at positions 105, 106, and 109, as well as all five J ⁇ segments (J ⁇ 1, J ⁇ 2, J ⁇ 3, J ⁇ 4, and J ⁇ 5).
  • a subsequent engineering step involved attachment of a 5′ arm carrying an FRT-UB-NEO-FRT cassette, and a 3′ arm carrying a mouse Ig ⁇ enhancers and constant region.
  • This targeting vector was electroporated into ES cells comprising deletion of the mouse Ig ⁇ variable locus (comprising ⁇ variable and joining gene segments), as depicted in FIG. 37A (RSS are omitted in this figure).
  • Targeted ES cells were screened by a modification of allele assay as described above, using primers and probes that detected the regions described above in Tables 1, 5, 8, and 9 (specifically, 1633h2, 1635h2, neo, Jxn 1-39/3-20, mIgKd2, and mIgKp15), as well as two additional sets of primers and probes listed in Table 13 below. The sequences of these two additional sets of primers and probes are included in the Sequence Listing.
  • a confirmed ES cell clone is then used to implant female mice to give rise to a litter of pups comprising DLC-5J light chain locus with four histidine modifications at each of the two present V L segment sequences, and expressing a human light chain variable domain fused with a mouse C ⁇ domain.
  • ES cells bearing the engineered light chain locus may be transfected with a construct that expresses FLP (e.g., FLPo) in order to remove the FRTed neomycin cassette introduced by the targeting construct (see FIG. 37B , RSS are omitted in this figure).
  • FLP FLP
  • the neomycin cassette is removed by breeding to mice that express FLP recombinase (e.g., U.S. Pat. No. 6,774,279).
  • the neomycin cassette is retained in the mice.
  • mice bearing an engineered human histidine-substituted dual light chain locus are bred with mice that contain a deletion of the endogenous ⁇ light chain locus to generate progeny that expresses, as their only light chains, the engineered histidine-substituted light chains derived from the dual light chain locus.
  • mice bearing an engineered human histidine-substituted dual light chain locus are bred with mice that contain a replacement of the endogenous mouse heavy chain variable locus with human heavy chain variable locus (see U.S. Pat. No. 6,596,541 and U.S. Pat. No. 8,502,018; the VELOCIMMUNE® mouse, Regeneron Pharmaceuticals, Inc.).
  • V kappa amplicons from splenic B cell mRNA was prepared using reverse-transcriptase PCR (RT-PCR) and high throughput screening.
  • mice from five heterozygous mice comprising two V kappa segments (V ⁇ 1-39 and V ⁇ 3-20) each containing three histidine substitutions (mice whose kappa locus is depicted in FIG. 35 ) and endogenous mouse heavy chains were harvested and homogenized in 1 ⁇ PBS (Gibco) using glass slides. Cells were pelleted in a centrifuge (500 ⁇ g for 5 minutes), and red blood cells were lysed in ACK Lysis buffer (Gibco) for 3 minutes. Cells were washed with 1 ⁇ PBS and filtered using a 0.7 ⁇ m cell strainer.
  • B-cells were isolated from spleen cells using MACS magnetic positive selection for CD19 (Miltenyi Biotec). Total RNA was isolated from pelleted B-cells using the RNeasy Plus kit (Qiagen). PolyA+ mRNA was isolated from total RNA using the Oligotex Direct mRNA mini kit (Qiagen).
  • Double-stranded cDNA was prepared from splenic B cell mRNA by 5′ RACE using the SMARTer Pico cDNA Synthesis Kit (Clontech). The Clontech reverse transcriptase and dNTPs were substituted with Superscript II and dNTPs from Invitrogen. Immunoglobulin light chain repertoires were amplified from the cDNA using primer specific for IgK constant region and the SMARTer 5′ RACE primer (Table 14). PCR products were cleaned up using a QIAquick PCR Purification Kit (Qiagen). A second round of PCR was done using the same 5′ RACE primer and a nested 3′ primer specific for the IgK constant region (Table 15).
  • Second round PCR products were purified using a SizeSelect E-gel system (Invitrogen). A third PCR was performed with primers that added 454 adapters and barcodes. Third round PCR products were purified using Agencourt AMPure XP Beads. Purified PCR products were quantified by SYBR-qPCR using a KAPA Library Quantification Kit (KAPA Biosystems). Pooled libraries were subjected to emulsion PCR (emPCR) using the 454 GS Junior Titanium Series Lib-A emPCR Kit (Roche Diagnostics) and bidirectional sequencing using Roche 454 GS Junior instrument according to the manufacturer's protocols.
  • emPCR emulsion PCR
  • the 454 sequence reads were sorted based on the sample barcode perfect match and trimmed for quality. Sequences were annotated based on alignment of rearranged Ig sequences to human germline V and J segments database using local installation of igblast (NCBI, v2.2.25+). A sequence was marked as ambiguous and removed from analysis when multiple best hits with identical score were detected. A set of perl scripts was developed to analyze results and store data in mysql database. CDR3 region of the kappa light chain was defined between conserved C codon and FGXG motif.
  • FIG. 38 represents alignments of amino acids sequence encoded by human germline IGKV3-20 ( FIG. 38A ) or IGKV1-39 ( FIG. 38B ) sequence with amino acid translations of exemplary V ⁇ sequences obtained from productively rearranged antibodies generated in mice comprising a histidine-modified DLC-5J (comprising a light chain variable locus comprising V ⁇ 1-39 and V ⁇ 3-20 gene segments, each segment with three histidine modifications as described above).
  • the sequence reads showed that the majority of productively rearranged light chains retained at least one histidine introduced into its germline CDR3.
  • mice comprising a rearranged heavy chain variable region nucleic acid sequence in the heavy chain locus (MAID6031; “UHC mouse”) were generated as described above. Briefly, in the UHC mouse, all endogenous functional heavy chain variable gene segments were deleted and replaced with a single rearranged heavy chain variable region nucleic acid sequence that encodes hV H 3-23/D/J H 4, which is operably linked to an endogenous heavy chain constant region nucleic acid sequence.
  • mice comprising genetically engineered light chain loci containing two human VK gene segments (e.g., a human V ⁇ 1-39 and human V ⁇ 3-20 gene segment) and either one human J ⁇ segment (J ⁇ 5; DLC-1J) or five human J ⁇ gene segments (hJ ⁇ 1-5; DLC-5J) were generated as described above.
  • one engineered light chain locus contains two human V ⁇ gene segments and five human J ⁇ gene segments (J ⁇ 1-5) in unrearranged configuration and is operably linked to an endogenous mouse K constant region sequence (MAID 1911 (DLC-5J); FIG. 19E ).
  • the other engineered light chain locus contains two human V ⁇ gene segments and one human J ⁇ (J ⁇ 1) gene segment in unrearranged configuration and is operably linked to an endogenous mouse K constant region sequence (MAID 1913(DLC-1J); FIG. 21D ).
  • the human gene segments were flanked 3′ with recombination signal sequences to allow for in vivo rearrangement of the human gene segments in B cells.
  • Homozygous UHC mice (MAID6031) described above were bred to homozygous DLC-5J (MAID1911) mice to produce a mouse heterozygous for the UHC allele and the DLC-5J allele.
  • homozygous UHC mice (MAID6031) were bred to homozygous DLC-1J (MAID1913) mice to generate a mouse heterozygous for the UHC allele and the DLC-1J allele.
  • F1 heterozygous mice generated from these crosses were bred each other to obtain mice homozygous for each allele.
  • the presence of the genetically modified alleles in the immunoglobulin heavy chain and light chain loci was confirmed by TAQMANTM screening and karyotyping using specific probes and primers described above.
  • mice heterozygous for the UHC allele and the DLC-5J were bred to each other to generate homozygotes (MAID 1912HO 6032HO; “DLC ⁇ UHC”) that express immunoglobulin “light” chains mostly from the genetically modified locus.
  • the MAID 1912HO 6032HO (homozygous DLC ⁇ UHC) mice comprise an insertion of the Universal Heavy Chain described herein (e.g., hV H 3-23/hD/hJ H 4) into the mouse heavy chain locus in which all endogenouse variable heavy chain VDJ genes have been deleted and DLC-5J (hV ⁇ 1-39 hV ⁇ 3-20 hJ ⁇ 1-5) the mouse kappa ( ⁇ ) light chain locus in which all mouse V ⁇ and J ⁇ genes have been deleted.
  • the Universal Heavy Chain described herein e.g., hV H 3-23/hD/hJ H 4
  • DLC-5J hV ⁇ 1-39 hV ⁇ 3-20 hJ ⁇ 1-5
  • mice All mice were housed and bred in specific pathogen-free conditions at Regeneron Pharmaceuticals.
  • Three F5 VELOCIMMUNE® (MAID 1293O 1640HO (“VI3”); see U.S. Pat. No. 8,502,018, incorporated by reference herein) mice (14 weeks old, male; Background: 26.5% C57/BL6, 22.75% 129 and 50.75% Balb/c) and three MAID 1912HO 6032HO F 2 mice ( FIG. 39 ; 7-8 weeks old, female; Background: 18.75 C57/BL6, 18.75% 129, and 62.5% Balb/c) were sacrificed, and spleens and bone marrow were harvested from the animals.
  • Bone marrow was collected from femurs by flushing with complete RPMI medium (RPMI medium supplemented with fetal calf serum, sodium pyruvate, Hepes, 2-mercaptoethanol, non-essential amino acids, and gentamycin). Red blood cells from spleen and bone marrow preparations were lysed with ACK lysis buffer and washed with complete RPMI medium.
  • complete RPMI medium RPMI medium supplemented with fetal calf serum, sodium pyruvate, Hepes, 2-mercaptoethanol, non-essential amino acids, and gentamycin.
  • FACS fluorescence-activated cell sorting
  • the MAID 1912HO 6032HO mice were also substantially similar to VI3 mice with respect to kappa and gamma light chain usage ( FIGS. 41A-41B ).
  • MAID 1912HO 6032HO (DLC ⁇ UHC) mice also demonstred increased surface IgM on splenic B cells (i.e., more IgM surface expression per cell) as compared to VI3 mice ( FIG. 42 ).
  • the MAID 1912HO 6032HO (DLC ⁇ UHC) mice demonstrated altered peripheral B cell development as progression of B cells through various stages in the splenic compartment (e.g., immature, mature, T1, T2 T3, marginal zone precursor, marginal zone, follicular-1, follicular-11, etc.) occurred in a different manner than observed in VI3 mice ( FIG. 43A ).
  • the MAID 1912HO 6032HO (DLC ⁇ UHC) mice demonstrated more immature, T1 and marginal zone (MZ) B cells in the splenic compartment as compared to VI3 mice.
  • the numbers of follicular-1 and follicular-11 cells in the MAID 1912HO 6032HO (DLC ⁇ UHC) mice were substantially the same as observed in VI3 mice ( FIG. 43B ).
  • MAID 1912HO 6032HO (DLC ⁇ UHC) mice demonstrated similar numbers of CD19+ B cells compare to VI3 mice controls ( FIGS. 44A-44B ). However, the MAID 1912HO 6032HO (DLC ⁇ UHC) mice demonstrated about 25-fold fewer pro-B cells in the bone marrow as compared to VI3 mice ( FIGS. 45A-45B ). The MAID 1912HO 6032HO (DLC ⁇ UHC) mice also demonstrated about 2-fold less immature B cells and 2-fold less mature B cells in the bone marrow compared to VI3 mice ( FIGS. 46A-46B ). Also, the MAID 1912HO 6032HO (DLC ⁇ UHC) mice demonstrated a preference (2-fold increase) for lambda expression compared to VI3 mice ( FIG. 47 ).
  • mice Five WT (75% C57BL6/25% 129 background) and seven F2 MAID1912HO 6031 HET (homozygous DLC ⁇ heterozygous UHC) mice were immunized in the footpad with 0.025 ml of a mixture containing 2.35 ⁇ g of an antigen X, 10 ⁇ g CpG oligonucleotide (ODN 1826, InvivoGen, cat# tlrl-1826), and 25 ⁇ g Aluminum Phosphate Gel Adjuvant (Brenntag cat#7784-30-7). Mice were boosted six times with the same dosage.
  • mice which are heterozygous with respect to the targeted allele containing the rearranged V H 3-23/D/J H 4 nucleotide sequence and homozygous with respect to the targeted allele containing DLC-5J, were able to produce antigen-specific IgG antibodies at levels comparable to those produced by wild type mice at both 23 days and 5 weeks after the primary immunization.
  • the MAID1912HO 6031 HET (homozygous DLC ⁇ heterozygous UHC) mice were also able to produce antigen-specific IgG antibodies at levels comparable to those produced by wild type mice after the 2 nd round of immunization.
  • mice produce antibodies comprising a reverse chimeric light chain (human light chain variable domain and mouse C ⁇ ) derived from a rearrangement of one of the two human V L gene segments (V ⁇ 1-39 or V ⁇ 3-20 gene segments) and human J ⁇ segments and a reverse chimeric heavy chain (human heavy chain variable domain and mouse C H ) derived from a single rearranged human heavy chain variable gene segment.
  • Reverse chimeric antibodies i.e., antibodies comprised of these reverse chimeric chains
  • mice bearing an engineered human light chain locus comprising a histidine-modified dual light chain are bred with mice that contain a replacement of the endogenous mouse heavy chain variable locus with universal human heavy chain locus (locus comprising a single rearranged human heavy chain variable domain as described herein above).
  • mice produce antibodies comprising a reverse chimeric light chain (human light chain variable domain and mouse C ⁇ ) derived from a rearrangement of one of the two histidine-modified human V L gene segments (V ⁇ 1-39 or V ⁇ 3-20 gene segments) and human J ⁇ segments and a reverse chimeric heavy chain (human heavy chain variable domain and mouse CH) derived from a single rearranged human heavy chain variable domain.
  • Reverse chimeric antibodies are obtained upon immunization with an antigen of interest. pH-dependent human antibodies generated in such mice are identified using antibody isolation and screening methods known in the art or described above.
  • Variable light and heavy chain region nucleotide sequences of B cells expressing the antibodies are identified, and fully human light and heavy chains are made by fusion of the variable light and heavy chain region nucleotide sequences to human C L and C H nucleotide sequences, respectively.
  • Light chains of interest e.g., light chains that bind to the antigen of interest (e.g., light chains from antibodies that also demonstrate pH-dependent antigen properties using a variety of assays known in the art, e.g., BIACORETM assay) are co-expressed in a suitable expression system with heavy chains derived from other antibodies, e.g., heavy chains derived from antibodies that comprise light chains derived from the same V L gene segment as that in the light chain of interest (e.g., V ⁇ 1-39 or V ⁇ 3-20), and the reconstituted antibody is tested for its ability to retain antigen-binding and pH-dependent antigen-binding properties.
  • the antigen of interest e.g., light chains from antibodies that also demonstrate pH-dependent antigen properties using a variety of assays known in the art, e.g., BIACORETM assay
  • heavy chains derived from other antibodies e.g., heavy chains derived from antibodies that comprise light chains derived from the same V L gene segment as that in
  • mice comprising a rearranged heavy chain variable region nucleic acid sequence in the kappa light chain locus (MAID6079; “UHC on kappa mouse”) were generated by similar methods to those described above for targeting the heavy chain locus. Briefly, in the UHC on kappa mouse, all endogenous functional light chain kappa variable V ⁇ and J ⁇ gene segments were deleted and replaced with a single rearranged heavy chain variable region nucleic acid sequence that encodes hV H 3-23/D/J H 4, which is operably linked to an endogenous light chain constant region nucleic acid sequence.
  • the final targeting construct for the creation of a genomic locus containing a rearranged human heavy chain variable domain sequence contains, from 5′ to 3′, (1) a 5′ homology arm containing about 22500 bp of a mouse genomic sequence upstream of the endogenous Ig light chain locus; (2) a 5′ FRT site; (3) a neomycin cassette; (4) a 3′ FRT site, (5) 2239 bp of hV H 3-23 promoter (SEQ ID NO: 139); (6) a rearranged human immunoglobulin heavy chain nucleotide sequence (hV H 3-23/D/J H 4; SEQ ID NO: 136); (7) an hJ H 4 intron (SEQ ID NO: 140); and (8) a 3′ homology arm containing about 75000 bp of a mouse genomic sequence downstream of the mouse JL gene segments.
  • mice bearing the modification were bred to each other to generate homozygotes (MAID 6079HO) that are capable of making immunoglobulin “light” chains only from the genetically modified locus.
  • the MAID 6079HO homozygous UHC on kappa mice comprise an insertion of the Universal Heavy Chain described herein (e.g., hV H 3-23/hD/hJ H 4) into the mouse kappa (K) light chain locus in which all mouse V ⁇ and J ⁇ genes have been deleted.
  • mice All mice were housed and bred in specific pathogen-free conditions at Regeneron Pharmaceuticals.
  • Four MAID 6079HO F 1 mice ( FIG. 49 ; 7-12.5 weeks old, male and female) and four MAID 6079 F1 wild type littermate control mice (7-12.5 weeks old, male and female) were sacrificed, and spleens and bone marrow were harvested from the animals.
  • Bone marrow was collected from femurs by flushing with complete RPMI medium (RPMI medium supplemented with fetal calf serum, sodium pyruvate, Hepes, 2-mercaptoethanol, non-essential amino acids, and gentamycin). Red blood cells from spleen and bone marrow preparations were lysed with ACK lysis buffer and washed with complete RPMI medium.
  • complete RPMI medium RPMI medium supplemented with fetal calf serum, sodium pyruvate, Hepes, 2-mercaptoethanol, non-essential amino acids, and gentamycin
  • FACS fluorescence-activated cell sorting
  • the MAID 6079HO mice demonstrated numbers of pro- and pre-B cells in the bone marrow compartment that are substantially the same as observed in wild type littermates ( FIGS. 50A-50B ). In contrast, they demonstrated lower numbers of immature and mature B cells in the bone marrow compartment compared to wild type littermates ( FIGS. 51A-51C ). In fact, the mice had 2-fold less immature B cells, and almost 4-fold less mature B cells.
  • the MAID 6079HO mice almost exclusively used lambda light chain sequences in immature and mature B cells in the bone marrow ( FIG. 52 ).
  • MAID 6079HO mice demonstrated fewer mature B cells compared to wild type littermates ( FIGS. 53A-53B ). Similar to what was observed in the bone marrow, MAID 6079HO mice almost exclusively used lambda light chain sequences in the splenic compartment ( FIGS. 54A-54B ). They also demonstrated fewer immature cells, an increase in marginal zone B cells and a decrease in follicular B cells compared to wild type littermates ( FIG. 55 ).
  • mice homozygous for a rearranged heavy chain variable region nucleic acid sequence in the light chain locus were generated as described above. These mice were crossed to mice homozygous (MAID 1994HO) for a kappa light chain variable region nucleic acid sequence in a heavy chain locus (kappa on heavy (“KoH”) mouse).
  • the MAID 1994 homozygous KoH mice comprise 40 human V ⁇ genes and all human J ⁇ genes, with long IGCR and mouse ADAM6, inserted into a mouse Ig heavy chain constant chain locus (i.e., a deleted mouse Ig heavy chain locus)).
  • KoH have been described previously; see, e.g., U.S. pre-grant publication 2012/0096572, incorporated herein by reference.
  • mice All mice were housed and bred in specific pathogen-free conditions at Regeneron Pharmaceuticals.
  • Bone marrow was collected from femurs by flushing with complete RPMI medium (RPMI medium supplemented with fetal calf serum, sodium pyruvate, Hepes, 2-mercaptoethanol, non-essential amino acids, and gentamycin). Red blood cells from spleen and bone marrow preparations were lysed with ACK lysis buffer and washed with complete RPMI medium.
  • complete RPMI medium RPMI medium supplemented with fetal calf serum, sodium pyruvate, Hepes, 2-mercaptoethanol, non-essential amino acids, and gentamycin.
  • MAID 1994HO 6079HO mice demonstrated lower CD19+ and pre-B cell frequencies in the bone marrow compartment compared to VI3 mice ( FIG. 57A ). Specifically, the MAID 19940 6079HO mice demonstrated about a 2-fold lower CD19+ and pre-B cell numbers in the bone marrow compared to VI3 mice ( FIG. 57B ). Additionally, the MAID 1994HO 6079HO mice demonstrated about 3-fold less immature B cells in the bone marrow compartment relative to VI3 mice ( FIGS. 58A and 58B ). It was also found that B cells from the MAID 1994HO 6079HO mice essentially lack expression of lambda light chain in the bone marrow ( FIG. 59 ).
  • MAID1994HO 6079HO mice demonstrated a lower frequency of B cells in the splenic compartment. Specifically, MAID 1994HO 6079HO mice had fewer splenic B cells (about 2-fold less) and mature B cells (about 3-fold less) numbers relative to VI3 mice ( FIGS. 60A-60B . They again demonstrated a lack expression of lambda light chain as compared to VI3 mice ( FIG. 61 ).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US14/185,679 2013-02-20 2014-02-20 Non-human animals with modified immunoglobulin heavy chain sequences Abandoned US20140245468A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US14/185,679 US20140245468A1 (en) 2013-02-20 2014-02-20 Non-human animals with modified immunoglobulin heavy chain sequences
US14/498,523 US9204624B2 (en) 2013-02-20 2014-09-26 Non-human animals with modifed immunoglobulin heavy chain sequences
US14/961,642 US9930871B2 (en) 2013-02-20 2015-12-07 Non-human animals with modified immunoglobulin heavy chain sequences
US16/990,517 US20210076648A1 (en) 2013-02-20 2020-08-11 Non-human animals with modified immunoglobulin heavy chain sequences

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361766765P 2013-02-20 2013-02-20
US201361879338P 2013-09-18 2013-09-18
US14/185,679 US20140245468A1 (en) 2013-02-20 2014-02-20 Non-human animals with modified immunoglobulin heavy chain sequences

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14/498,523 Continuation US9204624B2 (en) 2013-02-20 2014-09-26 Non-human animals with modifed immunoglobulin heavy chain sequences
US14/961,642 Continuation US9930871B2 (en) 2013-02-20 2015-12-07 Non-human animals with modified immunoglobulin heavy chain sequences
US201916435801A Continuation 2013-02-20 2019-06-10

Publications (1)

Publication Number Publication Date
US20140245468A1 true US20140245468A1 (en) 2014-08-28

Family

ID=51389721

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/185,679 Abandoned US20140245468A1 (en) 2013-02-20 2014-02-20 Non-human animals with modified immunoglobulin heavy chain sequences
US14/498,523 Active US9204624B2 (en) 2013-02-20 2014-09-26 Non-human animals with modifed immunoglobulin heavy chain sequences
US14/961,642 Active US9930871B2 (en) 2013-02-20 2015-12-07 Non-human animals with modified immunoglobulin heavy chain sequences
US16/990,517 Abandoned US20210076648A1 (en) 2013-02-20 2020-08-11 Non-human animals with modified immunoglobulin heavy chain sequences

Family Applications After (3)

Application Number Title Priority Date Filing Date
US14/498,523 Active US9204624B2 (en) 2013-02-20 2014-09-26 Non-human animals with modifed immunoglobulin heavy chain sequences
US14/961,642 Active US9930871B2 (en) 2013-02-20 2015-12-07 Non-human animals with modified immunoglobulin heavy chain sequences
US16/990,517 Abandoned US20210076648A1 (en) 2013-02-20 2020-08-11 Non-human animals with modified immunoglobulin heavy chain sequences

Country Status (26)

Country Link
US (4) US20140245468A1 (es)
EP (2) EP2840892B1 (es)
JP (3) JP5993102B2 (es)
KR (2) KR20160025033A (es)
CN (3) CN109769752A (es)
AU (3) AU2014218915B2 (es)
BR (1) BR112015019350A2 (es)
CA (1) CA2897963A1 (es)
CY (1) CY1120770T1 (es)
DK (1) DK2840892T3 (es)
ES (1) ES2678221T3 (es)
HK (2) HK1207251A1 (es)
HR (1) HRP20181151T1 (es)
HU (1) HUE039214T2 (es)
IL (3) IL239905A (es)
LT (1) LT2840892T (es)
MX (1) MX355105B (es)
MY (2) MY185881A (es)
PL (1) PL2840892T3 (es)
PT (1) PT2840892T (es)
RS (1) RS57582B1 (es)
RU (2) RU2017114166A (es)
SG (3) SG10201600539UA (es)
SI (1) SI2840892T1 (es)
TR (1) TR201810255T4 (es)
WO (1) WO2014130690A1 (es)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150315274A1 (en) * 2013-09-13 2015-11-05 Beigene, Ltd. Anti-PD1 Antibodies and their Use as Therapeutics and Diagnostics
WO2016044745A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
WO2017201476A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
WO2017210586A1 (en) 2016-06-03 2017-12-07 Regeneron Pharmaceuticals, Inc. Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
US9932398B2 (en) 2011-10-17 2018-04-03 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
US9930871B2 (en) 2013-02-20 2018-04-03 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
US20180134770A1 (en) * 2008-06-27 2018-05-17 Merus N.V. Antibody producing non-human animals
US10238093B2 (en) 2012-06-12 2019-03-26 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
CN109996441A (zh) * 2016-11-04 2019-07-09 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物
US10428146B2 (en) 2014-07-22 2019-10-01 Cb Therapeutics, Inc. Anti PD-1 antibodies
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
WO2019190922A1 (en) 2018-03-24 2019-10-03 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
US10435470B2 (en) 2014-08-05 2019-10-08 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
CN110305874A (zh) * 2019-06-19 2019-10-08 浙江省肿瘤医院 长爪沙鼠免疫球蛋白IgG1、IgG2重组蛋白、基因及其应用
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
WO2021026409A1 (en) 2019-08-08 2021-02-11 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
US11408095B2 (en) 2011-09-26 2022-08-09 Merus N.V. Generation of binding molecules
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008259939B2 (en) * 2007-06-01 2014-03-13 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
PL2564695T3 (pl) 2009-07-08 2015-10-30 Kymab Ltd Modele zwierzęce i cząsteczki terapeutyczne
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
CA2846322A1 (en) 2011-09-19 2013-03-28 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG10201700360VA (en) 2012-03-16 2017-03-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
AU2015227453B2 (en) * 2012-03-16 2017-05-25 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EP3348140B1 (en) 2012-03-16 2020-12-30 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
SG10201607727PA (en) 2012-03-16 2016-11-29 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
ES2738679T3 (es) * 2013-09-18 2020-01-24 Regeneron Pharma Anticuerpos de cadena ligera diseñados genéticamente con histidina y animales no humanos modificados genéticamente para generar los mismos
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
CN109906030B (zh) 2016-11-04 2022-03-18 安健基因公司 用于产生仅重链抗体的经基因修饰的非人动物和方法
US20190380316A1 (en) * 2018-06-14 2019-12-19 Regeneron Pharmaceuticals, Inc. Non-human animals capable of engineered dh-dh rearrangement and uses thereof
JP7443376B2 (ja) * 2018-12-31 2024-03-05 メルス ナムローゼ フェンノートシャップ 混合結合ドメイン
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
TW202110323A (zh) * 2019-06-05 2021-03-16 美商再生元醫藥公司 具有表現自κ 基因座的有限λ 輕鏈組庫的非人類動物及其用途
AU2021283564A1 (en) * 2020-06-02 2022-12-08 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
EP4051700A1 (en) 2020-12-23 2022-09-07 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
CN117186227A (zh) * 2020-12-23 2023-12-08 瑞泽恩制药公司 编码锚修饰的抗体的核酸以及其用途
WO2023179620A1 (en) * 2022-03-21 2023-09-28 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin and mhc loci
CN117587070B (zh) * 2024-01-19 2024-04-30 北京仁源欣生生物科技有限公司 一种经遗传修饰的非人哺乳动物的制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO2002066630A1 (en) * 2001-02-16 2002-08-29 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
EP0942968B1 (en) 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
CN1203922A (zh) 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) * 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CA2373638A1 (en) 1999-05-27 2000-12-07 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
RU2262511C2 (ru) * 2000-05-18 2005-10-20 Джапан Тобакко, Инк. Человеческое моноклональное антитело против ailim, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение
CA2634294A1 (en) 2000-08-03 2002-02-14 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
CN1789416B (zh) 2001-05-11 2011-11-16 协和发酵麒麟株式会社 含人抗体λ轻链基因的人类人工染色体
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
WO2003047336A2 (en) * 2001-11-30 2003-06-12 Abgenix, Inc. TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES
US7741077B2 (en) * 2001-12-22 2010-06-22 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
CN101537180B (zh) 2002-07-18 2016-02-10 莫鲁斯有限公司 抗体混合物的重组生产
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
WO2005007696A2 (en) 2003-07-15 2005-01-27 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
WO2005019463A1 (en) 2003-08-11 2005-03-03 Therapeutic Human Polyclonals, Inc. Improved transgenesis with humanized immunoglobulin loci
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
WO2005038001A2 (en) 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
GB2416768A (en) * 2004-07-22 2006-02-08 Univ Erasmus Heavy chain immunoglobulin complexes
AU2006242854A1 (en) 2005-04-29 2006-11-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Transgenic animals and methods of making recombinant antibodies
CA2638117A1 (en) 2006-01-25 2007-08-30 Erasmus University Medical Center Rotterdam Generation of heavy-chain only antibodies in transgenic animals
EP2505058A1 (en) 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
LT2769992T (lt) * 2006-10-02 2021-04-12 Regeneron Pharmaceuticals, Inc. Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
AU2008259939B2 (en) 2007-06-01 2014-03-13 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
US20110119779A1 (en) 2007-12-10 2011-05-19 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
CN107488228A (zh) * 2008-04-11 2017-12-19 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
US8012714B2 (en) 2008-04-14 2011-09-06 Innovative Targeting Solutions, Inc. Sequence diversity generation in immunoglobulins
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
US9346873B2 (en) 2008-09-30 2016-05-24 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
CN112715482B (zh) 2008-12-18 2022-11-11 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP2975051B1 (en) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
PL2564695T3 (pl) 2009-07-08 2015-10-30 Kymab Ltd Modele zwierzęce i cząsteczki terapeutyczne
WO2011158009A1 (en) 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
US20120204278A1 (en) * 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
CN110079550A (zh) 2009-12-10 2019-08-02 瑞泽恩制药公司 生产重链抗体的小鼠
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
ES2603559T5 (es) * 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
SI2480676T1 (sl) 2010-06-22 2016-10-28 Regeneron Pharmaceuticals, Inc. Hibridna mišja lahka veriga
CN113150121A (zh) 2010-08-02 2021-07-23 瑞泽恩制药公司 制造包含vl结构域的结合蛋白的小鼠
EP2638155A1 (en) 2010-11-08 2013-09-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
RS59413B2 (sr) 2011-02-25 2023-06-30 Regeneron Pharma Adam6 miševi
SI3572517T1 (sl) 2011-08-05 2021-09-30 Regeneron Pharmaceuticals, Inc. Humanizirana miš z univerzalno lahko verigo
EP2758534B1 (en) 2011-09-19 2020-04-29 Kymab Limited Animals, repertoires & methods for the production of human antibodies
CA2846322A1 (en) 2011-09-19 2013-03-28 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
DK2627773T3 (en) * 2011-10-17 2017-10-02 Regeneron Pharma MOUSE WITH LIMITED IMMUNOGLOBULIN HEAVY CHAIN
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR102038974B1 (ko) 2011-12-20 2019-10-31 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
HUE046744T2 (hu) 2012-02-01 2020-03-30 Regeneron Pharma VL doméneket tartalmazó nehézláncokat expresszáló humanizált egér
SG10201607727PA (en) * 2012-03-16 2016-11-29 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
EP3348140B1 (en) 2012-03-16 2020-12-30 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
SG10201700360VA (en) * 2012-03-16 2017-03-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
SG11201405059XA (en) 2012-03-28 2014-09-26 Kymab Ltd Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
HUE047266T2 (hu) * 2012-06-12 2020-04-28 Regeneron Pharma Korlátozott immunglobulin nehézlánc lókuszokkal rendelkezõ, humanizált, nem humán élõlények
SI2840892T1 (en) * 2013-02-20 2018-08-31 Regeneron Pharmaceuticals, Inc. Animals other than humans with modified immunoglobulin heavy chain sequences
EP3501272B1 (en) * 2013-03-13 2023-03-01 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO2002066630A1 (en) * 2001-02-16 2002-08-29 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10966411B2 (en) 2008-06-27 2021-04-06 Merus N.V. Antibody producing non-human mammals
US11925174B2 (en) 2008-06-27 2024-03-12 Merus N.V. Antibody producing non-human animals
US11785924B2 (en) 2008-06-27 2023-10-17 Merus N.V. Antibody producing non-human animals
US11559049B2 (en) * 2008-06-27 2023-01-24 Merus N.V. Antibody producing non-human animals
US20180134770A1 (en) * 2008-06-27 2018-05-17 Merus N.V. Antibody producing non-human animals
US20180142006A1 (en) * 2008-06-27 2018-05-24 Merus N.V. Antibody producing non-human animals
US11408095B2 (en) 2011-09-26 2022-08-09 Merus N.V. Generation of binding molecules
US11261248B2 (en) 2011-10-17 2022-03-01 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
US9932398B2 (en) 2011-10-17 2018-04-03 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
US10246509B2 (en) 2011-10-17 2019-04-02 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
US10238093B2 (en) 2012-06-12 2019-03-26 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
US11666040B2 (en) 2012-06-12 2023-06-06 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
US11559050B2 (en) 2012-06-12 2023-01-24 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
US10542735B2 (en) 2012-06-12 2020-01-28 Regerneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
US9930871B2 (en) 2013-02-20 2018-04-03 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
US9988450B2 (en) 2013-09-13 2018-06-05 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
US11673951B2 (en) 2013-09-13 2023-06-13 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
US9834606B2 (en) * 2013-09-13 2017-12-05 Beigene, Ltd Anti-PD1 antibodies and their use as therapeutics and diagnostics
US10519235B2 (en) 2013-09-13 2019-12-31 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
US11186637B2 (en) 2013-09-13 2021-11-30 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
US20150315274A1 (en) * 2013-09-13 2015-11-05 Beigene, Ltd. Anti-PD1 Antibodies and their Use as Therapeutics and Diagnostics
US11512132B2 (en) 2014-07-03 2022-11-29 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
US10981994B2 (en) 2014-07-22 2021-04-20 Apollomics Inc. Anti PD-1 antibodies
US11560429B2 (en) 2014-07-22 2023-01-24 Apollomics Inc. Anti PD-1 antibodies
US10428146B2 (en) 2014-07-22 2019-10-01 Cb Therapeutics, Inc. Anti PD-1 antibodies
US11111300B2 (en) 2014-08-05 2021-09-07 Apollomics Inc. Anti PD-L1 antibodies
US11827707B2 (en) 2014-08-05 2023-11-28 Apollomics Inc. Anti PD-L1 antibodies
US10435470B2 (en) 2014-08-05 2019-10-08 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
WO2016044745A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EP4368637A2 (en) 2016-05-20 2024-05-15 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
WO2017201476A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
EP4218408A1 (en) 2016-06-03 2023-08-02 Regeneron Pharmaceuticals, Inc. Rodents expressing exogenous terminal deoxynucleotidyltransferase
WO2017210586A1 (en) 2016-06-03 2017-12-07 Regeneron Pharmaceuticals, Inc. Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
US10980221B2 (en) 2016-06-03 2021-04-20 Regeneron Pharmaceuticals, Inc. Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
US11534431B2 (en) 2016-07-05 2022-12-27 Beigene Switzerland Gmbh Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
CN109996441A (zh) * 2016-11-04 2019-07-09 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
WO2019190922A1 (en) 2018-03-24 2019-10-03 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
US11576984B2 (en) 2018-03-26 2023-02-14 Regeneron Pharmaceuticals, Inc. Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
CN110305874A (zh) * 2019-06-19 2019-10-08 浙江省肿瘤医院 长爪沙鼠免疫球蛋白IgG1、IgG2重组蛋白、基因及其应用
WO2021026409A1 (en) 2019-08-08 2021-02-11 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors

Also Published As

Publication number Publication date
IL239905A (en) 2017-04-30
IL250460A0 (en) 2017-03-30
AU2019200538A1 (en) 2019-02-14
SI2840892T1 (en) 2018-08-31
HRP20181151T1 (hr) 2018-09-21
CN104994730B (zh) 2018-12-28
KR20160025033A (ko) 2016-03-07
CY1120770T1 (el) 2019-12-11
LT2840892T (lt) 2018-07-25
PT2840892T (pt) 2018-07-20
IL257303A (en) 2018-04-09
IL239905A0 (en) 2015-08-31
JP2016513957A (ja) 2016-05-19
WO2014130690A1 (en) 2014-08-28
ES2678221T3 (es) 2018-08-09
JP5993102B2 (ja) 2016-09-14
HK1258227A1 (zh) 2019-11-08
SG10201600539UA (en) 2016-02-26
BR112015019350A2 (pt) 2017-08-22
AU2014218915B2 (en) 2017-01-19
EP2840892B1 (en) 2018-04-18
JP6473423B2 (ja) 2019-02-20
AU2014218915A1 (en) 2015-08-13
AU2016269388A1 (en) 2016-12-22
EP3351095A1 (en) 2018-07-25
KR101764800B1 (ko) 2017-08-04
RU2015135884A (ru) 2017-03-22
US9204624B2 (en) 2015-12-08
CA2897963A1 (en) 2014-08-28
EP2840892A1 (en) 2015-03-04
SG10201900580RA (en) 2019-02-27
SG11201505383UA (en) 2015-08-28
MX355105B (es) 2018-04-05
US20170135326A9 (en) 2017-05-18
PL2840892T3 (pl) 2018-09-28
US9930871B2 (en) 2018-04-03
HK1207251A1 (en) 2016-01-29
JP2016127840A (ja) 2016-07-14
JP2018164465A (ja) 2018-10-25
CN109769752A (zh) 2019-05-21
CN104994730A (zh) 2015-10-21
HUE039214T2 (hu) 2018-12-28
MY185881A (en) 2021-06-14
US20160100561A1 (en) 2016-04-14
US20210076648A1 (en) 2021-03-18
RS57582B1 (sr) 2018-11-30
AU2016269388B2 (en) 2018-11-08
IL250460B (en) 2018-02-28
MY178882A (en) 2020-10-21
RU2017114166A (ru) 2019-01-29
TR201810255T4 (tr) 2018-08-27
MX2015010832A (es) 2016-02-09
CN105734081A (zh) 2016-07-06
EP2840892A4 (en) 2015-09-30
US20150020224A1 (en) 2015-01-15
KR20150118135A (ko) 2015-10-21
RU2618886C2 (ru) 2017-05-11
DK2840892T3 (en) 2018-07-23

Similar Documents

Publication Publication Date Title
US20210076648A1 (en) Non-human animals with modified immunoglobulin heavy chain sequences
US20220217955A1 (en) Non-Human Animals Expressing pH-Sensitive Immunoglobulin Sequences
US20240156070A1 (en) Common light chain mouse
US11026407B2 (en) Mice expressing a limited immunoglobulin light chain repertoire
WO2014160202A1 (en) Mice expressing a limited immunoglobulin light chain repertoire
AU2017219080B2 (en) Non-human animals expressing ph-sensitive immunoglobulin sequences
NZ711776B2 (en) Mice expressing a limited immunoglobulin light chain repertoire

Legal Events

Date Code Title Description
AS Assignment

Owner name: REGENERON PHARMACEUTICALS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCWHIRTER, JOHN;GURER, CAGAN;MEAGHER, KAROLINA A.;AND OTHERS;SIGNING DATES FROM 20140425 TO 20140505;REEL/FRAME:032846/0801

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION